{
  "dexchlorpheniramine maleate": {
    "ingredient": "dexchlorpheniramine maleate",
    "is_drug": true,
    "canonical_name": "dexchlorpheniramine",
    "fda_search_term": "dexchlorpheniramine maleate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Corphena",
      "VanaCof 2",
      "WesTussin DM"
    ],
    "generic_names": [
      "CHLOPHEDIANOL HCL, DEXCHLORPHENIRAMINE MALEATE",
      "DEXCHLORPHENIRAMINE MALEATE",
      "DEXCHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL"
    ],
    "manufacturers": [
      "BluCrest Pharmaceuticals LLC",
      "GM Pharmaceuticals, INC",
      "Westminster Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Ask a doctor before use if you have ■ a cough that lasts or is chronic such as occurs with smoking, asthma, or emphysema ■ a cough that occurs with too much phlegm (mucus) ■ a breathing problem such as emphysema or chronic bronchitis ■ trouble urinating due to an enlarged prostate gland ■ g",
      "A persistent cough may be a sign of a serious condition",
      "■ new symptoms occur If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [
      "Drug Interaction MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS General: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and the throat",
      "Cardiovascular System: Hemolytic anemia, thrombocytopenia, agranulocytosis",
      "Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis",
      "Nervous System: Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesias, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions",
      "System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation",
      "System: Urinary frequency, difficult urination, urinary retention, early menses",
      "Respiratory System: Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness",
      "Call your doctor for medical advice about side effects",
      "You may voluntarily report side effects to FDA at 1-800-FDA-1088",
      "Questions or comments?",
      "Call BluCrest Pharmaceuticals, LLC at 1-844-700-5011"
    ],
    "indications": [
      "Uses ■ temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes ■ cough due to minor throat and bronchial irritation"
    ]
  },
  "dexlansoprazole": {
    "ingredient": "dexlansoprazole",
    "is_drug": true,
    "canonical_name": "dexlansoprazole",
    "fda_search_term": "dexlansoprazole",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dexlansoprazole",
      "Dexlansoprazole delayed release"
    ],
    "generic_names": [
      "DEXLANSOPRAZOLE"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Limited",
      "Bryant Ranch Prepack"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with dexlansoprazole and instructions for preventing or managing them",
      "Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs",
      "Clinically Relevant Interactions Affecting Drugs Coadministered with Dexlansoprazole and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable",
      "The clinical importance and the mechanisms behind these interactions are not always known",
      "Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with dexlansoprazole may reduce antiviral effect and promote the development of drug resistance ",
      "Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with dexlansoprazole may increase toxicity of the antiretroviral drugs",
      "There are other antiretroviral drugs which do not result in clinically relevant interactions with dexlansoprazole",
      "Intervention: Rilpivirine-containing products : Concomitant use with dexlansoprazole is contraindicated [see Contraindications (4)] ",
      "See prescribing information",
      "Atazanavir : See prescribing information for atazanavir for dosing information"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in labeling:",
      "Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2)]",
      "Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.3)]",
      "Bone Fracture [see Warnings and Precautions (5.4)]",
      "Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.5)]",
      "Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions (5.6)]",
      "Cyanocobalamin (Vitamin B12) Deficiency [see Warnings and Precautions (5.7)]",
      "Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.8)]",
      "Fundic Gland Polyps [see Warnings and Precautions (5.11)]",
      "Risk of Heart Valve Thickening in Pediatric Patients Less than Two Years of Age [see Warnings and Precautions (5.12)] The most common adverse reactions are:",
      "Adults (≥2%): diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence",
      "Patients 12 to 17 years of age (≥5%): headache, abdominal pain, diarrhea, nasopharyngitis, and oropharyngeal pain",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adults The safety of dexlansoprazole was evaluated in 4548 adult patients in controlled and single-arm clinical trials, including 863 patients treated for at least six months and 203 patients treated for one year"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Dexlansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for:",
      "Healing of all grades of erosive esophagitis (EE)",
      "Maintenance of healed EE and relief of heartburn",
      "Treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD)",
      "( 1.3 ) 1.1 Healing of Erosive Esophagitis Dexlansoprazole delayed-release capsules are indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks"
    ]
  },
  "dexmedetomidine": {
    "ingredient": "dexmedetomidine",
    "is_drug": true,
    "canonical_name": "dexmedetomidine",
    "fda_search_term": "dexmedetomidine",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dexmedetomidine",
      "Dexmedetomidine Hydrochloride",
      "Dexmedetomidine in Dextrose"
    ],
    "generic_names": [
      "DEXMEDETOMIDINE",
      "DEXMEDETOMIDINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Medical Purchasing Solutions, LLC",
      "WG Critical Care, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Anesthetics, Sedatives, Hypnotics, Opioids: Enhancement of pharmacodynamic effects",
      "Reduction in dosage of dexmedetomidine or the concomitant medication may be required",
      "(7.1) 7.1 Anesthetics, Sedatives, Hypnotics, Opioids Co-administration of dexmedetomidine with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects",
      "Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam",
      "No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil and midazolam have been demonstrated",
      "However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine or the concomitant anesthetic, sedative, hypnotic or opioid may be required",
      "7.2 Neuromuscular Blockers In one study of 10 healthy adult volunteers, administration of dexmedetomidine for 45 minutes at a plasma concentration of one ng/mL resulted in no clinically meaningful increases in the magnitude of neuromuscular blockade associated with rocuronium administration"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:",
      "Hypotension, bradycardia and sinus arrest [see Warnings and Precautions (5.2)]",
      "Transient hypertension [see Warnings and Precautions (5.3)]",
      "The most common adverse reactions (incidence >2%) in adults are hypotension, bradycardia, and dry mouth",
      "Adverse reactions in adults, associated with infusions >24 hours in duration include ARDS, respiratory failure, and agitation",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact WG Critical Care at 1-866-562-4708 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Most common treatment-emergent adverse reactions, occurring in greater than 2% of adult patients in both Intensive Care Unit and procedural sedation studies include hypotension, bradycardia and dry mouth",
      "Intensive Care Unit Sedation Adverse reaction information is derived from the continuous infusion trials of dexmedetomidine for sedation in the Intensive Care Unit setting in which 1,007 adult patients received dexmedetomidine",
      "The mean total dose was 7.4 mcg/kg (range: 0.8 to 84.1), mean dose per hour was 0.5 mcg/kg/hr (range: 0.1 to 6.0) and the mean duration of infusion of 15.9 hours (range: 0.2 to 157.2)",
      "The population was between 17 to 88 years of age, 43% ≥65 years of age, 77% male and 93% Caucasian",
      "Treatment-emergent adverse reactions occurring at an incidence of >2% are provided in Table 2",
      "The most frequent adverse reactions were hypotension, bradycardia and dry mouth [see Warnings and Precautions (5.2)] ",
      "Table 2: Adverse Reactions with an Incidence >2%— Adult Intensive Care Unit Sedation Population <24 hours * Adverse Event All Dexmede"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is a alpha 2 adrenergic receptor agonist indicated for:",
      "Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting",
      "Administer Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection by continuous infusion not to exceed 24 hours",
      "Sedation of non-intubated adult patients prior to and/or during surgical and other procedures",
      "(1.2) 1.1 Intensive Care Unit Sedation Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting"
    ]
  },
  "dexpanthenol": {
    "ingredient": "dexpanthenol",
    "is_drug": true,
    "canonical_name": "dexpanthenol",
    "fda_search_term": "dexpanthenol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "BABYSONS",
      "Pediatric Infuvite Multiple Vitamins",
      "Vitamin B Complex"
    ],
    "generic_names": [
      "ASCORBIC ACID, VITAMIN A PALMITATE, CHOLECALCIFEROL, THIAMINE HYDROCHLORIDE, RIBOFLAVIN-5 PHOSPHATE SODIUM, PYRIDOXINE HYDROCHLORIDE, NIACINAMIDE, DEXPANTHENOL, ALPHA-TOCOPHEROL ACETATE, VITAMIN K1, FOLIC ACID, BIOTIN, CYANOCOBALAMIN",
      "DEXPANTHENOL",
      "THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE"
    ],
    "manufacturers": [
      "Laboratorios Quimica Son's, S.A. de C.V",
      "Mylan Institutional LLC",
      "Sandoz Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Anaphylactogenesis may occur with parenteral thiamine",
      "Use with caution",
      "An intradermal test dose is recommended prior to administration in patients suspected of being sensitive to the drug"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS A number of interactions between vitamins and drugs have been reported",
      "The following are examples of these types of interactions",
      "Effect of INFUVITE PEDIATRIC on other drugs :",
      "Antibiotics: Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin ( 7.1 )",
      "Bleomycin: Ascorbic acid and riboflavin may reduce the activity of bleomycin ( 7.1 )",
      "Levodopa: Pyridoxine may decrease blood levels of levodopa and levodopa efficacy may decrease ( 7.1 )",
      "Phenytoin: Folic acid may decrease phenytoin blood levels and increase risk of seizure activity ( 7.1 )",
      "Methotrexate: Folic acid may decrease response to methotrexate ( 7.1 ) Effects of other drugs on INFUVITE PEDIATRIC:",
      "Hydralazine, Isoniazid: Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements ( 7.2 )",
      "Phenytoin: May decrease folic acid concentrations ( 7.2 ) 7.1 Drug Interactions Affecting Co-administered Drugs Warfarin : Vitamin K, a component of INFUVITE PEDIATRIC, antagonizes the anticoagulant action of warfarin"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Mild transient diarrhea, polycythemia vera, peripheral vascular thrombosis, itching transitory exanthema, feeling of swelling of entire body, anaphylactic shock and death",
      "Sensitivity to the ingredients listed may occur (see WARNINGS )",
      "Use should be discontinued upon observance of any untoward reaction",
      "Pain upon intramuscular injection may be noted"
    ],
    "indications": [
      "INDICATIONS AND USAGE In disorders requiring parenteral administration of vitamins, i.e",
      "and post-operative treatment, when requirements are increased as in fever, severe burns, increased metabolism, pregnancy, gastrointestinal disorders interfering with intake or absorption of vitamins, prolonged or wasting diseases, alcoholism and where other deficiencies exist"
    ]
  },
  "dexrazoxane": {
    "ingredient": "dexrazoxane",
    "is_drug": true,
    "canonical_name": "dexrazoxane",
    "fda_search_term": "dexrazoxane",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dexrazoxane"
    ],
    "generic_names": [
      "DEXRAZOXANE",
      "DEXRAZOXANE FOR INJECTION"
    ],
    "manufacturers": [
      "Almaject, Inc.",
      "Hikma Pharmaceuticals USA Inc.",
      "Novadoz Pharmaceuticals LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS No drug interactions have been identified [see Clinical Pharmacology (12.3) ] "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS In clinical studies, dexrazoxane for injection was administered to patients also receiving chemotherapeutic agents for cancer",
      "Pain on injection was observed more frequently in patients receiving dexrazoxane for injection versus placebo",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc",
      "at 1-877-845-0689, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice",
      "The adverse reaction profile described in this section was identified from randomized, placebo",
      "controlled, double-blind studies in patients with metastatic breast cancer who received the combination of the FAC chemotherapy regimen with or without dexrazoxane for injection",
      "The dose of doxorubicin was 50 mg/m 2 in each of these trials",
      "Treatment was administered every three weeks until disease progression or cardiac toxicity",
      "Patients in clinical trials who received FAC with dexrazoxane for injection experienced more severe leukopenia, granulocytopenia, and thrombocytopenia than patients receiving FAC without dexrazoxane for injection [see Warnings and Precautions (5.1 )] ",
      "Table 1 below lists the incidence of adverse reactions for patients receiving FAC with either dexrazoxane for injection or placebo in the breast cancer studies",
      "Adverse experiences occurring during courses 1 through 6 are displayed for patients receiving dexrazoxane for injection or placebo with FAC beginning with their first course of therapy (columns 1 and 3, respectively)",
      "Adverse experiences occurring at course 7 and beyond for patients who received placebo with FAC during the first six courses and who then received either dexrazoxane for injection or placebo with FAC are also displayed (columns 2 and 4, respectively)",
      "The adverse reactions"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive do",
      "Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2 )] ",
      "Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive dox",
      "Do not use dexrazoxane for injection with doxorubicin initiation"
    ]
  },
  "dextran": {
    "ingredient": "dextran",
    "is_drug": true,
    "canonical_name": "dextran",
    "fda_search_term": "dextran",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Colirio Ocusan",
      "GoodSense Eye Drops Advanced Relief Moisturizer",
      "Sunmark Eye Drops Advanced Moisturizer/Lubricant"
    ],
    "generic_names": [
      "DEXTRAN, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE",
      "DEXTRAN, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HCL",
      "TETRAHYDROZOLINE HYDROCHLORIDE, POLYETHYLENE GLYCOL 400, POVIDONE, UNSPECIFIED, AND DEXTRAN 70"
    ],
    "manufacturers": [
      "DLC Laboratories, Inc.",
      "Preferred PHarmaceuticals Inc.",
      "Strategic Sourcing Services LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Ask a doctor before use if you have narrow angle glaucoma Stop use and ask a doctor if you experience",
      "changes in vision",
      "continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours When using this product",
      "pupils may become enlarged temporarily",
      "to avoid contamination, do not touch tip of container to any surface",
      "Replace cap after using",
      "if solution changed color or becomes cloudy, do not use",
      "overuse may produce increased redness of the eye",
      "remove contact lens before using If pregnant or breast-feeding , ask a health professional before use",
      "Keep out of reach of children"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "relieves redness of the eye due to minor eye irritations",
      "as a lubricant to prevent further irritation or to relieve dryness of the eye"
    ]
  },
  "dextrometh": {
    "ingredient": "dextrometh",
    "is_drug": true,
    "canonical_name": "dextromethorphan",
    "fda_search_term": "dextromethorphan",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Daytime Cold and Flu",
      "Rompe Pechito DM for Kids",
      "basic care daytime severe cold and flu"
    ],
    "generic_names": [
      "ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL",
      "ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, PHENYLEPHRINE HYDROCHLORIDE",
      "DEXTROMETHORPHAN HBR, GUAIFENESIN"
    ],
    "manufacturers": [
      "Amazon.com Services LLC",
      "Efficient Laboratories Inc",
      "Family Dollar (FAMILY WELLNESS)"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Liver warning: This product contains acetaminophen",
      "Severe liver damage may occur if you take: more than 4,000 mg of acetaminophen in 24 hours with other drugs containing acetaminophen 3 or more alcoholic drinks every day while using this product Allergy alert: Acetaminophen may cause severe skin reactions",
      "Symptoms may inclide: skin reddening blisters rash If a skin reaction occurs, stop use and seek medical help right away",
      "Sore throat warning: If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly",
      "Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease) or for 2 weeks after stopping the MAOI drug",
      "If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product",
      "with any other drug containing acetaminophen (prescription or non-prescription)",
      "If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist",
      "Ask a doctor before use if you have liver disease heart disease diabetes high blood pressure thyroid disease trouble urinating due to an enlarged prostate gland cough that occurs with too much phlegm (mucus) persistent or chronic cough such as occurs with smoking, asthma, or emphysema Ask a doctor o",
      "When using this product, do not exceed recommended dosage Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur pain, cough, or nasal congestion gets worse or lasts more than 7 days fever gets worse or lasts more than 3 days redness or swelling is present new symptoms occur cou"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses temporarily relieves these symptoms due to a cold minor aches and pains headache nasal and sinus congestion sore throat cough due to minor throat and bronchial irritation temporarily reduces fever"
    ]
  },
  "dextromethorphan": {
    "ingredient": "dextromethorphan",
    "is_drug": true,
    "canonical_name": "dextromethorphan",
    "fda_search_term": "dextromethorphan",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Daytime Cold and Flu",
      "Rompe Pechito DM for Kids",
      "basic care daytime severe cold and flu"
    ],
    "generic_names": [
      "ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL",
      "ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, PHENYLEPHRINE HYDROCHLORIDE",
      "DEXTROMETHORPHAN HBR, GUAIFENESIN"
    ],
    "manufacturers": [
      "Amazon.com Services LLC",
      "Efficient Laboratories Inc",
      "Family Dollar (FAMILY WELLNESS)"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Liver warning: This product contains acetaminophen",
      "Severe liver damage may occur if you take: more than 4,000 mg of acetaminophen in 24 hours with other drugs containing acetaminophen 3 or more alcoholic drinks every day while using this product Allergy alert: Acetaminophen may cause severe skin reactions",
      "Symptoms may inclide: skin reddening blisters rash If a skin reaction occurs, stop use and seek medical help right away",
      "Sore throat warning: If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly",
      "Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease) or for 2 weeks after stopping the MAOI drug",
      "If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product",
      "with any other drug containing acetaminophen (prescription or non-prescription)",
      "If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist",
      "Ask a doctor before use if you have liver disease heart disease diabetes high blood pressure thyroid disease trouble urinating due to an enlarged prostate gland cough that occurs with too much phlegm (mucus) persistent or chronic cough such as occurs with smoking, asthma, or emphysema Ask a doctor o",
      "When using this product, do not exceed recommended dosage Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur pain, cough, or nasal congestion gets worse or lasts more than 7 days fever gets worse or lasts more than 3 days redness or swelling is present new symptoms occur cou"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses temporarily relieves these symptoms due to a cold minor aches and pains headache nasal and sinus congestion sore throat cough due to minor throat and bronchial irritation temporarily reduces fever"
    ]
  },
  "dextromethorphan hydrobromide": {
    "ingredient": "dextromethorphan hydrobromide",
    "is_drug": true,
    "canonical_name": "dextromethorphan",
    "fda_search_term": "dextromethorphan",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Daytime Cold and Flu",
      "Rompe Pechito DM for Kids",
      "basic care daytime severe cold and flu"
    ],
    "generic_names": [
      "ACETAMINOPHEN, DEXTROMETHORPHAN HBR, PHENYLEPHRINE HCL",
      "ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, PHENYLEPHRINE HYDROCHLORIDE",
      "DEXTROMETHORPHAN HBR, GUAIFENESIN"
    ],
    "manufacturers": [
      "Amazon.com Services LLC",
      "Efficient Laboratories Inc",
      "Family Dollar (FAMILY WELLNESS)"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Liver warning: This product contains acetaminophen",
      "Severe liver damage may occur if you take: more than 4,000 mg of acetaminophen in 24 hours with other drugs containing acetaminophen 3 or more alcoholic drinks every day while using this product Allergy alert: Acetaminophen may cause severe skin reactions",
      "Symptoms may inclide: skin reddening blisters rash If a skin reaction occurs, stop use and seek medical help right away",
      "Sore throat warning: If sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly",
      "Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease) or for 2 weeks after stopping the MAOI drug",
      "If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product",
      "with any other drug containing acetaminophen (prescription or non-prescription)",
      "If you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist",
      "Ask a doctor before use if you have liver disease heart disease diabetes high blood pressure thyroid disease trouble urinating due to an enlarged prostate gland cough that occurs with too much phlegm (mucus) persistent or chronic cough such as occurs with smoking, asthma, or emphysema Ask a doctor o",
      "When using this product, do not exceed recommended dosage Stop use and ask a doctor if nervousness, dizziness, or sleeplessness occur pain, cough, or nasal congestion gets worse or lasts more than 7 days fever gets worse or lasts more than 3 days redness or swelling is present new symptoms occur cou"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses temporarily relieves these symptoms due to a cold minor aches and pains headache nasal and sinus congestion sore throat cough due to minor throat and bronchial irritation temporarily reduces fever"
    ]
  },
  "dextrose": {
    "ingredient": "dextrose",
    "is_drug": true,
    "canonical_name": "glucose",
    "fda_search_term": "glucose",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Discount Drug Mart nausea control Cherry Flavor",
      "Glucose Drops 2031",
      "The Melanin Skin Protectant Cream"
    ],
    "generic_names": [
      "DEXTROSE(GLUCOSE),LEVULOSE(FRUCTOSE),PHOSPHORIC ACID",
      "GLUCOSE DROPS",
      "PURIFIED WATER, GLYCERIN, PROPYLENE GLYCOL, LAUROCAPRAM, NIACINAMIDE, XANTHAN GUM, BUTYLENE GLYCOL, TOCOPHEROL, CETEARYL ALCOHOL, ISOHEXADECANE, ETHYLHEXYL PALMITATE, CAPRYLIC/CAPRIC TRIGLYCERIDE, HYDROGENATED LECITHIN, CETEARYL GLUCOSIDE, POLYACRYLAMIDE, C13-14 ISOPARAFFIN, 1,2-HEXANEDIOL, DISODIUM EDTA, ERGOTHIONEINE, SELAGINELLA TAMARISCINA EXTRACT, ETHYLHEXYLGLYCERIN, GLUCOSE, FRAGRANCE, GINKGO BILOBA LEAF EXTRACT, PRUNELLA VULGAIRS EXTRACT, CROTON LECHLERI RESIN EXTRACT"
    ],
    "manufacturers": [
      "DISCOUNT DRUG MART",
      "Professional Complementary Health Formulas",
      "Reedfresh Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings this product contains fructose and should not be taken by persons with hereditary fructose intolerance (HFI)",
      "Do not use if you have allergic reactions to any of the ingredients in this product Ask a doctor before use if you have diabetes Stop use and ask a doctor if symptoms persist, return or get worse If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "(1-800-222-1222)"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses for relief of upset stomach associated with nausea"
    ]
  },
  "dhea": {
    "ingredient": "dhea",
    "is_drug": true,
    "canonical_name": "dehydroepiandrosterone",
    "fda_search_term": "dehydroepiandrosterone",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hormone Combination",
      "Hormone Harmony",
      "Professional Weight Support"
    ],
    "generic_names": [
      "ACETALDEHYDE, DOPAMINE HYDROCHLORIDE, DHEA (DEHYDROEPIANDROSTERONE), 7-OXO- DEHYDROEPIANDROSTERONE 3-ACETATE, FOLLICULINUM, OOPHORINUM (SUIS), CHOLESTERINUM, PROGESTERONE, TESTOSTERONE, CORTISONE ACETICUM, ALDOSTERONE, ANDROSTERONE, FOLLICLE STIMULATING HORMONE",
      "ASCLEPIAS VINCETOXICUM, ECHINACEA (ANGUSTIFOLIA), HYPOTHALAMUS (SUIS), HEPAR SUIS, KIDNEY (SUIS), METHYLCOBALAMIN, GAMBOGIA, GRAPHITES, NUX VOMICA, PHYTOLACCA DECANDRA, 7-OXO-DEHYDROEPIANDROSTERONE 3B-ACETATE, ADENOSINUM TRIPHOSPHORICUM DINATRUM, INSULINUM (HUMAN), PANCREAS SUIS, SARCOLACTICUM ACIDUM, PROTEUS (VULGARIS)"
    ],
    "manufacturers": [
      "Deseret Biologicals",
      "Deseret Biologicals, Inc.",
      "Pro Weight Loss Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "If pregnant or breast-feeding, ask a healthcare professional before use",
      "Tamper seal: sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "HOMEOPATHIC INDICATIONS: Temporary relief of symptoms related to hormone imbalances of insufficiencies in men and women, including low energy, inability to handle stress, trouble focusing, changes in mood, infertility, irregular menstrual cycles (females), and lack of libido.** **These statements ar",
      "They have not been reviewed by the Food and Drug Administration"
    ]
  },
  "di methicone": {
    "ingredient": "di methicone",
    "is_drug": true,
    "canonical_name": "dimethicone",
    "fda_search_term": "dimethicone",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Baby XtraCare Oatmeal",
      "Gas Relief Ultra Strength"
    ],
    "generic_names": [
      "DIMETHICONE",
      "SIMETHICONE"
    ],
    "manufacturers": [
      "Rejoice International",
      "Walgreens"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For extenal use only",
      "When using this product avoid contact with eyes",
      "In case of eye contact, flush with water",
      "Stop use and ask a doctor if condition worsens",
      "Symptoms last more than 7days or clear up and occur again within a few days"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Baby XtraCare® Oatmeal Daily Moisturizing Lotion Lightly Scented Dimethicon Skin Protectant with Natural Oat Extract Helps Soothe & Soften Baby's Skin 12 FL OZ (354 mL)"
    ]
  },
  "diatrizoate meglumine": {
    "ingredient": "diatrizoate meglumine",
    "is_drug": true,
    "canonical_name": "diatrizoate",
    "fda_search_term": "diatrizoate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Cystografin",
      "Diatrizoate Meglumine and Diatrizoate Sodium",
      "Gastrografin"
    ],
    "generic_names": [
      "DIATRIZOATE MEGLUMINE",
      "DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM"
    ],
    "manufacturers": [
      "BRACCO DIAGNOSTICS INC",
      "Bracco Diagnostics Inc",
      "Camber Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Severe sensitivity reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents",
      "A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Retrograde genitourinary procedures may cause such complications as hematuria, perforation of the urethra or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria",
      "If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered",
      "Hypersensitivity or anaphylactoid reactions may occur",
      "Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs",
      "Endocrine: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants",
      "Some patients were treated for hypothyroidism"
    ],
    "indications": [
      "INDICATION Cystografin is indicated for retrograde cystourethrography"
    ]
  },
  "diatrizoate sodium": {
    "ingredient": "diatrizoate sodium",
    "is_drug": true,
    "canonical_name": "diatrizoate",
    "fda_search_term": "diatrizoate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Cystografin",
      "Diatrizoate Meglumine and Diatrizoate Sodium",
      "Gastrografin"
    ],
    "generic_names": [
      "DIATRIZOATE MEGLUMINE",
      "DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM"
    ],
    "manufacturers": [
      "BRACCO DIAGNOSTICS INC",
      "Bracco Diagnostics Inc",
      "Camber Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Severe sensitivity reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents",
      "A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Retrograde genitourinary procedures may cause such complications as hematuria, perforation of the urethra or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria",
      "If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered",
      "Hypersensitivity or anaphylactoid reactions may occur",
      "Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs",
      "Endocrine: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants",
      "Some patients were treated for hypothyroidism"
    ],
    "indications": [
      "INDICATION Cystografin is indicated for retrograde cystourethrography"
    ]
  },
  "diazepam": {
    "ingredient": "diazepam",
    "is_drug": true,
    "canonical_name": "diazepam",
    "fda_search_term": "diazepam",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Diazepam"
    ],
    "generic_names": [
      "DIAZEPAM"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Bryant Ranch Prepack"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepiones, including diazepam tablets, and opioids may result in profound sedation, respiratory depression, coma, and death",
      "Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate",
      "Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone",
      "If a decision is made to prescribe diazepam tablets concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation",
      "In patients already receiving an opioid analgesic, prescribe a lower initial dose of diazepam tablets than indicated in the absence of an opioid and titrate based on clinical response",
      "If an opioid is initiated in a patient already taking diazepam tablets, prescribe a lower initial dose of the opioid and titrate based upon clinical response",
      "Advise both patients and caregivers about the risks of respiratory depression and sedation when diazepam tablets are used with opioids",
      "Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see PRECAUTIONS: Drug Interactions )",
      "Abuse, Misuse, and Addiction The use of benzodiazepines, including diazepam tablets, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death",
      "Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, "
    ],
    "drug_interactions": [
      "Drug Interactions Opioids The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration",
      "Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors",
      "When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists",
      "Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation",
      "Centrally Acting Agents If diazepam tablets are to be combined with other centrally acting agents, careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of diazepam tablets, such as phenothiazi",
      "Alcohol Concomitant use with alcohol is not recommended due to enhancement of the sedative effect",
      "Antacids Diazepam peak concentrations are 30% lower when antacids are administered concurrently",
      "However, there is no effect on the extent of absorption",
      "The lower peak concentrations appear due to a slower rate of absorption, with the time required to achieve peak concentrations on average 20-25 minutes greater in the presence of antacids",
      "However, this difference was not statistically significant"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Side effects most commonly reported were drowsiness, fatigue, muscle weakness, and ataxia",
      "The following have also been reported: Central Nervous System: confusion, depression, dysarthria, headache, slurred speech, tremor, vertigo Gastrointestinal System: constipation, nausea, gastrointestinal disturbances Special Senses: blurred vision, diplopia, dizziness Cardiovascular System: hypotens",
      "Inappropriate behavior and other adverse behavioral effects have been reported when using benzodiazepines",
      "Should these occur, use of the drug should be discontinued",
      "They are more likely to occur in children and in the elderly",
      "Urogenital System: incontinence, changes in libido, urinary retention Skin and Appendages: skin reactions Laboratories: elevated transaminases and alkaline phosphatase Other: changes in salivation, including dry mouth, hypersalivation Antegrade amnesia may occur using therapeutic dosages, the risk i",
      "Amnestic effects may be associated with inappropriate behavior",
      "Minor changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after diazepam tablets therapy and are of no known significance",
      "Because of isolated reports of neutropenia and jaundice, periodic blood counts and liver function tests are advisable during long-term therapy",
      "Postmarketing Experience Injury, Poisoning and Procedural Complications There have been reports of falls and fractures in benzodiazepine users",
      "The risk is increased in those taking concomitant sedatives (including alcohol), and in the elderly"
    ],
    "indications": [
      "INDICATIONS AND USAGE Diazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety",
      "Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic",
      "In acute alcohol withdrawal, diazepam tablets may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis",
      "Diazepam tablets are a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stif",
      "Oral diazepam tablets may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy"
    ]
  },
  "diazolidinyl urea": {
    "ingredient": "diazolidinyl urea",
    "is_drug": true,
    "canonical_name": "diazolidinyl urea",
    "fda_search_term": "diazolidinyl urea",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Medi Fect Antiseptic Hand Wash"
    ],
    "generic_names": [
      "ETHYL ALCOHOL"
    ],
    "manufacturers": [
      "Medical Chemical Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: Flammable, keep away from fire or flame",
      "For external use only",
      "Do no use in the eyes",
      "Discontinue use if irritation or redness develops",
      "Keep out of reach of children",
      "In case of ingestion contact poison control center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Indications for use: For hospital and professional use only",
      "Medi-Fect is intended to be used as a hand-wash to reduce bacteria that can potentially cause disease",
      "Recommended for repeated use"
    ]
  },
  "diclofenac": {
    "ingredient": "diclofenac",
    "is_drug": true,
    "canonical_name": "diclofenac",
    "fda_search_term": "diclofenac",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ARTHRITIS PAIN RELIEVER",
      "Diclofenac Sodium",
      "Diclofenac sodium"
    ],
    "generic_names": [
      "DICLOFENAC SODIUM"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "H E B",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Allergy alert: Diclofenac may cause a severe allergic reaction, especially in people allergic to aspirin",
      "Symptoms may include: hives asthma (wheezing) skin reddening blisters facial swelling shock rash If an allergic reaction occurs, stop use and seek medical help right away",
      "Liver warning: This product contains diclofenac",
      "Liver damage may occur if you apply more or for a longer time than directed when using other drugs containing diclofenac Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding",
      "The chance is small but higher if you are age 60 or older have had stomach ulcers or bleeding problems take a blood thinning (anticoagulant) or steroid drug take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others) have 3 or more alcoholic drinks ev",
      "These can be fatal",
      "The risk is higher if you use more than directed or for longer than directed",
      "Do not use if you have ever had an allergic reaction to any other pain reliever or to a fever reducer for strains, sprains, bruises or sports injuries",
      "This product has not been shown to work for these types of injuries",
      "right before or after heart surgery on more than 2 body areas at the same time in the eyes, nose or mouth Ask a doctor before us if you have problems or serious side effects from taking pain relievers or fever reducers stomach bleeding warning applies to you you have a history of stomach problems, s"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 3 for clinically significant drug interactions with diclofenac",
      "Table 3: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of diclofenac and anticoagulants have increased the risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of diclofenac sodium topical solution with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Wa",
      "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions ( 5.2 )] Intervention: Concomitant use of diclofenac sodium topical solution and analge",
      "Diclofenac sodium topical solution is not a substitute for low dose aspirin for cardiovascular protection",
      "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ] GI Bleeding, Ulceration and Perforation [ see Warnings and Precautions ( 5.2 ) ] Hepatotoxicity [ see Warni",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc",
      "at 1-866-210-9797or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Diclofenac Sodium Topical Solution The data described below reflect exposure to diclofenac sodium topical solution of 130 patients treated for 4 weeks (mean duration of 28 days) in one Phase 2 controlled trial",
      "This population's mean age was approximately 60 years, 85% of patients were Caucasian, 65% were females, and all patients had primary osteoarthritis",
      "The most common adverse events with diclofenac sodium topical solution were application site skin reactions",
      "These events were the most common reason for withdrawing from the study",
      "Application Site Reactions: In this controlled trial, application site reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%"
    ],
    "indications": [
      "Uses for the temporary relief of arthritis pain ONLY in the following areas: hand, wrist, elbow (upper body areas) foot, ankle, knee (lower body areas) this product may take up to 7 days to work for arthritis pain; it is not for immediate relief",
      "If no pain relief in 7 days, stop use"
    ]
  },
  "diclofenac diethylamine": {
    "ingredient": "diclofenac diethylamine",
    "is_drug": true,
    "canonical_name": "diclofenac",
    "fda_search_term": "diclofenac",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ARTHRITIS PAIN RELIEVER",
      "Diclofenac Sodium",
      "Diclofenac sodium"
    ],
    "generic_names": [
      "DICLOFENAC SODIUM"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "H E B",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Allergy alert: Diclofenac may cause a severe allergic reaction, especially in people allergic to aspirin",
      "Symptoms may include: hives asthma (wheezing) skin reddening blisters facial swelling shock rash If an allergic reaction occurs, stop use and seek medical help right away",
      "Liver warning: This product contains diclofenac",
      "Liver damage may occur if you apply more or for a longer time than directed when using other drugs containing diclofenac Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding",
      "The chance is small but higher if you are age 60 or older have had stomach ulcers or bleeding problems take a blood thinning (anticoagulant) or steroid drug take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others) have 3 or more alcoholic drinks ev",
      "These can be fatal",
      "The risk is higher if you use more than directed or for longer than directed",
      "Do not use if you have ever had an allergic reaction to any other pain reliever or to a fever reducer for strains, sprains, bruises or sports injuries",
      "This product has not been shown to work for these types of injuries",
      "right before or after heart surgery on more than 2 body areas at the same time in the eyes, nose or mouth Ask a doctor before us if you have problems or serious side effects from taking pain relievers or fever reducers stomach bleeding warning applies to you you have a history of stomach problems, s"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 3 for clinically significant drug interactions with diclofenac",
      "Table 3: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of diclofenac and anticoagulants have increased the risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of diclofenac sodium topical solution with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Wa",
      "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions ( 5.2 )] Intervention: Concomitant use of diclofenac sodium topical solution and analge",
      "Diclofenac sodium topical solution is not a substitute for low dose aspirin for cardiovascular protection",
      "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ] GI Bleeding, Ulceration and Perforation [ see Warnings and Precautions ( 5.2 ) ] Hepatotoxicity [ see Warni",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc",
      "at 1-866-210-9797or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Diclofenac Sodium Topical Solution The data described below reflect exposure to diclofenac sodium topical solution of 130 patients treated for 4 weeks (mean duration of 28 days) in one Phase 2 controlled trial",
      "This population's mean age was approximately 60 years, 85% of patients were Caucasian, 65% were females, and all patients had primary osteoarthritis",
      "The most common adverse events with diclofenac sodium topical solution were application site skin reactions",
      "These events were the most common reason for withdrawing from the study",
      "Application Site Reactions: In this controlled trial, application site reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%"
    ],
    "indications": [
      "Uses for the temporary relief of arthritis pain ONLY in the following areas: hand, wrist, elbow (upper body areas) foot, ankle, knee (lower body areas) this product may take up to 7 days to work for arthritis pain; it is not for immediate relief",
      "If no pain relief in 7 days, stop use"
    ]
  },
  "diclofenac potassium": {
    "ingredient": "diclofenac potassium",
    "is_drug": true,
    "canonical_name": "diclofenac",
    "fda_search_term": "diclofenac",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ARTHRITIS PAIN RELIEVER",
      "Diclofenac Sodium",
      "Diclofenac sodium"
    ],
    "generic_names": [
      "DICLOFENAC SODIUM"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "H E B",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Allergy alert: Diclofenac may cause a severe allergic reaction, especially in people allergic to aspirin",
      "Symptoms may include: hives asthma (wheezing) skin reddening blisters facial swelling shock rash If an allergic reaction occurs, stop use and seek medical help right away",
      "Liver warning: This product contains diclofenac",
      "Liver damage may occur if you apply more or for a longer time than directed when using other drugs containing diclofenac Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding",
      "The chance is small but higher if you are age 60 or older have had stomach ulcers or bleeding problems take a blood thinning (anticoagulant) or steroid drug take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others) have 3 or more alcoholic drinks ev",
      "These can be fatal",
      "The risk is higher if you use more than directed or for longer than directed",
      "Do not use if you have ever had an allergic reaction to any other pain reliever or to a fever reducer for strains, sprains, bruises or sports injuries",
      "This product has not been shown to work for these types of injuries",
      "right before or after heart surgery on more than 2 body areas at the same time in the eyes, nose or mouth Ask a doctor before us if you have problems or serious side effects from taking pain relievers or fever reducers stomach bleeding warning applies to you you have a history of stomach problems, s"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 3 for clinically significant drug interactions with diclofenac",
      "Table 3: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of diclofenac and anticoagulants have increased the risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of diclofenac sodium topical solution with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Wa",
      "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions ( 5.2 )] Intervention: Concomitant use of diclofenac sodium topical solution and analge",
      "Diclofenac sodium topical solution is not a substitute for low dose aspirin for cardiovascular protection",
      "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ] GI Bleeding, Ulceration and Perforation [ see Warnings and Precautions ( 5.2 ) ] Hepatotoxicity [ see Warni",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc",
      "at 1-866-210-9797or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Diclofenac Sodium Topical Solution The data described below reflect exposure to diclofenac sodium topical solution of 130 patients treated for 4 weeks (mean duration of 28 days) in one Phase 2 controlled trial",
      "This population's mean age was approximately 60 years, 85% of patients were Caucasian, 65% were females, and all patients had primary osteoarthritis",
      "The most common adverse events with diclofenac sodium topical solution were application site skin reactions",
      "These events were the most common reason for withdrawing from the study",
      "Application Site Reactions: In this controlled trial, application site reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%"
    ],
    "indications": [
      "Uses for the temporary relief of arthritis pain ONLY in the following areas: hand, wrist, elbow (upper body areas) foot, ankle, knee (lower body areas) this product may take up to 7 days to work for arthritis pain; it is not for immediate relief",
      "If no pain relief in 7 days, stop use"
    ]
  },
  "diclofenac sodium": {
    "ingredient": "diclofenac sodium",
    "is_drug": true,
    "canonical_name": "diclofenac",
    "fda_search_term": "diclofenac",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ARTHRITIS PAIN RELIEVER",
      "Diclofenac Sodium",
      "Diclofenac sodium"
    ],
    "generic_names": [
      "DICLOFENAC SODIUM"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "H E B",
      "NuCare Pharmaceuticals,Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Allergy alert: Diclofenac may cause a severe allergic reaction, especially in people allergic to aspirin",
      "Symptoms may include: hives asthma (wheezing) skin reddening blisters facial swelling shock rash If an allergic reaction occurs, stop use and seek medical help right away",
      "Liver warning: This product contains diclofenac",
      "Liver damage may occur if you apply more or for a longer time than directed when using other drugs containing diclofenac Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding",
      "The chance is small but higher if you are age 60 or older have had stomach ulcers or bleeding problems take a blood thinning (anticoagulant) or steroid drug take other drugs containing prescription or nonprescription NSAIDs (aspirin, ibuprofen, naproxen, or others) have 3 or more alcoholic drinks ev",
      "These can be fatal",
      "The risk is higher if you use more than directed or for longer than directed",
      "Do not use if you have ever had an allergic reaction to any other pain reliever or to a fever reducer for strains, sprains, bruises or sports injuries",
      "This product has not been shown to work for these types of injuries",
      "right before or after heart surgery on more than 2 body areas at the same time in the eyes, nose or mouth Ask a doctor before us if you have problems or serious side effects from taking pain relievers or fever reducers stomach bleeding warning applies to you you have a history of stomach problems, s"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 3 for clinically significant drug interactions with diclofenac",
      "Table 3: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of diclofenac and anticoagulants have increased the risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of diclofenac sodium topical solution with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Wa",
      "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions ( 5.2 )] Intervention: Concomitant use of diclofenac sodium topical solution and analge",
      "Diclofenac sodium topical solution is not a substitute for low dose aspirin for cardiovascular protection",
      "ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers Clinical Impact: NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ] GI Bleeding, Ulceration and Perforation [ see Warnings and Precautions ( 5.2 ) ] Hepatotoxicity [ see Warni",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc",
      "at 1-866-210-9797or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Diclofenac Sodium Topical Solution The data described below reflect exposure to diclofenac sodium topical solution of 130 patients treated for 4 weeks (mean duration of 28 days) in one Phase 2 controlled trial",
      "This population's mean age was approximately 60 years, 85% of patients were Caucasian, 65% were females, and all patients had primary osteoarthritis",
      "The most common adverse events with diclofenac sodium topical solution were application site skin reactions",
      "These events were the most common reason for withdrawing from the study",
      "Application Site Reactions: In this controlled trial, application site reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%"
    ],
    "indications": [
      "Uses for the temporary relief of arthritis pain ONLY in the following areas: hand, wrist, elbow (upper body areas) foot, ankle, knee (lower body areas) this product may take up to 7 days to work for arthritis pain; it is not for immediate relief",
      "If no pain relief in 7 days, stop use"
    ]
  },
  "dicloxacillin": {
    "ingredient": "dicloxacillin",
    "is_drug": true,
    "canonical_name": "dicloxacillin",
    "fda_search_term": "dicloxacillin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dicloxacillin Sodium"
    ],
    "generic_names": [
      "DICLOXACILLIN SODIUM"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Bryant Ranch Prepack",
      "PD-Rx Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have occurred in patients receiving penicillin",
      "The incidence of anaphylactic shock in all penicillin-treated patients is between 0.015% and 0.04%",
      "Anaphylactic shock resulting in death has occurred in approximately 0.002% of the patients treated",
      "Although anaphylaxis is more frequent following a parenteral administration, it has occurred in patients receiving oral penicillins",
      "When penicillin therapy is indicated, it should be initiated only after a comprehensive patient drug and allergy history has been obtained",
      "If an allergic reaction occurs, dicloxacillin should be discontinued and appropriate therapy instituted",
      "Individuals with a history of penicillin hypersensitivity may also experience allergic reactions when treated with a cephalosporin",
      "Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including dicloxacillin sodium, and may range in severity from mild diarrhea to fatal colitis",
      "Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C",
      "difficile produces toxins A and B which contribute to the development of CDAD"
    ],
    "drug_interactions": [
      "Drug Interactions Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided",
      "Probenecid administered concomitantly with penicillins increases and prolongs serum penicillin levels (see DOSAGE AND ADMINISTRATION )",
      "Penicillinase-resistant penicillins, like other penicillins, are physically and/or chemically incompatible with aminoglycosides and can inactivate the drugs in vitro",
      "In vitro mixing of penicillins and aminoglycosides should be avoided during concomitant therapy and the drugs should be administered separately",
      "Penicillins can inactivate aminoglycosides in vitro in serum samples from patients receiving both drugs, which could produce falsely decreased results in serum aminoglycoside assays of the serum samples",
      "Dicloxacillin may reduce the anticoagulant response to dicumarol and warfarin",
      "Careful monitoring of prothrombin times is suggested during concomitant therapy, and dosage of the anticoagulant should be adjusted as required",
      "The mechanism of this possible interaction is unclear, but may be due to hepatic enzyme induction"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Hypersensitive Reactions The reported incidence of allergic reactions to penicillin ranges from 0.7% to 10% (see WARNINGS )",
      "Sensitization is usually the result of treatment, but some individuals have had immediate reactions to penicillin when first treated",
      "In such cases, it is thought that the patients may have had prior exposure to the drug via trace amounts present in milk and vaccines",
      "Two types of allergic reactions to penicillin are noted clinically, immediate and delayed",
      "Immediate reactions usually occur within 20 minutes of administration and range in severity from urticaria and pruritus to angioneurotic edema, laryngospasm, bronchospasm, hypotension, vascular collapse and death",
      "Such immediate anaphylactic reactions are very rare (see WARNINGS ) and usually occur after parenteral therapy, but have occurred in patients receiving oral therapy",
      "Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 48 hours after administration and may include urticaria, pruritus and fever",
      "Although laryngeal edema, laryngospasm and hypotension occasionally occur, fatality is uncommon",
      "Delayed allergic reactions to penicillin therapy usually occur after 48 hours and sometimes as late as two to four weeks after initiation of therapy",
      "Manifestations of this type of reaction include serum sickness-like symptoms (i.e., fever, malaise, urticaria, myalgia, arthralgia, abdominal pain) and various skin rashes",
      "Gastrointestinal Reactions Nausea, vomiting, diarrhea, stomatitis, black or hairy tongue and other symptoms of gastrointestinal irritation may occur, especially during oral penicillin therapy",
      "Pseudomembranous colitis has been reported with the use of dicloxacillin",
      "Therefore, it is important to consider its diagnosis in patients who develop diarrhea in association with dicloxacillin use",
      "Reports have been received during postmarketing surveillance of esophageal burning, esophagitis, and esophageal ulceration, particular"
    ],
    "indications": [
      "INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be cause",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug",
      "Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Testing ) "
    ]
  },
  "dicyclomine": {
    "ingredient": "dicyclomine",
    "is_drug": true,
    "canonical_name": "dicyclomine",
    "fda_search_term": "dicyclomine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DICYCLOMINE HYDROCHLORIDE",
      "Dicyclomine Hydrochloride",
      "Dicyclomine hydrochloride"
    ],
    "generic_names": [
      "DICYCLOMINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Bionpharma Inc.",
      "Golden State Medical Supply, Inc.",
      "Rising Pharma Holdings, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Antiglaucoma agents : anticholinergics antagonize antiglaucoma agents and may increase intraoccular pressure (7) Anticholinergic agents : may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs ",
      "Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids",
      "Use of dicyclomine hydrochloride in patients with glaucoma is not recommended [see Contraindications (4) ]",
      "7.2 Other Drugs with Anticholinergic Activity The following agents may increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), b",
      "7.3 Other Gastrointestinal Motility Drugs Interaction with other gastrointestinal motility drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide",
      "7.4 Effect of Antacids Because antacids may interfere with the absorption of anticholinergic agents including dicyclomine hydrochloride, simultaneous use of these drugs should be avoided",
      "7.5 Effect on Absorption of Other Drugs Anticholinergic agents may affect gastrointestinal absorption of various drugs by affecting on gastrointestinal motility, such as slowly dissolving dosage forms of digoxin; increased serum digoxin concentration may result",
      "7.6 Effect on Gastric Acid Secretion The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonize"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The pattern of adverse effects seen with dicyclomine is mostly related to its pharmacological actions at muscarinic receptors [see Clinical Pharmacology (12) ] ",
      "They are a consequence of the inhibitory effect on muscarinic receptors within the autonomic nervous system",
      "These effects are dose-related and are usually reversible when treatment is discontinued",
      "The most serious adverse reactions reported with dicyclomine hydrochloride include cardiovascular and central nervous system symptoms [see Warnings and Precautions (5.2, 5.3) ]",
      "The most serious adverse reactions include cardiovascular and central nervous system symptoms",
      "The most common adverse reactions (> 5% of patients) are dizziness, dry mouth, vision blurred, nausea, somnolence, asthenia and nervousness (6) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc",
      "at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.com 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of",
      "The data described below reflect exposure in controlled clinical trials involving over 100 patients treated for functional bowel/irritable bowel syndrome with dicyclomine hydrochloride at initial doses of 160 mg daily (40 mg four times a day)",
      "In these trials most of the side effects were typically anticholinergic in nature and were reported by 61% of the patients",
      "Table 1 presents adverse reactions ( MedDRA 13.0 preferred terms) by decreasing order of frequency in a side-by-side comparison with placebo",
      "Table 1: Adverse reactions experienced in controlled clinical trials with decreasing order of frequency MedDRA Preferred Term Dicyclomine Hydrochloride(40 mg four times a day) % Placebo % Dry Mouth 33 5 Dizziness 40 5 Vision blurred 27 2 Nausea 14"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Dicyclomine hydrochloride capsules, USP are indicated for the treatment of patients with functional bowel/irritable bowel syndrome",
      "Dicyclomine hydrochloride capsules, USP are an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome (1)"
    ]
  },
  "diemthicone": {
    "ingredient": "diemthicone",
    "is_drug": true,
    "canonical_name": "dimethicone",
    "fda_search_term": "dimethicone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Baby XtraCare Oatmeal",
      "Gas Relief Ultra Strength"
    ],
    "generic_names": [
      "DIMETHICONE",
      "SIMETHICONE"
    ],
    "manufacturers": [
      "Rejoice International",
      "Walgreens"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For extenal use only",
      "When using this product avoid contact with eyes",
      "In case of eye contact, flush with water",
      "Stop use and ask a doctor if condition worsens",
      "Symptoms last more than 7days or clear up and occur again within a few days"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Baby XtraCare® Oatmeal Daily Moisturizing Lotion Lightly Scented Dimethicon Skin Protectant with Natural Oat Extract Helps Soothe & Soften Baby's Skin 12 FL OZ (354 mL)"
    ]
  },
  "dienogest": {
    "ingredient": "dienogest",
    "is_drug": true,
    "canonical_name": "dienogest",
    "fda_search_term": "dienogest",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Estradiol Valerate and Estradiol Valerate/Dienogest",
      "Natazia"
    ],
    "generic_names": [
      "ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST"
    ],
    "manufacturers": [
      "Bayer HealthCare Pharmaceuticals Inc.",
      "Sandoz Inc"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations ",
      "Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of COCs or increase breakthrough bleeding",
      "Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs",
      "( 7.1 ) 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Dienogest is a substrate of CYP3A4",
      "Women who take medications that are strong CYP3A4 inducers should not choose Natazia as their oral contraceptive while using these inducers and for at least 28 days after discontinuation of these inducers due to the possibility of increased breakthrough bleeding and/or decreased contraceptive effica",
      "Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding",
      "Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St",
      "Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure",
      "Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability",
      "Multiple dose co-administration of the strong CYP3A4 inducer rifampin with estradiol valerate/dienogest tablets in healthy postmenopausal women led to a decrease in dienogest and estradiol systemic exposure at steady state"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling:",
      "Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ( 5.1 )]",
      "Vascular events [see Warnings and Precautions ( 5.1 )]",
      "Liver disease [see Warnings and Precautions ( 5.3 )] Adverse reactions commonly reported by COC users are:",
      "Irregular uterine bleeding",
      "Breast tenderness",
      "Headache The most common adverse reactions (≥ 2%) in clinical trials for Natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea/vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc",
      "at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of ano",
      "Contraception and Heavy Menstrual Bleeding Studies A total of 2,131 women, 18 to 54 years of age, who took at least one dose of Natazia were enrolled in four clinical phase 3 trials",
      "A total of 1,867 subjects were included in two clinical phase 3 studies with a treatment duration up to 28 cycles with Natazia as an oral contraceptive and 264 subjects in the two phase 3 clinical trials with a treatment duration of 7 cycles evaluating Natazia in the treatment of heavy, prolonged, a",
      "Adverse Reactions Leading to Study Discontinuation : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregula"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE",
      "Natazia is a combination of dienogest , a progestin, and estradiol valerate, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy",
      "The efficacy of Natazia in females of reproductive potential with a body mass index (BMI) of >30 kg/m 2 has not been evaluated",
      "Treatment of heavy menstrual bleeding in females of reproductive potential without organic pathology who choose to use an oral contraceptive as their method of contraception",
      "( 1.2 ) 1.1 Oral Contraception Natazia ® is indicated for use by women to prevent pregnancy"
    ]
  },
  "diethylamine salicylate": {
    "ingredient": "diethylamine salicylate",
    "is_drug": true,
    "canonical_name": "salicylic acid",
    "fda_search_term": "salicylic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CeraVe Developed with Dermatologists Acne Control Cleanser",
      "Clear Acne Spot Treatment",
      "Quick Action"
    ],
    "generic_names": [
      "ACNE SPOT TREATMENT",
      "SALICYLIC ACID"
    ],
    "manufacturers": [
      "Kamedis",
      "L'Oreal USA Products Inc",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTION Information: 1-888-287-1915 or Walmart.com/help DISTRIBUTED BY: Walmart Inc., Bentonville, AR 72716 PLASTIC TUBE Do Not Recycle how2recycle.info Made in the USA with domestic and imported ingredients",
      "Factory Certified"
    ],
    "indications": [
      "Use for the treatment of acne"
    ]
  },
  "diflucortolone valerate": {
    "ingredient": "diflucortolone valerate",
    "is_drug": true,
    "canonical_name": "diflucortolone valerate",
    "fda_search_term": "diflucortolone valerate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Natazia"
    ],
    "generic_names": [
      "ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST"
    ],
    "manufacturers": [
      "Bayer HealthCare Pharmaceuticals Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS FLAMMABLE",
      "AVOID FIRE, FLAME OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION",
      "Keep out of reach of children",
      "Contents under pressure",
      "Do not puncture or incinerate container",
      "Do not expose to heat or store at temperatures above 120°F (49°C)",
      "Manufactured for Stiefel Laboratories, Inc",
      "Research Triangle Park, NC 27709 Made in Italy For additional information visit www.luxiq.com Questions: Call 1-888-784-3335 (1-888-STIEFEL)",
      "Side effects should be reported to this number",
      "P/N: LUXIQ is a registered trademark of Stiefel Laboratories, Inc"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations ",
      "Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of COCs or increase breakthrough bleeding",
      "Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs",
      "( 7.1 ) 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Dienogest is a substrate of CYP3A4",
      "Women who take medications that are strong CYP3A4 inducers should not choose Natazia as their oral contraceptive while using these inducers and for at least 28 days after discontinuation of these inducers due to the possibility of increased breakthrough bleeding and/or decreased contraceptive effica",
      "Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding",
      "Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St",
      "Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure",
      "Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability",
      "Multiple dose co-administration of the strong CYP3A4 inducer rifampin with estradiol valerate/dienogest tablets in healthy postmenopausal women led to a decrease in dienogest and estradiol systemic exposure at steady state"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings",
      "These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae"
    ],
    "indications": [
      "INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of cortico-steroid-responsive dermatoses"
    ]
  },
  "diflucortrolone valerate": {
    "ingredient": "diflucortrolone valerate",
    "is_drug": true,
    "canonical_name": "diflucortolone valerate",
    "fda_search_term": "diflucortolone valerate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Natazia"
    ],
    "generic_names": [
      "ESTRADIOL VALERATE AND ESTRADIOL VALERATE/DIENOGEST"
    ],
    "manufacturers": [
      "Bayer HealthCare Pharmaceuticals Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS FLAMMABLE",
      "AVOID FIRE, FLAME OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION",
      "Keep out of reach of children",
      "Contents under pressure",
      "Do not puncture or incinerate container",
      "Do not expose to heat or store at temperatures above 120°F (49°C)",
      "Manufactured for Stiefel Laboratories, Inc",
      "Research Triangle Park, NC 27709 Made in Italy For additional information visit www.luxiq.com Questions: Call 1-888-784-3335 (1-888-STIEFEL)",
      "Side effects should be reported to this number",
      "P/N: LUXIQ is a registered trademark of Stiefel Laboratories, Inc"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations ",
      "Drugs or herbal products that induce certain enzymes (for example, CYP3A4) may decrease the effectiveness of COCs or increase breakthrough bleeding",
      "Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs",
      "( 7.1 ) 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substances diminishing the efficacy of COCs: Dienogest is a substrate of CYP3A4",
      "Women who take medications that are strong CYP3A4 inducers should not choose Natazia as their oral contraceptive while using these inducers and for at least 28 days after discontinuation of these inducers due to the possibility of increased breakthrough bleeding and/or decreased contraceptive effica",
      "Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding",
      "Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampin, topiramate and products containing St",
      "Interactions between oral contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure",
      "Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability",
      "Multiple dose co-administration of the strong CYP3A4 inducer rifampin with estradiol valerate/dienogest tablets in healthy postmenopausal women led to a decrease in dienogest and estradiol systemic exposure at steady state"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings",
      "These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae"
    ],
    "indications": [
      "INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of cortico-steroid-responsive dermatoses"
    ]
  },
  "diflunisal": {
    "ingredient": "diflunisal",
    "is_drug": true,
    "canonical_name": "diflunisal",
    "fda_search_term": "diflunisal",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Diflunisal",
      "diflunisal"
    ],
    "generic_names": [
      "DIFLUNISAL"
    ],
    "manufacturers": [
      "Chartwell RX, LLC",
      "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.",
      "Zydus Pharmaceuticals (USA) Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Cardiovascular Effects Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can ",
      "Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs",
      "The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease",
      "However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate",
      "Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment",
      "The increase in CV thrombotic risk has been observed most consistently at higher doses",
      "To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible",
      "Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms",
      "Patients should be informed about the symptoms of serious CV events and the steps to take if they occur",
      "There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use"
    ],
    "drug_interactions": [
      "Drug Interactions ACE-inhibitors and Angiotensin II Anagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists",
      "These interactions should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors or angiotensin II antagonists",
      "In some patients with compromised renal function, the coadministration of an NSAID and an ACE-inhibitor or an angiotensin II antagonist may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible",
      "Acetaminophen In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen",
      "Acetaminophen had no effect on plasma levels of diflunisal",
      "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal tablets and acetaminophen should be used cautiously, with careful monitoring of patients",
      "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen), resulted in greater gastrointestinal toxicity than when either drug was administered ",
      "The clinical significance of these findings has not been established",
      "Antacids Concomitant administration of antacids may reduce plasma levels of diflunisal",
      "This effect is small with occasional doses of antacids, but may be clinically significant when antacids are used on a continuous schedule"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The adverse reactions observed in controlled clinical trials encompass observations in 2,427 patients",
      "Listed below are the adverse reactions reported in the 1,314 of these patients who received treatment in studies of two weeks or longer",
      "Five hundred thirteen patients were treated for at least 24 weeks, 255 patients were treated for at least 48 weeks, and 46 patients were treated for 96 weeks",
      "In general, the adverse reactions listed below were 2 to 14 times less frequent in the 1,113 patients who received short-term treatment for mild to moderate pain",
      "Incidence Greater Than 1% Gastrointestinal The most frequent types of adverse reactions occurring with diflunisal are gastrointestinal: these include nausea*, vomiting, dyspepsia*, gastrointestinal pain*, diarrhea*, constipation, and flatulence",
      "Psychiatric Somnolence, insomnia",
      "Central Nervous System Dizziness",
      "Special Senses Tinnitus",
      "Dermatologic Rash*",
      "Miscellaneous Headache*, fatigue/tiredness",
      "* Incidence between 3% and 9%",
      "Those reactions occurring in 1% to 3% are not marked with an asterisk",
      "Incidence Less Than 1 in 100 The following adverse reactions, occurring less frequently than 1 in 100, were reported in clinical trials or since the drug was marketed",
      "The probability exists of a causal relationship between diflunisal and these adverse reactions",
      "Dermatologic Erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria, pruritus, sweating, dry mucous membranes, stomatitis, photosensitivity"
    ],
    "indications": [
      "INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets",
      "Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS )",
      "Diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: Mild to moderate pain Osteoarthritis Rheumatoid arthritis"
    ]
  },
  "difluprednate": {
    "ingredient": "difluprednate",
    "is_drug": true,
    "canonical_name": "difluprednate",
    "fda_search_term": "difluprednate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DIFLUPREDNATE",
      "Difluprednate",
      "Difluprednate Ophthalmic"
    ],
    "generic_names": [
      "DIFLUPREDNATE",
      "DIFLUPREDNATE OPHTHALMIC"
    ],
    "manufacturers": [
      "Caplin Steriles Limited",
      "Leading Pharma, LLC",
      "Sandoz Inc"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious reactions are found elsewhere in the labeling: Elevated intraocular pressure [see Warnings and Precautions (5.1) ] Posterior subcapsular cataract formation [see Warnings and Precautions (5.2) ] Secondary ocular infection [see Warnings and Precautions (5.4) ]",
      "Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis",
      "Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis",
      "Most of these reactions may have been the consequence of the surgical procedure",
      "6.2 Endogenous Anterior Uveitis A total of 200 subjects participated in the clinical trials for endogenous anterior uveitis, of which 106 were exposed to difluprednate ophthalmic emulsion",
      "The most common adverse reactions of those exposed to difluprednate ophthalmic emulsion occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis",
      "Adverse reactions occurring in 2-5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Difluprednate ophthalmic emulsion is a topical corticosteroid that is indicated for: The treatment of inflammation and pain associated with ocular surgery (1.1) The treatment of endogenous anterior uveitis (1.2) 1.1 Ocular Surgery Difluprednate ophthalmic emulsion 0.05%, a to",
      "1.2 Endogenous Anterior Uveitis Difluprednate ophthalmic emulsion is also indicated for the treatment of endogenous anterior uveitis"
    ]
  },
  "digezyme": {
    "ingredient": "digezyme",
    "is_drug": true,
    "canonical_name": "pancrelipase",
    "fda_search_term": "pancrelipase",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Creon",
      "FESTAL PLUS",
      "OHM Pancreas Aid"
    ],
    "generic_names": [
      "CELLULASE AP3 , PANCREATIN, SIMETHICONE",
      "HELONIAS DIOICA, LACTICUM ACIDUM, PANCREAS SUIS, PANCREATINUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, SYZYGIUM JAMBOLANUM, THYROIDINUM, URANIUM NITRICUM.",
      "PANCRELIPASE"
    ],
    "manufacturers": [
      "AbbVie Inc.",
      "Lydia Co., Ltd.",
      "OHM PHARMA INC."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: IF PREGNANT OR BREAST-FEEDING, ask a health professional before use",
      "If symptoms worsen or persist for more than a week, discontinue use and contact a doctor",
      "​KEEP OUT OF REACH OF CHILDREN"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious or otherwise important adverse reactions are described elsewhere in the labeling: Fibrosing Colonopathy [see Warnings and Precautions ( 5.1 )] Irritation of the Oral Mucosa [see Warnings and Precautions ( 5.2 )] Hyperuricemia [see Warnings and Precautions ( ",
      "4 months to 6 years (6%): vomiting, irritability, decreased appetite",
      "C hronic pancreatitis or pancreatectomy patient s: Adults (≥ 4%): hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, nasopharyngitis",
      "To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc",
      "at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The data described below reflect exposure to CREON in 92 patients: 67 patients aged 4 months to 43 years with exocrine pancreatic insufficiency due to cystic fibrosis (Studies 1, 2, and 3) and 25 adults with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy (Study 4) [s",
      "Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis in Adult and Pediatric Patients Adult and Pediatric Patients 7 Years of Age and Older The most common adverse reactions, reported in at least 2 CREON-treated patients (greater than or equal to 4%) and at a higher rate than in placebo-treated p"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE CREON ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients",
      "CREON is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients"
    ]
  },
  "digoxin": {
    "ingredient": "digoxin",
    "is_drug": true,
    "canonical_name": "digoxin",
    "fda_search_term": "digoxin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Digoxin"
    ],
    "generic_names": [
      "DIGOXIN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Bryant Ranch Prepack",
      "Hikma Pharmaceuticals USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Digoxin has a narrow therapeutic index, increased monitoring of serum digoxin concentrations and for potential signs and symptoms of clinical toxicity is necessary when initiating, adjusting, or discontinuing drugs that may interact with digoxin",
      "Prescribers should consult the prescribing information of any drug which is co-prescribed with digoxin for potential drug interaction information",
      "PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics",
      "( 7.1 ) The potential for drug-drug interactions must be considered prior to and during drug therapy",
      "See full prescribing information",
      "( 7.2 , 7.3 , 12.3 ) 7.1 P-Glycoprotein (PGP) Inducers/Inhibitors Digoxin is a substrate of P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary–intestinal secretion",
      "Therefore, drugs that induce/inhibit P-glycoprotein have the potential to alter digoxin pharmacokinetics",
      "7.2 Pharmacokinetic Drug Interactions Digoxin concentrations increased greater than 50% Digoxin Serum Concentration Increase Digoxin AUC Increase Recommendations Amiodarone 70% NA Measure serum digoxin concentrations before initiating concomitant drugs",
      "Reduce digoxin concentrations by decreasing dose by approximately 30-50% or by modifying the dosing frequency and continue monitoring",
      "Captopril 58% 39% Clarithromycin NA 70% Dronedarone NA 150% Gentamicin 129-212% NA Erythromycin 100% NA Itraconazole 80% NA Lapatinib NA 180% Propafenone NA 60-270% Quinidine 100% NA Ranolazine 50% NA Ritonavir NA 86% Telaprevir 50% 85% Tetracycline 100% NA Verapamil 50-75% NA Digoxin concentrations"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are included in more detail in the Warnings and Precautions section of the label: Cardiac arrhythmias [see Warnings and Precautions (5.1 , 5.2 )] Digoxin Toxicity [see Warnings and Precautions (5.3) ] The overall incidence of adverse reactions with",
      "Cardiac toxicity accounts for about one-half, gastrointestinal disturbances for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics at 1-877-200-6088 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "In general, the adverse reactions of digoxin are dose-dependent and occur at doses higher than those needed to achieve a therapeutic effect",
      "Hence, adverse reactions are less common when digoxin is used within the recommended dose range, is maintained within the therapeutic serum concentration range, and when there is careful attention to concurrent medications and conditions",
      "In the DIG trial (a trial investigating the effect of digoxin on mortality and morbidity in patients with heart failure), the incidence of hospitalization for suspected digoxin toxicity was 2% in patients taking digoxin tablets compared to 0.9% in patients taking placebo [see Clinical Studies (14.1)",
      "The overall incidence of adverse reactions with digoxin has been reported as 5-20%, with 15-20% of adverse events considered serious",
      "Cardiac toxicity accounts for about one-half, gastrointestinal disturbances for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events"
    ],
    "indications": [
      "1 INDICATIONS & USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults",
      "( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure",
      "( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults",
      "( 1.3 ) 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults",
      "Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality"
    ]
  },
  "dihydroxyaluminum sodium carbonate": {
    "ingredient": "dihydroxyaluminum sodium carbonate",
    "is_drug": true,
    "canonical_name": "aluminum hydroxide",
    "fda_search_term": "aluminum hydroxide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GERI-LANTA ANTACID ANTIGAS",
      "GERI-MOX ANTACID ANTIGAS",
      "Mag-Al Plus"
    ],
    "generic_names": [
      "ALUMINUM HYDROXIDE, MAGNESIUM HYDROXIDE, AND SIMETHICONE",
      "ALUMINUM HYDROXIDE, MAGNESIUM HYDROXIDE, DIMETHICONE"
    ],
    "manufacturers": [
      "ATLANTIC BIOLOGICALS CORP.",
      "Cardinal Health 107, LLC",
      "Geri-Care Pharmaceuticals, Corp"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Ask a doctor before use if you have kidney disease a magnesium-restricted diet Ask a doctor or pharmacist before use if you are presently taking a prescription drug",
      "Antacids may interact with certain prescription drugs",
      "Stop use and ask a doctor if symptoms last more than 2 weeks If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses relieves heartburn sour stomach acid indigestion the symptoms referred to as gas"
    ]
  },
  "diloxanide furoate": {
    "ingredient": "diloxanide furoate",
    "is_drug": true,
    "canonical_name": "diloxanide furoate",
    "fda_search_term": "diloxanide furoate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Fluticasone Propionate and Salmeterol",
      "Mometasone Furoate"
    ],
    "generic_names": [
      "FLUTICASONE PROPIONATE AND SALMETEROL",
      "MOMETASONE FUROATE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Glenmark Pharmaceuticals Inc., USA"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS No drug-drug interaction studies have been conducted with mometasone furoate cream"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Most common adverse reactions are: burning, pruritus, and skin atrophy",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Taro Pharmaceuticals U.S.A., Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "In controlled clinical trials involving 319 subjects, the incidence of adverse reactions associated with the use of mometasone furoate cream was 1.6%",
      "Reported reactions included burning, pruritus, and skin atrophy",
      "Reports of rosacea associated with the use of mometasone furoate cream have also been received",
      "In controlled clinical trials (n=74) involving pediatric subjects 2 to 12 years of age, the incidence of adverse experiences associated with the use of mometasone furoate cream was approximately 7%",
      "Reported reactions included stinging, pruritus, and furunculosis",
      "The following adverse reactions were reported to be possibly or probably related to treatment with mometasone furoate cream during clinical trials in 4% of 182 pediatric subjects 6 months to 2 years of age: decreased glucocorticoid levels, 2; paresthesia, 2; folliculitis, 1; moniliasis, 1; bacterial",
      "The following signs of skin atrophy were also observed among 97 subjects treated with mometasone furoate cream in a clinical trial: shininess, 4; telangiectasia, 1; loss of elasticity, 4; loss of normal skin markings, 4; thinness, 1; and bruising, 1",
      "6.2 Postmarketing Experience Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure",
      "Postmarketing reports for local adverse reaction"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Mometasone Furoate Cream USP, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older",
      "Mometasone Furoate Cream USP, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients ≥2 years of age"
    ]
  },
  "diltiazem": {
    "ingredient": "diltiazem",
    "is_drug": true,
    "canonical_name": "diltiazem",
    "fda_search_term": "diltiazem",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Diltiazem Hydrochloride",
      "Diltiazem Hydrochloride Extended-Release",
      "diltiazem hydrochloride"
    ],
    "generic_names": [
      "DILTIAZEM HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "Bryant Ranch Prepack",
      "Mayne Pharma"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Cardiac Conduction : Diltiazem hydrochloride prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome",
      "This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second",
      "or third-degree AV block (13 of 3290 patients or 0.40%)",
      "Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction",
      "A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem (see ADVERSE REACTIONS )",
      "Congestive Heart Failure : Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dP/dt)",
      "An acute study of oral diltiazem in patients with impaired ventricular function (ejection fraction 24% ± 6%) showed improvement in indices of ventricular function without significant decrease in contractile function (dP/dt)",
      "Worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function",
      "Experience with the use of diltiazem hydrochloride in combination with beta-blockers in patients with impaired ventricular function is limited",
      "Caution should be exercised when using this combination"
    ],
    "drug_interactions": [
      "Drug Interactions Because of the potential for additive effects, slow titration is warranted in patients receiving diltiazem hydrochloride concomitantly with other agents known to affect cardiac contractility and/or conduction (see WARNINGS )",
      "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with diltiazem hydrochloride (see WARNINGS )",
      "Diltiazem is both a substrate and an inhibitor of the cytochrome P450 3A4 enzyme system",
      "Other drugs that are specific substrates, inhibitors, or inducers of this enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem",
      "Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels",
      "Anesthetics : The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers",
      "When used concomitantly, titrate anesthetics and calcium blockers slowly",
      "Benzodiazepines : Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3",
      "to 4-fold and the C max by 2-fold, compared to placebo",
      "The elimination half-life of midazolam and triazolam also increased (1.5"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies",
      "The following table presents the most common adverse reactions reported in placebo-controlled angina and hypertension trials in patients receiving diltiazem hydrochloride extended-release capsules up to 360 mg with rates in placebo patients shown for comparison",
      "In addition, the following events were reported infrequently (less than 1%) in angina or hypertension trials: Cardiovascular: Congestive heart failure, palpitations, syncope, ventricular extrasystoles",
      "Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor",
      "G astrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase (see WARNINGS, Acute Hepatic Injury ), thirst, vomiting, weight increase",
      "Dermatological: Petechiae, photosensitivity, pruritus, urticaria",
      "Other: Amblyopia, CPK increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties",
      "The following postmarketing events have been reported infrequently in patients receiving diltiazem hydrochloride: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema (including facial or periorbital edema), asystole, erythema multiforme (including Stevens-Johnson syn"
    ],
    "indications": [
      "INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension",
      "It may be used alone or in combination with other antihypertensive medications",
      "Diltiazem hydrochloride extended-release capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm"
    ]
  },
  "diltiazem hcl": {
    "ingredient": "diltiazem hcl",
    "is_drug": true,
    "canonical_name": "diltiazem",
    "fda_search_term": "diltiazem",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Diltiazem Hydrochloride",
      "Diltiazem Hydrochloride Extended-Release",
      "diltiazem hydrochloride"
    ],
    "generic_names": [
      "DILTIAZEM HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "Bryant Ranch Prepack",
      "Mayne Pharma"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Cardiac Conduction : Diltiazem hydrochloride prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome",
      "This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second",
      "or third-degree AV block (13 of 3290 patients or 0.40%)",
      "Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction",
      "A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem (see ADVERSE REACTIONS )",
      "Congestive Heart Failure : Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dP/dt)",
      "An acute study of oral diltiazem in patients with impaired ventricular function (ejection fraction 24% ± 6%) showed improvement in indices of ventricular function without significant decrease in contractile function (dP/dt)",
      "Worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function",
      "Experience with the use of diltiazem hydrochloride in combination with beta-blockers in patients with impaired ventricular function is limited",
      "Caution should be exercised when using this combination"
    ],
    "drug_interactions": [
      "Drug Interactions Because of the potential for additive effects, slow titration is warranted in patients receiving diltiazem hydrochloride concomitantly with other agents known to affect cardiac contractility and/or conduction (see WARNINGS )",
      "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with diltiazem hydrochloride (see WARNINGS )",
      "Diltiazem is both a substrate and an inhibitor of the cytochrome P450 3A4 enzyme system",
      "Other drugs that are specific substrates, inhibitors, or inducers of this enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem",
      "Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels",
      "Anesthetics : The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers",
      "When used concomitantly, titrate anesthetics and calcium blockers slowly",
      "Benzodiazepines : Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3",
      "to 4-fold and the C max by 2-fold, compared to placebo",
      "The elimination half-life of midazolam and triazolam also increased (1.5"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies",
      "The following table presents the most common adverse reactions reported in placebo-controlled angina and hypertension trials in patients receiving diltiazem hydrochloride extended-release capsules up to 360 mg with rates in placebo patients shown for comparison",
      "In addition, the following events were reported infrequently (less than 1%) in angina or hypertension trials: Cardiovascular: Congestive heart failure, palpitations, syncope, ventricular extrasystoles",
      "Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor",
      "G astrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase (see WARNINGS, Acute Hepatic Injury ), thirst, vomiting, weight increase",
      "Dermatological: Petechiae, photosensitivity, pruritus, urticaria",
      "Other: Amblyopia, CPK increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties",
      "The following postmarketing events have been reported infrequently in patients receiving diltiazem hydrochloride: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema (including facial or periorbital edema), asystole, erythema multiforme (including Stevens-Johnson syn"
    ],
    "indications": [
      "INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension",
      "It may be used alone or in combination with other antihypertensive medications",
      "Diltiazem hydrochloride extended-release capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm"
    ]
  },
  "diltiazem hydrochloride": {
    "ingredient": "diltiazem hydrochloride",
    "is_drug": true,
    "canonical_name": "diltiazem",
    "fda_search_term": "diltiazem",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Diltiazem Hydrochloride",
      "Diltiazem Hydrochloride Extended-Release",
      "diltiazem hydrochloride"
    ],
    "generic_names": [
      "DILTIAZEM HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "Bryant Ranch Prepack",
      "Mayne Pharma"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Cardiac Conduction : Diltiazem hydrochloride prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome",
      "This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second",
      "or third-degree AV block (13 of 3290 patients or 0.40%)",
      "Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction",
      "A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem (see ADVERSE REACTIONS )",
      "Congestive Heart Failure : Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dP/dt)",
      "An acute study of oral diltiazem in patients with impaired ventricular function (ejection fraction 24% ± 6%) showed improvement in indices of ventricular function without significant decrease in contractile function (dP/dt)",
      "Worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function",
      "Experience with the use of diltiazem hydrochloride in combination with beta-blockers in patients with impaired ventricular function is limited",
      "Caution should be exercised when using this combination"
    ],
    "drug_interactions": [
      "Drug Interactions Because of the potential for additive effects, slow titration is warranted in patients receiving diltiazem hydrochloride concomitantly with other agents known to affect cardiac contractility and/or conduction (see WARNINGS )",
      "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with diltiazem hydrochloride (see WARNINGS )",
      "Diltiazem is both a substrate and an inhibitor of the cytochrome P450 3A4 enzyme system",
      "Other drugs that are specific substrates, inhibitors, or inducers of this enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem",
      "Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels",
      "Anesthetics : The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers",
      "When used concomitantly, titrate anesthetics and calcium blockers slowly",
      "Benzodiazepines : Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3",
      "to 4-fold and the C max by 2-fold, compared to placebo",
      "The elimination half-life of midazolam and triazolam also increased (1.5"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies",
      "The following table presents the most common adverse reactions reported in placebo-controlled angina and hypertension trials in patients receiving diltiazem hydrochloride extended-release capsules up to 360 mg with rates in placebo patients shown for comparison",
      "In addition, the following events were reported infrequently (less than 1%) in angina or hypertension trials: Cardiovascular: Congestive heart failure, palpitations, syncope, ventricular extrasystoles",
      "Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor",
      "G astrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase (see WARNINGS, Acute Hepatic Injury ), thirst, vomiting, weight increase",
      "Dermatological: Petechiae, photosensitivity, pruritus, urticaria",
      "Other: Amblyopia, CPK increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties",
      "The following postmarketing events have been reported infrequently in patients receiving diltiazem hydrochloride: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema (including facial or periorbital edema), asystole, erythema multiforme (including Stevens-Johnson syn"
    ],
    "indications": [
      "INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension",
      "It may be used alone or in combination with other antihypertensive medications",
      "Diltiazem hydrochloride extended-release capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm"
    ]
  },
  "dimenhydrinate": {
    "ingredient": "dimenhydrinate",
    "is_drug": true,
    "canonical_name": "dimenhydrinate",
    "fda_search_term": "dimenhydrinate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dramamine for Kids",
      "Motion Sickness Relief"
    ],
    "generic_names": [
      "DIMENHYDRINATE",
      "DIMENHYDRINATE 50 MG"
    ],
    "manufacturers": [
      "Chain Drug Marketing Association, Inc.",
      "Medtech Products Inc.",
      "TARGET CORPORATION"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Do not use for children under 2 years of age unless directed by a doctor",
      "Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers",
      "When using this product marked drowsiness may occur alcohol, sedatives, and tranquilizers may increase drowsiness use caution when driving a motor vehicle or operating machinery avoid alcoholic beverages If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness"
    ]
  },
  "dimet": {
    "ingredient": "dimet",
    "is_drug": true,
    "canonical_name": "dimethicone",
    "fda_search_term": "dimethicone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Baby XtraCare Oatmeal",
      "Gas Relief Ultra Strength"
    ],
    "generic_names": [
      "DIMETHICONE",
      "SIMETHICONE"
    ],
    "manufacturers": [
      "Rejoice International",
      "Walgreens"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For extenal use only",
      "When using this product avoid contact with eyes",
      "In case of eye contact, flush with water",
      "Stop use and ask a doctor if condition worsens",
      "Symptoms last more than 7days or clear up and occur again within a few days"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Baby XtraCare® Oatmeal Daily Moisturizing Lotion Lightly Scented Dimethicon Skin Protectant with Natural Oat Extract Helps Soothe & Soften Baby's Skin 12 FL OZ (354 mL)"
    ]
  },
  "dimethic": {
    "ingredient": "dimethic",
    "is_drug": true,
    "canonical_name": "dimethicone",
    "fda_search_term": "dimethicone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Baby XtraCare Oatmeal",
      "Gas Relief Ultra Strength"
    ],
    "generic_names": [
      "DIMETHICONE",
      "SIMETHICONE"
    ],
    "manufacturers": [
      "Rejoice International",
      "Walgreens"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For extenal use only",
      "When using this product avoid contact with eyes",
      "In case of eye contact, flush with water",
      "Stop use and ask a doctor if condition worsens",
      "Symptoms last more than 7days or clear up and occur again within a few days"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Baby XtraCare® Oatmeal Daily Moisturizing Lotion Lightly Scented Dimethicon Skin Protectant with Natural Oat Extract Helps Soothe & Soften Baby's Skin 12 FL OZ (354 mL)"
    ]
  },
  "dimethico": {
    "ingredient": "dimethico",
    "is_drug": true,
    "canonical_name": "dimethicone",
    "fda_search_term": "dimethicone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Baby XtraCare Oatmeal",
      "Gas Relief Ultra Strength"
    ],
    "generic_names": [
      "DIMETHICONE",
      "SIMETHICONE"
    ],
    "manufacturers": [
      "Rejoice International",
      "Walgreens"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For extenal use only",
      "When using this product avoid contact with eyes",
      "In case of eye contact, flush with water",
      "Stop use and ask a doctor if condition worsens",
      "Symptoms last more than 7days or clear up and occur again within a few days"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Baby XtraCare® Oatmeal Daily Moisturizing Lotion Lightly Scented Dimethicon Skin Protectant with Natural Oat Extract Helps Soothe & Soften Baby's Skin 12 FL OZ (354 mL)"
    ]
  },
  "dimethicone copolyol": {
    "ingredient": "dimethicone copolyol",
    "is_drug": true,
    "canonical_name": "dimethicone",
    "fda_search_term": "dimethicone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Baby XtraCare Oatmeal",
      "Gas Relief Ultra Strength"
    ],
    "generic_names": [
      "DIMETHICONE",
      "SIMETHICONE"
    ],
    "manufacturers": [
      "Rejoice International",
      "Walgreens"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For extenal use only",
      "When using this product avoid contact with eyes",
      "In case of eye contact, flush with water",
      "Stop use and ask a doctor if condition worsens",
      "Symptoms last more than 7days or clear up and occur again within a few days"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Baby XtraCare® Oatmeal Daily Moisturizing Lotion Lightly Scented Dimethicon Skin Protectant with Natural Oat Extract Helps Soothe & Soften Baby's Skin 12 FL OZ (354 mL)"
    ]
  },
  "dimethiconeglycerin": {
    "ingredient": "dimethiconeglycerin",
    "is_drug": true,
    "canonical_name": "dimethicone",
    "fda_search_term": "dimethicone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Baby XtraCare Oatmeal",
      "Gas Relief Ultra Strength"
    ],
    "generic_names": [
      "DIMETHICONE",
      "SIMETHICONE"
    ],
    "manufacturers": [
      "Rejoice International",
      "Walgreens"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For extenal use only",
      "When using this product avoid contact with eyes",
      "In case of eye contact, flush with water",
      "Stop use and ask a doctor if condition worsens",
      "Symptoms last more than 7days or clear up and occur again within a few days"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Baby XtraCare® Oatmeal Daily Moisturizing Lotion Lightly Scented Dimethicon Skin Protectant with Natural Oat Extract Helps Soothe & Soften Baby's Skin 12 FL OZ (354 mL)"
    ]
  },
  "dimethiconol": {
    "ingredient": "dimethiconol",
    "is_drug": true,
    "canonical_name": "dimethicone",
    "fda_search_term": "dimethicone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Baby XtraCare Oatmeal",
      "Gas Relief Ultra Strength"
    ],
    "generic_names": [
      "DIMETHICONE",
      "SIMETHICONE"
    ],
    "manufacturers": [
      "Rejoice International",
      "Walgreens"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For extenal use only",
      "When using this product avoid contact with eyes",
      "In case of eye contact, flush with water",
      "Stop use and ask a doctor if condition worsens",
      "Symptoms last more than 7days or clear up and occur again within a few days"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Baby XtraCare® Oatmeal Daily Moisturizing Lotion Lightly Scented Dimethicon Skin Protectant with Natural Oat Extract Helps Soothe & Soften Baby's Skin 12 FL OZ (354 mL)"
    ]
  },
  "dimethyl fumarate": {
    "ingredient": "dimethyl fumarate",
    "is_drug": true,
    "canonical_name": "dimethyl fumarate",
    "fda_search_term": "dimethyl fumarate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DIMETHYL FUMARATE",
      "Dimethyl Fumarate"
    ],
    "generic_names": [
      "DIMETHYL FUMARATE"
    ],
    "manufacturers": [
      "Aurobindo Pharma Limited",
      "MSN LABORATORIES PRIVATE LIMITED",
      "Quallent Pharmaceuticals Health LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following important adverse reactions are described elsewhere in labeling: Anaphylaxis and Angioedema [see Warnings and Precautions (5.1) ]",
      "Progressive multifocal leukoencephalopathy [see Warnings and Precautions (5.2) ]",
      "Herpes Zoster and Other Serious Opportunistic Infections [ see Warnings and Precautions (5.3) ]",
      "Lymphopenia [ see Warnings and Precautions (5.4) ]",
      "Liver Injury [ see Warnings and Precautions (5.5) ]",
      "Flushing [ see Warnings and Precautions (5.6) ]",
      "Most common adverse reactions (incidence ≥10% and ≥2% placebo) were flushing, abdominal pain, diarrhea, and nausea",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact MSN pharmaceuticals Inc",
      "at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice",
      "The most common adverse reactions (incidence ≥10% and ≥2% more than placebo) for dimethyl fumarate were flushing, abdominal pain, diarrhea, and nausea",
      "Adverse Reactions in Placebo-Controlled Trials In the two well-controlled studies demonstrating effectiveness, 1529 patients received dimethyl fumarate with an overall exposure of 2244 person-years [ see Clinical Studies (14) ]",
      "The adverse reactions presented in the table below are based on safety information from 769 patients treated with dimethyl fumarate 240 mg twice a day and 771 placebo-treated patients",
      "Table 1:Adverse Reactions in Study 1 and 2 reported for dimethyl fumarate 240 mg BID at ≥ 2% higher incidence than placebo Dimethyl Fumarate N=769 % Placebo N=771 % Flushing 40 6 Abdominal pain 18 10 Diarrhea 14 11 Nausea 12 9 Vomiting 9 5 Pruritus 8 4 Rash 8 3 Albumin urine present 6 4 Erythema 5 1"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults",
      "Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )"
    ]
  },
  "dimethylaminoethanol bitartrate": {
    "ingredient": "dimethylaminoethanol bitartrate",
    "is_drug": true,
    "canonical_name": "dimethylethanolamine bitartrate",
    "fda_search_term": "dimethylethanolamine bitartrate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [],
    "generic_names": [],
    "manufacturers": [],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Lorazepam is not recommended for use in patients with a primary depressive disorder of psychosis",
      "As with all patients on CNS-acting drugs, patients receiving lorazepam should be warned not to operate dangerous machinery or motor vehicles and that their tolerance for alcohol and other CNS depressants will be diminished"
    ],
    "drug_interactions": [
      "Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur",
      "Patients should be followed carefully to detect side reactions or unusual manifestations of drug idiosyncrasy",
      "Patients may require reduced doses of anesthetics when on methyldopa",
      "If hypotension does occur during anesthesia, it usually can be controlled by vasopressors",
      "The adrenergic receptors remain sensitive during treatment with methyldopa",
      "When methyldopa and lithium are given concomitantly, the patient should be carefully monitored for symptoms of lithium toxicity",
      "Read the circular for lithium preparations",
      "Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate",
      "This may adversely affect blood pressure control in patients treated with methyldopa",
      "Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Adverse reactions, if they occur, are usually observed at the beginning of therapy and generally disappear on continued medication or upon decreasing the dose",
      "In a sample of about 3,500 anxious patients, the most frequent adverse reaction to lorazepam is sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%)",
      "Less frequent adverse reactions are disorientation, depression, nausea, change in appetite, headache, sleep disturbance, agitation, dermatological symptoms, eye-function disturbance, together with various gastrointestinal symptoms and autonomic manifestations",
      "The incidence of sedation and unsteadiness increased with age",
      "Small decreases in blood pressure have been noted but are not clinically significant, probably being related to the relief of anxiety produced by lorazepam",
      "Transient amnesia or memory impairment has been reported in association with the use of benzodiazepines"
    ],
    "indications": [
      "INDICATIONS AND USAGE Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms",
      "Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic",
      "The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies",
      "The physician should periodically reassess the usefulness of the drug for the individual patient"
    ]
  },
  "dimethylsulfoxide": {
    "ingredient": "dimethylsulfoxide",
    "is_drug": true,
    "canonical_name": "dimethyl sulfoxide",
    "fda_search_term": "dimethyl sulfoxide",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Mekinist",
      "RIMSO-50"
    ],
    "generic_names": [
      "DIMETHYL SULFOXIDE",
      "TRAMETINIB"
    ],
    "manufacturers": [
      "Mylan Institutional LLC",
      "Novartis Pharmaceuticals Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Dimethyl sulfoxide can initiate the liberation of histamine and there has been occasional hypersensitivity reaction with topical administration of dimethyl sulfoxide",
      "This hypersensitivity has been reported in one patients receiving intravesical RIMSO-50 ® ",
      "The physician should be cognizant of this possibility in prescribing RIMSO-50 ® ",
      "If anaphylactoid symptoms develop, appropriate therapy should be instituted"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: New Primary Malignancies [see Warnings and Precautions ( 5.1)] Hemorrhage [see Warnings and Precautions (5.2)] Colitis and Gastrointestinal Perforation [see Warnings and Precautions (5",
      "4 )] Cardiomyopathy [see Warnings and Precautions (5",
      "5 )] Ocular Toxicities [see Warnings and Precautions (5",
      "6 )] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5",
      "7 )] Serious Febrile Reactions [see Warnings and Precautions (5",
      "8 )] Serious Skin Toxicities [see Warnings and Precautions (5",
      "9 )] Hyperglycemia [see Warnings and Precautions (5",
      "10 )] Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5",
      "12 )] There are additional adverse reactions associated with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional information",
      "Most common adverse reactions (≥ 20%) for MEKINIST as a single agent include rash, diarrhea, and lymphedema",
      "( 6.1 ) Most common adverse reactions (≥ 20%) for MEKINIST in combination with dabrafenib include: Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema",
      "( 6.1 ) Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache, rash, chills, diarrhea, vomiting, arthralgia, and myalgia",
      "( 6.1 ) NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea",
      "( 6.1 ) Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",
      "( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test",
      "( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options"
    ]
  },
  "dimetyl dicarboxylate": {
    "ingredient": "dimetyl dicarboxylate",
    "is_drug": true,
    "canonical_name": "dimethyl dicarboxylate",
    "fda_search_term": "dimethyl dicarboxylate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dimethyl Fumarate",
      "Mekinist"
    ],
    "generic_names": [
      "DIMETHYL FUMARATE",
      "TRAMETINIB"
    ],
    "manufacturers": [
      "MSN LABORATORIES PRIVATE LIMITED",
      "Novartis Pharmaceuticals Corporation"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: New Primary Malignancies [see Warnings and Precautions ( 5.1)] Hemorrhage [see Warnings and Precautions (5.2)] Colitis and Gastrointestinal Perforation [see Warnings and Precautions (5",
      "4 )] Cardiomyopathy [see Warnings and Precautions (5",
      "5 )] Ocular Toxicities [see Warnings and Precautions (5",
      "6 )] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5",
      "7 )] Serious Febrile Reactions [see Warnings and Precautions (5",
      "8 )] Serious Skin Toxicities [see Warnings and Precautions (5",
      "9 )] Hyperglycemia [see Warnings and Precautions (5",
      "10 )] Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5",
      "12 )] There are additional adverse reactions associated with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional information",
      "Most common adverse reactions (≥ 20%) for MEKINIST as a single agent include rash, diarrhea, and lymphedema",
      "( 6.1 ) Most common adverse reactions (≥ 20%) for MEKINIST in combination with dabrafenib include: Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema",
      "( 6.1 ) Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache, rash, chills, diarrhea, vomiting, arthralgia, and myalgia",
      "( 6.1 ) NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea",
      "( 6.1 ) Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",
      "( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test",
      "( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options"
    ]
  },
  "dimithicone": {
    "ingredient": "dimithicone",
    "is_drug": true,
    "canonical_name": "dimethicone",
    "fda_search_term": "dimethicone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Baby XtraCare Oatmeal",
      "Gas Relief Ultra Strength"
    ],
    "generic_names": [
      "DIMETHICONE",
      "SIMETHICONE"
    ],
    "manufacturers": [
      "Rejoice International",
      "Walgreens"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For extenal use only",
      "When using this product avoid contact with eyes",
      "In case of eye contact, flush with water",
      "Stop use and ask a doctor if condition worsens",
      "Symptoms last more than 7days or clear up and occur again within a few days"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Baby XtraCare® Oatmeal Daily Moisturizing Lotion Lightly Scented Dimethicon Skin Protectant with Natural Oat Extract Helps Soothe & Soften Baby's Skin 12 FL OZ (354 mL)"
    ]
  },
  "dinoprostone": {
    "ingredient": "dinoprostone",
    "is_drug": true,
    "canonical_name": "dinoprostone",
    "fda_search_term": "dinoprostone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CERVIDIL",
      "Prepidil"
    ],
    "generic_names": [
      "DINOPROSTONE"
    ],
    "manufacturers": [
      "Ferring Pharmaceuticals Inc.",
      "Pharmacia & Upjohn Company LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS FOR HOSPITAL USE ONLY Dinoprostone, as with other potent oxytocic agents, should be used only with strict adherence to recommended dosages",
      "Dinoprostone should be administered by physicians in a hospital that can provide immediate intensive care and acute surgical facilities",
      "Women aged 30 years or older, those with complications during pregnancy and those with a gestational age over 40 weeks have been shown to have an increased risk of post-partum disseminated intravascular coagulation",
      "In addition, these factors may further increase the risk associated with labor induction (see ADVERSE REACTIONS )",
      "Therefore, in these women, use of dinoprostone should be undertaken with caution",
      "Measures should be applied to detect as soon as possible an evolving fibrinolysis in the immediate post-partum phase",
      "The Clinician should be alert that the intracervical placement of dinoprostone gel may result in inadvertent disruption and subsequent embolization of antigenic tissue causing in rare circumstances the development of Anaphylactoid Syndrome of Pregnancy (Amniotic Fluid Embolism)",
      "There have been post-marketing reports of serious and life-threatening hypersensitivity reactions including anaphylaxis and angioedema with PREPIDIL Gel (dinoprostone)",
      "Onset of these reported reactions occurred within minutes to hours after initiation with PREPIDIL Gel (dinoprostone)",
      "If a hypersensitivity reaction is suspected, if possible remove PREPIDIL Gel (dinoprostone)"
    ],
    "drug_interactions": [
      "Drug Interactions PREPIDIL Gel may augment the activity of other oxytocic agents and their concomitant use is not recommended",
      "For the sequential use of oxytocin following PREPIDIL Gel administration, a dosing interval of 6–12 hours is recommended"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS PREPIDIL Gel is generally well-tolerated",
      "In controlled trials, in which 1731 women were entered, the following events were reported at an occurrence of ≥ 1%: Adverse Reaction PGE 2 (N = 884) Control placebo gel or no treatment (N = 847) Maternal N (%) N (%) Uterine contractile abnormality 58 (6.6) 34 (4.0) Any gastrointestinal effect 50 (5",
      "Uterine rupture has been reported in association with the use of PREPIDIL Gel intracervically",
      "Additional events reported in the literature, associated by the authors with the use of PREPIDIL Gel, included premature rupture of membranes, fetal depression (1 min Apgar < 7), and fetal acidosis (umbilical artery pH < 7.15)",
      "Post-marketing surveillance Blood and lymphatic system disorders An increased risk of post-partum disseminated intravascular coagulation has been described in patients whose labor was induced by pharmacological means, either with dinoprostone or oxytocin (see WARNINGS ) ",
      "The frequency of this adverse event, however, appears to be rare (<1 per 1,000 labors)",
      "Immune system disorders Hypersensitivity reactions (e.g., Anaphylactic reaction, Anaphylactic shock, Anaphylactoid reaction)"
    ],
    "indications": [
      "INDICATIONS AND USAGE PREPIDIL Gel is indicated for ripening an unfavorable cervix in pregnant women at or near term with a medical or obstetrical need for labor induction"
    ]
  },
  "diosmin": {
    "ingredient": "diosmin",
    "is_drug": true,
    "canonical_name": "diosmin",
    "fda_search_term": "diosmin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Bruselix Bruising"
    ],
    "generic_names": [
      "VITAMIN C, ZINC, ARNICA MONTANA EXTRACT, BROMELAIN, DIOSMIN, RUTIN, CITRUS BIOFLAVONOIDS, HESPERIDIN METHYL CHALCONE"
    ],
    "manufacturers": [
      "Puretek Corporation"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "Drug Interactions: The use of anticoagulants, such as warfarin or aspirin, may increase the risk of bleeding when combined with Bromelain",
      "High doses of zinc can interfere with the absorption of iron when taken alongside iron supplements",
      "Additionally, citrus bioflavonoids have the potential to enhance the effects of blood pressure-lowering medications"
    ],
    "adverse_reactions": [
      "Adverse Reactions: Adverse reactions associated with the use of Bruising Tablets may include mild gastrointestinal discomfort, nausea, or allergic reactions such as skin rash",
      "In rare cases, more serious reactions, such as prolonged bleeding or hypersensitivity reactions (e.g., difficulty breathing, swelling), may occur",
      "If you experience any serious adverse effects, discontinue use and seek medical attention immediately"
    ],
    "indications": [
      "INDICATIONS AND USAGE: Bruselix™ Bruising Tablets are formulated to provide nutritional support during the body’s natural recovery process",
      "They may be helpful for individuals experiencing bruising due to minor injuries, surgical procedures, or sensitive skin",
      "The formula contains antioxidants, enzymes, and natural extracts that are traditionally used to support overall skin health and recovery"
    ]
  },
  "dipalmitate": {
    "ingredient": "dipalmitate",
    "is_drug": true,
    "canonical_name": "dipalmitate",
    "fda_search_term": "dipalmitate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Kojic Clear Concentre"
    ],
    "generic_names": [
      "KOJIC CLEAR CONCENTRE"
    ],
    "manufacturers": [
      "Guangzhou Kadiya Biotechnology Co., Ltd."
    ],
    "dosage_forms": [],
    "warnings": [
      "1、For external use only, avoid contact with eyes when used 2、Keep out of reach of children"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "For Skin Whitonina Moieturizina Rriahtonina And Antinvidantl Indicatione",
      "For whitonina moisturisino and hriohtonino facial ekinll"
    ]
  },
  "diphenhydramine": {
    "ingredient": "diphenhydramine",
    "is_drug": true,
    "canonical_name": "diphenhydramine",
    "fda_search_term": "diphenhydramine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Childrens Allergy Relief",
      "Childrens Delsym Cough Plus Cold Night Time",
      "Diphenhydramine"
    ],
    "generic_names": [
      "ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE, AND PHENYLEPHRINE HYDROCHLORIDE",
      "DIPHENHYDRAMINE HCL",
      "DIPHENHYDRAMINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Avenacy, LLC",
      "Best Choice",
      "RB Health (US) LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Do not use ■ with any other product containing diphenhydramine, even one used on skin ■ to make a child sleepy Ask a doctor before use if the child has ■ glaucoma ■ a breathing problem such as chronic bronchitis"
    ],
    "drug_interactions": [
      "Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.) MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequent adverse reactions are italicized",
      "General Urticaria; drug rash; anaphylactic shock; photosensitivity; excessive perspiration; chills; dryness of mouth, nose and throat",
      "Cardiovascular System Hypotension, headache, palpitations, tachycardia, extrasystoles",
      "Hematologic System Hemolytic anemia, thrombocytopenia, agranulocytosis",
      "Nervous System Sedation, sleepiness, dizziness, disturbed coordination , fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions",
      "Gastrointestinal System Epigastric distress , anorexia, nausea, vomiting, diarrhea, constipation",
      "Genitourinary System Urinary frequency, difficult urination, urinary retention, early menses",
      "Respiratory System Thickening of bronchial secretions , tightness of chest and wheezing, nasal stuffiness",
      "To report SUSPECTED ADVERSE REACTIONS, contact Avenacy at 1-855-283-6229 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: ■ sneezing ■ itching of the nose or throat ■ runny nose ■ itchy watery eyes ■temporarily relieves these symptoms due to the common cold: ■ sneezing ■ runny nose"
    ]
  },
  "diphenhydramine hcl": {
    "ingredient": "diphenhydramine hcl",
    "is_drug": true,
    "canonical_name": "diphenhydramine",
    "fda_search_term": "diphenhydramine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Childrens Allergy Relief",
      "Childrens Delsym Cough Plus Cold Night Time",
      "Diphenhydramine"
    ],
    "generic_names": [
      "ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE, AND PHENYLEPHRINE HYDROCHLORIDE",
      "DIPHENHYDRAMINE HCL",
      "DIPHENHYDRAMINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Avenacy, LLC",
      "Best Choice",
      "RB Health (US) LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Do not use ■ with any other product containing diphenhydramine, even one used on skin ■ to make a child sleepy Ask a doctor before use if the child has ■ glaucoma ■ a breathing problem such as chronic bronchitis"
    ],
    "drug_interactions": [
      "Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.) MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequent adverse reactions are italicized",
      "General Urticaria; drug rash; anaphylactic shock; photosensitivity; excessive perspiration; chills; dryness of mouth, nose and throat",
      "Cardiovascular System Hypotension, headache, palpitations, tachycardia, extrasystoles",
      "Hematologic System Hemolytic anemia, thrombocytopenia, agranulocytosis",
      "Nervous System Sedation, sleepiness, dizziness, disturbed coordination , fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions",
      "Gastrointestinal System Epigastric distress , anorexia, nausea, vomiting, diarrhea, constipation",
      "Genitourinary System Urinary frequency, difficult urination, urinary retention, early menses",
      "Respiratory System Thickening of bronchial secretions , tightness of chest and wheezing, nasal stuffiness",
      "To report SUSPECTED ADVERSE REACTIONS, contact Avenacy at 1-855-283-6229 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: ■ sneezing ■ itching of the nose or throat ■ runny nose ■ itchy watery eyes ■temporarily relieves these symptoms due to the common cold: ■ sneezing ■ runny nose"
    ]
  },
  "diphenhydramine hydrochloride": {
    "ingredient": "diphenhydramine hydrochloride",
    "is_drug": true,
    "canonical_name": "diphenhydramine",
    "fda_search_term": "diphenhydramine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Childrens Allergy Relief",
      "Childrens Delsym Cough Plus Cold Night Time",
      "Diphenhydramine"
    ],
    "generic_names": [
      "ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE, AND PHENYLEPHRINE HYDROCHLORIDE",
      "DIPHENHYDRAMINE HCL",
      "DIPHENHYDRAMINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Avenacy, LLC",
      "Best Choice",
      "RB Health (US) LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Do not use ■ with any other product containing diphenhydramine, even one used on skin ■ to make a child sleepy Ask a doctor before use if the child has ■ glaucoma ■ a breathing problem such as chronic bronchitis"
    ],
    "drug_interactions": [
      "Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.) MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequent adverse reactions are italicized",
      "General Urticaria; drug rash; anaphylactic shock; photosensitivity; excessive perspiration; chills; dryness of mouth, nose and throat",
      "Cardiovascular System Hypotension, headache, palpitations, tachycardia, extrasystoles",
      "Hematologic System Hemolytic anemia, thrombocytopenia, agranulocytosis",
      "Nervous System Sedation, sleepiness, dizziness, disturbed coordination , fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions",
      "Gastrointestinal System Epigastric distress , anorexia, nausea, vomiting, diarrhea, constipation",
      "Genitourinary System Urinary frequency, difficult urination, urinary retention, early menses",
      "Respiratory System Thickening of bronchial secretions , tightness of chest and wheezing, nasal stuffiness",
      "To report SUSPECTED ADVERSE REACTIONS, contact Avenacy at 1-855-283-6229 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: ■ sneezing ■ itching of the nose or throat ■ runny nose ■ itchy watery eyes ■temporarily relieves these symptoms due to the common cold: ■ sneezing ■ runny nose"
    ]
  },
  "diphenylhydramine": {
    "ingredient": "diphenylhydramine",
    "is_drug": true,
    "canonical_name": "diphenhydramine",
    "fda_search_term": "diphenhydramine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Childrens Allergy Relief",
      "Childrens Delsym Cough Plus Cold Night Time",
      "Diphenhydramine"
    ],
    "generic_names": [
      "ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE, AND PHENYLEPHRINE HYDROCHLORIDE",
      "DIPHENHYDRAMINE HCL",
      "DIPHENHYDRAMINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Avenacy, LLC",
      "Best Choice",
      "RB Health (US) LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Do not use ■ with any other product containing diphenhydramine, even one used on skin ■ to make a child sleepy Ask a doctor before use if the child has ■ glaucoma ■ a breathing problem such as chronic bronchitis"
    ],
    "drug_interactions": [
      "Drug Interactions Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.) MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequent adverse reactions are italicized",
      "General Urticaria; drug rash; anaphylactic shock; photosensitivity; excessive perspiration; chills; dryness of mouth, nose and throat",
      "Cardiovascular System Hypotension, headache, palpitations, tachycardia, extrasystoles",
      "Hematologic System Hemolytic anemia, thrombocytopenia, agranulocytosis",
      "Nervous System Sedation, sleepiness, dizziness, disturbed coordination , fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions",
      "Gastrointestinal System Epigastric distress , anorexia, nausea, vomiting, diarrhea, constipation",
      "Genitourinary System Urinary frequency, difficult urination, urinary retention, early menses",
      "Respiratory System Thickening of bronchial secretions , tightness of chest and wheezing, nasal stuffiness",
      "To report SUSPECTED ADVERSE REACTIONS, contact Avenacy at 1-855-283-6229 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: ■ sneezing ■ itching of the nose or throat ■ runny nose ■ itchy watery eyes ■temporarily relieves these symptoms due to the common cold: ■ sneezing ■ runny nose"
    ]
  },
  "diphtheria antitoxin": {
    "ingredient": "diphtheria antitoxin",
    "is_drug": true,
    "canonical_name": "diphtheria antitoxin",
    "fda_search_term": "diphtheria antitoxin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Methocarbamol"
    ],
    "generic_names": [
      "METHOCARBAMOL"
    ],
    "manufacturers": [
      "Sagent Pharmaceuticals"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Penicillin G procaine should only be prescribed for the indications listed in this insert",
      "NOTE: This drug is no longer indicated in the treatment of gonorrhea",
      "Anaphylaxis SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY",
      "THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS",
      "THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS",
      "BEFORE INITIATING THERAPY WITH ANY PENICILLIN, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS",
      "IF AN ALLERGIC REACTION OCCURS, THE DRUG SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED",
      "SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE",
      "OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED",
      "Pseudomembranous Colitis Pseudomembranous colitis has been reported with nearly all antibacterial agents, including penicillin G, and may range in severity from mild to life-threatening"
    ],
    "drug_interactions": [
      "Drug Interactions Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided",
      "Concurrent administration of penicillin and probenecid increases and prolongs serum penicillin levels by decreasing the apparent volume of distribution and slowing the rate of excretion by competitively inhibiting renal tubular secretion of penicillin"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Allergic Reactions Penicillin is a substance of low toxicity but does possess a significant index of sensitization",
      "The following hypersensitivity reactions associated with use of penicillin have been reported: Skin rashes, ranging from maculopapular eruptions to exfoliative dermatitis; urticaria; serum-sicknesslike reactions, including chills, fever, edema, arthralgia, and prostration",
      "Severe and often fatal anaphylaxis has been reported (see WARNINGS )",
      "As with other treatments for syphilis, the Jarisch-Herxheimer reaction has been reported",
      "Procaine toxicity manifestations and hypersensitivity reactions have been reported (see WARNINGS and PRECAUTIONS )",
      "Gastrointestinal Pseudomembranous colitis has been reported with the use of penicillin G",
      "Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS )"
    ],
    "indications": [
      "INDICATIONS AND USAGE Penicillin G procaine is indicated in the treatment of moderately severe infections in both adults and pediatric patients due to penicillin-G-susceptible microorganisms that are susceptible to the low and persistent serum levels common to this particular dosage form in the indi",
      "Therapy should be guided by bacteriological studies (including susceptibility tests) and by clinical response",
      "NOTE: When high, sustained serum levels are required, aqueous penicillin G, either IM or IV, should be used",
      "The following infections will usually respond to adequate dosages of intramuscular penicillin G procaine: Moderately severe to severe infections of the upper respiratory tract, skin and soft-tissue infections, scarlet fever, and erysipelas due to susceptible streptococci (Group A-without bacteremia)",
      "NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G"
    ]
  },
  "dipotussium chlorazepate": {
    "ingredient": "dipotussium chlorazepate",
    "is_drug": true,
    "canonical_name": "chlorzoxazone",
    "fda_search_term": "chlorzoxazone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CHLORZOXAZONE",
      "Chlorzoxazone"
    ],
    "generic_names": [
      "CHLORZOXAZONE"
    ],
    "manufacturers": [
      "Cintex Services, LLC",
      "Lifsa Drugs LLC",
      "Proficient Rx LP"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone",
      "The mechanism is unknown but appears to be idiosyncratic and unpredictable",
      "Factors predisposing patients to this rare event are not known",
      "Patients should be instructed to report early signs and/or symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice",
      "Chlorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develop",
      "Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.) The concomitant use of alcohol or other central nervous system depressants may have an additive effect",
      "Usage in Pregnancy The safe use of chlorzoxazone has not been established with respect to the possible adverse effects upon fetal development",
      "Therefore, it should be used in women of childbearing potential only when, in the judgment of the physician, the potential benefits outweigh the possible risks"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Chlorzoxazone containing products are usually well tolerated",
      "It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding",
      "Drowsiness, dizziness, lightheadedness, malaise, or over-stimulation may be noted by an occasional patient",
      "Rarely, allergic type skin rashes, petechiae, or ecchymoses may develop during treatment",
      "Angioneurotic edema or anaphylactic reactions are extremely rare",
      "There is no evidence that the drug will cause renal damage",
      "Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone",
      "This finding is of no known clinical significance",
      "To report SUSPECTED ADVERSE EVENTS, contact Aurobindo Pharma USA, Inc",
      "at 1-866-850-2876 or FDA at 1-800",
      "FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions"
    ],
    "indications": [
      "INDICATIONS Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions",
      "The mode of action of this drug has not been clearly identified, but may be related to its sedative properties",
      "Chlorzoxazone does not directly relax tense skeletal muscles in man"
    ]
  },
  "dipyridamol": {
    "ingredient": "dipyridamol",
    "is_drug": true,
    "canonical_name": "dipyridamole",
    "fda_search_term": "dipyridamole",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE",
      "Dipyridamole"
    ],
    "generic_names": [
      "ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE",
      "DIPYRIDAMOLE"
    ],
    "manufacturers": [
      "Henry Schein, Inc.",
      "Micro Labs Limited",
      "Zydus Pharmaceuticals USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Serious adverse reactions associated with the administration of intravenous Dipyridamole Injection have included cardiac death, fatal and non-fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylact",
      "There have been reported cases of asystole, sinus node arrest, sinus node depression and conduction block",
      "Patients with abnormalities of cardiac impulse formation/conduction or severe coronary artery disease may be at increased risk for these events",
      "In a study of 3911 patients given intravenous dipyridamole as an adjunct to thallium myocardial perfusion imaging, two types of serious adverse events were reported: 1",
      "four cases of myocardial infarction (0.1%), two fatal (0.05%) and two non-fatal (0.05%) and 2",
      "six cases of severe bronchospasm (0.2%)",
      "Although the incidence of these serious adverse events was small (0.3%, 10 of 3911), the potential clinical information to be gained through use of intravenous dipyridamole thallium imaging (see INDICATIONS AND USAGE noting the rate of false positive and false negative results) must be weighed again",
      "Patients with a history of unstable angina may be at a greater risk for severe myocardial ischemia",
      "Patients with a history of asthma may be at a greater risk for bronchospasm during Dipyridamole Injection use",
      "When thallium myocardial perfusion imaging is performed with intravenous dipyridamole, parenteral aminophylline should be readily available for relieving adverse events such as bronchospasm or chest pain"
    ],
    "drug_interactions": [
      "Drug Interactions No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets",
      "The following information was obtained from the literature",
      "Adenosinergic agents (e.g., adenosine, regadenoson) Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine",
      "Adjustment of adenosine dosage may be necessary",
      "Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A 2A -receptor agonist",
      "The potential risk of cardiovascular side effects with intravenous adenosinergic agents may be increased during the testing period when dipyridamole is not held 48 hours prior to stress testing",
      "Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Adverse reactions at therapeutic doses are usually minimal and transient",
      "On long-term use of dipyridamole tablets initial side effects usually disappear",
      "The following reactions in Table 1 were reported in two heart valve replacement trials comparing dipyridamole tablets and warfarin therapy to either warfarin alone or warfarin and placebo: Table 1 Adverse Reactions Reported in 2 Heart Valve Replacement Trials Adverse Reaction Dipyridamole Tablets/ P",
      "1% 3.5% Headache 2.3% 0.0% Rash 2.3% 1.1% Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus",
      "In addition, angina pectoris has been reported rarely and there have been rare reports of liver dysfunction",
      "On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication",
      "When dipyridamole tablets were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone",
      "In rare cases, increased bleeding during or after surgery has been observed",
      "In post-marketing reporting experience, there have been rare reports of hypersensitivity reactions (such as rash, urticaria, severe bronchospasm, and angioedema), larynx edema, fatigue, malaise, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, thrombocytopenia, alopecia, cholelithiasis"
    ],
    "indications": [
      "INDICATIONS AND USAGE Dipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement"
    ]
  },
  "dipyridamole": {
    "ingredient": "dipyridamole",
    "is_drug": true,
    "canonical_name": "dipyridamole",
    "fda_search_term": "dipyridamole",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE",
      "Dipyridamole"
    ],
    "generic_names": [
      "ASPIRIN AND EXTENDED-RELEASE DIPYRIDAMOLE",
      "DIPYRIDAMOLE"
    ],
    "manufacturers": [
      "Henry Schein, Inc.",
      "Micro Labs Limited",
      "Zydus Pharmaceuticals USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Serious adverse reactions associated with the administration of intravenous Dipyridamole Injection have included cardiac death, fatal and non-fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylact",
      "There have been reported cases of asystole, sinus node arrest, sinus node depression and conduction block",
      "Patients with abnormalities of cardiac impulse formation/conduction or severe coronary artery disease may be at increased risk for these events",
      "In a study of 3911 patients given intravenous dipyridamole as an adjunct to thallium myocardial perfusion imaging, two types of serious adverse events were reported: 1",
      "four cases of myocardial infarction (0.1%), two fatal (0.05%) and two non-fatal (0.05%) and 2",
      "six cases of severe bronchospasm (0.2%)",
      "Although the incidence of these serious adverse events was small (0.3%, 10 of 3911), the potential clinical information to be gained through use of intravenous dipyridamole thallium imaging (see INDICATIONS AND USAGE noting the rate of false positive and false negative results) must be weighed again",
      "Patients with a history of unstable angina may be at a greater risk for severe myocardial ischemia",
      "Patients with a history of asthma may be at a greater risk for bronchospasm during Dipyridamole Injection use",
      "When thallium myocardial perfusion imaging is performed with intravenous dipyridamole, parenteral aminophylline should be readily available for relieving adverse events such as bronchospasm or chest pain"
    ],
    "drug_interactions": [
      "Drug Interactions No pharmacokinetic drug-drug interaction studies were conducted with dipyridamole tablets",
      "The following information was obtained from the literature",
      "Adenosinergic agents (e.g., adenosine, regadenoson) Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine",
      "Adjustment of adenosine dosage may be necessary",
      "Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A 2A -receptor agonist",
      "The potential risk of cardiovascular side effects with intravenous adenosinergic agents may be increased during the testing period when dipyridamole is not held 48 hours prior to stress testing",
      "Cholinesterase Inhibitors Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Adverse reactions at therapeutic doses are usually minimal and transient",
      "On long-term use of dipyridamole tablets initial side effects usually disappear",
      "The following reactions in Table 1 were reported in two heart valve replacement trials comparing dipyridamole tablets and warfarin therapy to either warfarin alone or warfarin and placebo: Table 1 Adverse Reactions Reported in 2 Heart Valve Replacement Trials Adverse Reaction Dipyridamole Tablets/ P",
      "1% 3.5% Headache 2.3% 0.0% Rash 2.3% 1.1% Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus",
      "In addition, angina pectoris has been reported rarely and there have been rare reports of liver dysfunction",
      "On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication",
      "When dipyridamole tablets were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone",
      "In rare cases, increased bleeding during or after surgery has been observed",
      "In post-marketing reporting experience, there have been rare reports of hypersensitivity reactions (such as rash, urticaria, severe bronchospasm, and angioedema), larynx edema, fatigue, malaise, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, thrombocytopenia, alopecia, cholelithiasis"
    ],
    "indications": [
      "INDICATIONS AND USAGE Dipyridamole tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement"
    ]
  },
  "disodium": {
    "ingredient": "disodium",
    "is_drug": true,
    "canonical_name": "disodium",
    "fda_search_term": "disodium",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Balsalazide Disodium",
      "Pemetrexed",
      "Prostate"
    ],
    "generic_names": [
      "BALSALAZIDE DISODIUM",
      "PEMETREXED DISODIUM",
      "PETROSELINUM SATIVUM, POPULUS TREMULOIDES, SABAL SERRULATA, CHIMAPHILA UMBELLATA, ADENOSINUM TRIPHOSPHORICUM DINATRUM, EQUOL, KREOSOTUM, NADIDUM, TESTOSTERONE, PROSTATE (SUIS), SUCCINICUM ACIDUM, HEPAR SULPHURIS CALCAREUM, CONIUM MACULATUM, PROTEUS (MIRABILIS), PROTEUS (VULGARIS)"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "Golden State Medical Supply, Inc.",
      "Ingenus Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: Keep out of reach of children",
      "In case of overdose, contact physician or Poison Control Center right away",
      "If pregnant or breast-feeding, ask a health professional before use",
      "Tamper seal: \"Sealed for Your Protection.\" Do not use if seal is broken or missing"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Nephrotoxic Agents including NSAIDs : Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions",
      "( 7.1 ) Azathioprine or 6-Mercaptopurine : Increased risk of blood disorders; monitor complete blood cell counts and platelet counts",
      "( 7.2 ) 7.1 Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs The concurrent use of mesalamine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs), may increase the risk of renal reactions",
      "Monitor patients taking nephrotoxic drugs for changes in renal function and mesalamine-related adverse reactions [see Warnings and Precautions ( 5.1 )] ",
      "7.2 Azathioprine or 6-Mercaptopurine The concurrent use of mesalamine with azathioprine or 6-mercaptopurine and/or any other drugs known to cause myelotoxicity may increase the risk for blood disorders, bone marrow failure, and associated complications",
      "If concomitant use of balsalazide disodium capsules and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts",
      "7.3 Interference With Urinary Normetanephrine Measurements Use of balsalazide disodium capsules, which is converted to mesalamine, may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection [see Warnings and Precautions",
      "Consider an alternative, selective assay for normetanephrine"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: Renal Impairment [see Warnings and Precautions ( 5.1 )] Mesalamine-Induced Acute Intolerance Syndrome [see Warnings and Precautions ( 5.2 )] Hypersensitivity Reactions [see Warnings and Pr",
      "Adverse reactions in pediatric patients were similar",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc",
      "at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adult Ulcerative Colitis: During clinical development, 259 adult patients with active ulcerative colitis were exposed to 6.75 g/day balsalazide in 4 controlled trials",
      "In the 4 controlled clinical trials patients receiving a balsalazide dose of 6.75 g/day most frequently reported the following adverse reactions: headache (8%), abdominal pain (6%), diarrhea (5%), nausea (5%), vomiting (4%), respiratory infection (4%), and arthralgia (4%)",
      "Withdrawal from therapy due to adverse reactions was comparable among patients on balsalazide and placebo",
      "Adverse reactions reported by 1% or more of patients who participated in the 4 well-controlled, Phase 3 trials are presented by treatment group (Table 1)",
      "The number of placeb"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older",
      "Limitations of Use: Safety and effectiveness of balsalazide disodium capsules beyond 8 weeks in pediatric patients 5 years to 17 years of age and 12 weeks in adults have not been established",
      "Balsalazide disodium capsules are an aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older",
      "( 1 ) Limitations of Use: Safety and effectiveness of balsalazide beyond 8 weeks in children (ages 5 to 17 years) and 12 weeks in adults have not been established"
    ]
  },
  "disodium edetate": {
    "ingredient": "disodium edetate",
    "is_drug": true,
    "canonical_name": "disodium edetate",
    "fda_search_term": "disodium edetate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Quick Action"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "SALICYLIC ACID"
    ],
    "manufacturers": [
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only: hands only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTION Information: 1-888-287-1915 or Walmart.com/help DISTRIBUTED BY: Walmart Inc., Bentonville, AR 72716 PLASTIC TUBE Do Not Recycle how2recycle.info Made in the USA with domestic and imported ingredients",
      "Factory Certified"
    ],
    "indications": [
      "Use For handwashing to decrease bacteria on the skin"
    ]
  },
  "disodium edta": {
    "ingredient": "disodium edta",
    "is_drug": true,
    "canonical_name": "disodium edetate",
    "fda_search_term": "disodium edetate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Quick Action"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "SALICYLIC ACID"
    ],
    "manufacturers": [
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only: hands only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTION Information: 1-888-287-1915 or Walmart.com/help DISTRIBUTED BY: Walmart Inc., Bentonville, AR 72716 PLASTIC TUBE Do Not Recycle how2recycle.info Made in the USA with domestic and imported ingredients",
      "Factory Certified"
    ],
    "indications": [
      "Use For handwashing to decrease bacteria on the skin"
    ]
  },
  "disodium etidronate": {
    "ingredient": "disodium etidronate",
    "is_drug": true,
    "canonical_name": "etidronic acid",
    "fda_search_term": "etidronic acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Spa/Pool Detox 6027"
    ],
    "generic_names": [
      "SPA/POOL DETOX"
    ],
    "manufacturers": [
      "Professional Complementary Health Formulas"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Consult a doctor if condition worsens or symptoms persist",
      "Keep out of the reach of children",
      "In case of overdose, get medical help or contact a poison control center right away",
      "If pregnant or breastfeeding, ask a healthcare professional before use",
      "Keep out of the reach of children",
      "If pregnant or breastfeeding, ask a healthcare professional before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS For the temporary relief of skin irritations, red or watery eyes, minor earache, stomach cramps, diarrhea, or vomiting due to sensitivity to or exposure to pool or spa chemicals or contaminants.*"
    ]
  },
  "disodium phosphate": {
    "ingredient": "disodium phosphate",
    "is_drug": true,
    "canonical_name": "disodium phosphate",
    "fda_search_term": "disodium phosphate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Mekinist"
    ],
    "generic_names": [
      "TRAMETINIB"
    ],
    "manufacturers": [
      "Novartis Pharmaceuticals Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: For external use only",
      "Do not use if you have sensitive skin and/or are sensitive to [active ingredient] When using this product skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time",
      "If irritation occurs, only use one topical acne medication at a time avoid unnecessary sun exposure and use sun screen, Acne Clearing Moisture with SPF 45 skin irritation may occur, characterized by redness, burning, itching, peeling, and possibly swelling",
      "Irritation may be reduced by using the product less frequently or in a lower concentration Stop use and ask a doctor if irritation becomes severe"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: New Primary Malignancies [see Warnings and Precautions ( 5.1)] Hemorrhage [see Warnings and Precautions (5.2)] Colitis and Gastrointestinal Perforation [see Warnings and Precautions (5",
      "4 )] Cardiomyopathy [see Warnings and Precautions (5",
      "5 )] Ocular Toxicities [see Warnings and Precautions (5",
      "6 )] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5",
      "7 )] Serious Febrile Reactions [see Warnings and Precautions (5",
      "8 )] Serious Skin Toxicities [see Warnings and Precautions (5",
      "9 )] Hyperglycemia [see Warnings and Precautions (5",
      "10 )] Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5",
      "12 )] There are additional adverse reactions associated with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional information",
      "Most common adverse reactions (≥ 20%) for MEKINIST as a single agent include rash, diarrhea, and lymphedema",
      "( 6.1 ) Most common adverse reactions (≥ 20%) for MEKINIST in combination with dabrafenib include: Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema",
      "( 6.1 ) Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache, rash, chills, diarrhea, vomiting, arthralgia, and myalgia",
      "( 6.1 ) NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea",
      "( 6.1 ) Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema"
    ],
    "indications": [
      "Directions: Acne Clearing Cleanser Acne Clearing Tonic Acne Clearing Treatment 101"
    ]
  },
  "disodium undecylenamido measulfosuccinate": {
    "ingredient": "disodium undecylenamido measulfosuccinate",
    "is_drug": true,
    "canonical_name": "disodium undecylenamidomethanesulfonate",
    "fda_search_term": "disodium undecylenamidomethanesulfonate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Balsalazide Disodium",
      "Pemetrexed",
      "Prostate"
    ],
    "generic_names": [
      "BALSALAZIDE DISODIUM",
      "PEMETREXED DISODIUM",
      "PETROSELINUM SATIVUM, POPULUS TREMULOIDES, SABAL SERRULATA, CHIMAPHILA UMBELLATA, ADENOSINUM TRIPHOSPHORICUM DINATRUM, EQUOL, KREOSOTUM, NADIDUM, TESTOSTERONE, PROSTATE (SUIS), SUCCINICUM ACIDUM, HEPAR SULPHURIS CALCAREUM, CONIUM MACULATUM, PROTEUS (MIRABILIS), PROTEUS (VULGARIS)"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "Golden State Medical Supply, Inc.",
      "Ingenus Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: Keep out of reach of children",
      "In case of overdose, contact physician or Poison Control Center right away",
      "If pregnant or breast-feeding, ask a health professional before use",
      "Tamper seal: \"Sealed for Your Protection.\" Do not use if seal is broken or missing"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Nephrotoxic Agents including NSAIDs : Increased risk of nephrotoxicity; monitor for changes in renal function and mesalamine-related adverse reactions",
      "( 7.1 ) Azathioprine or 6-Mercaptopurine : Increased risk of blood disorders; monitor complete blood cell counts and platelet counts",
      "( 7.2 ) 7.1 Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs The concurrent use of mesalamine with known nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs), may increase the risk of renal reactions",
      "Monitor patients taking nephrotoxic drugs for changes in renal function and mesalamine-related adverse reactions [see Warnings and Precautions ( 5.1 )] ",
      "7.2 Azathioprine or 6-Mercaptopurine The concurrent use of mesalamine with azathioprine or 6-mercaptopurine and/or any other drugs known to cause myelotoxicity may increase the risk for blood disorders, bone marrow failure, and associated complications",
      "If concomitant use of balsalazide disodium capsules and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts",
      "7.3 Interference With Urinary Normetanephrine Measurements Use of balsalazide disodium capsules, which is converted to mesalamine, may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection [see Warnings and Precautions",
      "Consider an alternative, selective assay for normetanephrine"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in labeling: Renal Impairment [see Warnings and Precautions ( 5.1 )] Mesalamine-Induced Acute Intolerance Syndrome [see Warnings and Precautions ( 5.2 )] Hypersensitivity Reactions [see Warnings and Pr",
      "Adverse reactions in pediatric patients were similar",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc",
      "at 1-800-962-8364 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adult Ulcerative Colitis: During clinical development, 259 adult patients with active ulcerative colitis were exposed to 6.75 g/day balsalazide in 4 controlled trials",
      "In the 4 controlled clinical trials patients receiving a balsalazide dose of 6.75 g/day most frequently reported the following adverse reactions: headache (8%), abdominal pain (6%), diarrhea (5%), nausea (5%), vomiting (4%), respiratory infection (4%), and arthralgia (4%)",
      "Withdrawal from therapy due to adverse reactions was comparable among patients on balsalazide and placebo",
      "Adverse reactions reported by 1% or more of patients who participated in the 4 well-controlled, Phase 3 trials are presented by treatment group (Table 1)",
      "The number of placeb"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older",
      "Limitations of Use: Safety and effectiveness of balsalazide disodium capsules beyond 8 weeks in pediatric patients 5 years to 17 years of age and 12 weeks in adults have not been established",
      "Balsalazide disodium capsules are an aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older",
      "( 1 ) Limitations of Use: Safety and effectiveness of balsalazide beyond 8 weeks in children (ages 5 to 17 years) and 12 weeks in adults have not been established"
    ]
  },
  "divalproex sodium": {
    "ingredient": "divalproex sodium",
    "is_drug": true,
    "canonical_name": "valproate",
    "fda_search_term": "valproate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Valproate Sodium"
    ],
    "generic_names": [
      "VALPROATE SODIUM"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "Hikma Pharmaceuticals USA Inc.",
      "Sagent Pharmaceuticals"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance",
      "Therefore increased monitoring of valproate and concomitant drug concentrations and dosage adjustment are indicated whenever enzyme-inducing or inhibiting drugs are introduced or withdrawn ( 7.1 )",
      "Aspirin, carbapenem antibiotics, estrogen-containing hormonal contraceptives: Monitoring of valproate concentrations is recommended ( 7.1 )",
      "Co-administration of valproate can affect the pharmacokinetics of other drugs (e.g",
      "diazepam, ethosuximide, lamotrigine, phenytoin) by inhibiting their metabolism or protein binding displacement ( 7.2 )",
      "Patients stabilized on rufinamide should begin valproate therapy at a low dose, and titrate to clinically effective dose ( 7.2 )",
      "Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with valproate ( 7.2 )",
      "Topiramate: Hyperammonemia and encephalopathy ( 5.9 , 7.3 ) 7.1 Effects of Co-Administered Drugs on Valproate Clearance Drugs that affect the level of expression of hepatic enzymes, particularly those that elevate levels of glucuronosyltransferases (such as ritonavir), may increase the clearance of ",
      "For example, phenytoin, carbamazepine, and phenobarbital (or primidone) can double the clearance of valproate"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling:",
      "Hepatic failure [see Warnings and Precautions ( 5.1 )]",
      "Birth defects [see Warnings and Precautions ( 5.2 )]",
      "Decreased IQ following in utero exposure [see Warnings and Precautions ( 5.3 )]",
      "Pancreatitis [see Warnings and Precautions ( 5.5 )]",
      "Hyperammonemic encephalopathy [see Warnings and Precautions ( 5.6 , 5.8 , 5.9 )]",
      "Bleeding and other hematopoietic disorders [see Warnings and Precautions ( 5.7 )]",
      "Hypothermia [see Warnings and Precautions ( 5.10 )]",
      "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan hypersensitivity reactions [see Warnings and Precautions ( 5.11 )]",
      "Somnolence in the elderly [see Warnings and Precautions ( 5.13 )] Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect",
      "The adverse reactions that can result from valproate sodium use include all of those associated with oral forms of valproate",
      "The following describes experience specifically with valproate sodium",
      "Valproate sodium has been generally well tolerated in clinical trials involving 111 healthy adult male volunteers and 352 patients with epilepsy, given at doses of 125 to 6,000 mg (total daily dose)",
      "A total of 2% of patients discontinued treatment with valproate sodium due to adverse reactions",
      "The most common adverse reactions leading to discontinuation were 2 cases each of nausea/vomiting and elevated amylase"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Valproate sodium injection is indicated as an intravenous alternative in patients in whom oral administration of valproate products is temporarily not feasible in the following conditions:",
      "Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 ) 1.1 Epilepsy Valproate sodium injection is indicated as an intravenous alternative in patients for wh",
      "Valproate sodium injection is also indicated for use as sole and adjunctive therapy in the treatment of patients with simple and complex absence seizures, and adjunctively in patients with multiple seizure types that include absence seizures",
      "Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs",
      "Complex absence is the term used when other signs are also present"
    ]
  },
  "dmdm": {
    "ingredient": "dmdm",
    "is_drug": true,
    "canonical_name": "dmdm hydantoin",
    "fda_search_term": "dmdm hydantoin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Naproxen",
      "Suds High Foaming Antiseptic Hand and Body Wash"
    ],
    "generic_names": [
      "CHLOROXYLENOL",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Pro chem, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: For external use only-hands",
      "Flammable Keep away from heat and flame",
      "When using this product Keep out of eyes",
      "In case of contact with eyes, flush thoroughly with water Avoid contact with broken skin Do not inhale or ingest"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with naproxen",
      "Table 1: Clinically Significant Drug Interactions with naproxen Drugs That Interfere with Hemostasis Clinical Impact:",
      "Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of naproxen tablets or naproxen sodium tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleedin",
      "Aspirin Clinical Impact: A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen ( ",
      "There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period",
      "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ]",
      "GI Bleeding, Ulceration, and Perforation [ see Warnings and Precautions ( 5.2 ) ]",
      "Hepatotoxicity [ see Warnings and Precautions ( 5.3 ) ]",
      "Hypertension [ see Warnings and Precautions ( 5.4 ) ]",
      "Heart Failure and Edema [ see Warnings and Precautions ( 5.5 ) ]",
      "Renal Toxicity and Hyperkalemia [ see Warnings and Precautions ( 5.6 ) ]",
      "Anaphylactic Reactions [ see Warnings and Precautions ( 5.7 ) ]",
      "Serious Skin Reactions [ see Warnings and Precautions ( 5.9 ) ]",
      "Hematologic Toxicity [ see Warnings and Precautions ( 5.12 ) ] Most common adverse reactions to naproxen were dyspepsia, abdominal pain, nausea, headache, rash, ecchymosis, and edema",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below",
      "In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea",
      "The most frequent complaints reported related to the gastrointestinal tract"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of:",
      "rheumatoid arthritis",
      "ankylosing spondylitis",
      "Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of:",
      "acute gout the management of:"
    ]
  },
  "dmdm hydantoin": {
    "ingredient": "dmdm hydantoin",
    "is_drug": true,
    "canonical_name": "dmdm hydantoin",
    "fda_search_term": "dmdm hydantoin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Naproxen",
      "Suds High Foaming Antiseptic Hand and Body Wash"
    ],
    "generic_names": [
      "CHLOROXYLENOL",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Pro chem, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: For external use only-hands",
      "Flammable Keep away from heat and flame",
      "When using this product Keep out of eyes",
      "In case of contact with eyes, flush thoroughly with water Avoid contact with broken skin Do not inhale or ingest"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with naproxen",
      "Table 1: Clinically Significant Drug Interactions with naproxen Drugs That Interfere with Hemostasis Clinical Impact:",
      "Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of naproxen tablets or naproxen sodium tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleedin",
      "Aspirin Clinical Impact: A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen ( ",
      "There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period",
      "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ]",
      "GI Bleeding, Ulceration, and Perforation [ see Warnings and Precautions ( 5.2 ) ]",
      "Hepatotoxicity [ see Warnings and Precautions ( 5.3 ) ]",
      "Hypertension [ see Warnings and Precautions ( 5.4 ) ]",
      "Heart Failure and Edema [ see Warnings and Precautions ( 5.5 ) ]",
      "Renal Toxicity and Hyperkalemia [ see Warnings and Precautions ( 5.6 ) ]",
      "Anaphylactic Reactions [ see Warnings and Precautions ( 5.7 ) ]",
      "Serious Skin Reactions [ see Warnings and Precautions ( 5.9 ) ]",
      "Hematologic Toxicity [ see Warnings and Precautions ( 5.12 ) ] Most common adverse reactions to naproxen were dyspepsia, abdominal pain, nausea, headache, rash, ecchymosis, and edema",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below",
      "In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea",
      "The most frequent complaints reported related to the gastrointestinal tract"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of:",
      "rheumatoid arthritis",
      "ankylosing spondylitis",
      "Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of:",
      "acute gout the management of:"
    ]
  },
  "dobutamine": {
    "ingredient": "dobutamine",
    "is_drug": true,
    "canonical_name": "dobutamine",
    "fda_search_term": "dobutamine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DOBUTAMINE IN DEXTROSE",
      "Dobutamine",
      "Dobutamine Hydrochloride in Dextrose"
    ],
    "generic_names": [
      "DOBUTAMINE",
      "DOBUTAMINE HYDROCHLORIDE",
      "DOBUTAMINE IN DEXTROSE"
    ],
    "manufacturers": [
      "Baxter Healthcare Corporation",
      "HF Acquisition Co. LLC, DBA HealthFirst",
      "Hikma Pharmaceuticals USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Increase in Heart Rate or Blood Pressure Dobutamine hydrochloride may cause a marked increase in heart rate or blood pressure, especially systolic pressure",
      "Approximately 10% of adult patients in clinical studies have had rate increases of 30 beats/minute or more, and about 7.5% have had a 50-mm Hg or greater increase in systolic pressure",
      "Usually, reduction of dosage reverses these effects",
      "Because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response",
      "In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine",
      "Patients with pre-existing hypertension appear to face an increased risk of developing an exaggerated pressure response",
      "Ectopic Activity Dobutamine may precipitate or exacerbate ventricular ectopic activity, but it rarely has caused ventricular tachycardia",
      "Hypersensitivity Reactions suggestive of hypersensitivity associated with administration of Dobutamine in 5% Dextrose Injection, USP, including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally",
      "Dobutamine in 5% Dextrose Injection, USP contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people",
      "The overall prevalence of sulfite sensitivity in the general population is unknown and probably low"
    ],
    "drug_interactions": [
      "Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protam",
      "Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone"
    ],
    "adverse_reactions": [
      "Increased Heart Rate, Blood Pressure, and Ventricular Ectopic Activity: A 10",
      "to 20-mm Hg increase in systolic blood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (see WARNINGS regarding exaggerated chronotropic and pressor effects)",
      "Approximately 5% of adult patients have had increased premature ventricular beats during infusions",
      "These effects are dose related",
      "Hypotension: Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy",
      "Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values",
      "In rare cases, however, intervention may be required and reversibility may not be immediate",
      "Stress Cardiomyopathy: Stress cardiomyopathy has been reported with dobutamine in association with cardiac stress testing",
      "Reactions at Sites of Intravenous Infusion: Phlebitis has occasionally been reported",
      "Local inflammatory changes have been described following inadvertent infiltration",
      "Miscellaneous Uncommon Effects: The following adverse effects have been reported in 1% to 3% of adult patients: nausea, headache, anginal pain, nonspecific chest pain, palpitations, and shortness of breath",
      "Administration of dobutamine, like other catecholamines, has been associated with decreases in serum potassium concentrations, rarely to hypokalemic values"
    ],
    "indications": [
      "Dobutamine in 5% Dextrose Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures",
      "Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions",
      "Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure",
      "In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death",
      "Patients with NYHA Class IV symptoms appeared to be at particular risk"
    ]
  },
  "docetaxel": {
    "ingredient": "docetaxel",
    "is_drug": true,
    "canonical_name": "docetaxel",
    "fda_search_term": "docetaxel",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Docetaxel"
    ],
    "generic_names": [
      "DOCETAXEL",
      "DOCETAXEL ANHYDROUS"
    ],
    "manufacturers": [
      "Armas Pharmaceuticals Inc.",
      "Baxter Healthcare Corporation",
      "Hospira, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Docetaxel is a CYP3A4 substrate",
      "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4",
      "In vivo studies showed that the exposure of docetaxel increased 2.2-fold when it was coadministered with ketoconazole, a potent inhibitor of CYP3A4",
      "Protease inhibitors, particularly ritonavir, may increase the exposure of docetaxel",
      "Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided",
      "In patients receiving treatment with Docetaxel Injection close monitoring for toxicity and a Docetaxel Injection dose reduction could be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided [ see Dosage and Administration (2.7) , Clinical Pharmacology (12.3) ]",
      "Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most serious adverse reactions from docetaxel are:",
      "Toxic Deaths [ see Boxed Warning , Warnings and Precautions (5.1) ]",
      "Hepatic Impairment [ see Boxed Warning , Warnings and Precautions (5.2) ]",
      "Hematologic Effects [ see Boxed Warning , Warnings and Precautions (5.3) ]",
      "Enterocolitis and Neutropenic Colitis [ see Warnings and Precautions (5.4) ]",
      "Hypersensitivity Reactions [ see Boxed Warning , Warnings and Precautions (5.5) ]",
      "Fluid Retention [ see Boxed Warning , Warnings and Precautions (5.6) ]",
      "Second Primary Malignancies [ see Warnings and Precautions (5.7) ]",
      "Cutaneous Reactions [ see Warnings and Precautions (5.8) ]",
      "Neurologic Reactions [ see Warnings and Precautions (5.9) ]",
      "Eye Disorders [ see Warnings and Precautions (5.10) ]",
      "Asthenia [ see Warnings and Precautions (5.11) ]",
      "Alcohol Content [ see Warnings and Precautions (5.13) ] The most common adverse reactions across all docetaxel indications are infections, neutropenia, anemia, febrile neutropenia, hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid reten",
      "Incidence varies depending on the indication",
      "Adverse reactions are described according to indication"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for:",
      "Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 )",
      "Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 )",
      "Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 )",
      "Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 )"
    ]
  },
  "docosahexaenoic acid": {
    "ingredient": "docosahexaenoic acid",
    "is_drug": true,
    "canonical_name": "docosahexaenoic acid",
    "fda_search_term": "docosahexaenoic acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Prenate Pixie"
    ],
    "generic_names": [
      "ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, LEVOMEFOLATE CALCIUM, FOLIC ACID, FERROUS ASPARTO GLYCINATE, POTASSIUM IODIDE, PYRIDOXINE HYDROCHLORIDE, .ALPHA.-TOCOPHEROL ACETATE, DL-, DOCOSAHEXAENOIC ACID, AND BLUEBERRY"
    ],
    "manufacturers": [
      "Avion Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid"
    ],
    "indications": [
      "INDICATIONS: PRENATE PIXIE ® is a multivitamin/multimineral fatty acid dietary supplement indicated for use in improving the nutritional status of women throughout pregnancy and in the postnatal period for both lactating and nonlactating mothers"
    ]
  },
  "docosanol": {
    "ingredient": "docosanol",
    "is_drug": true,
    "canonical_name": "docosanol",
    "fda_search_term": "docosanol",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Cold Sore Fever Blister Treatment",
      "Docosanol",
      "Julie Cold Sore Treatment"
    ],
    "generic_names": [
      "DOCOSANOL"
    ],
    "manufacturers": [
      "AAFES/Your Military Exchanges",
      "Julie Products Inc",
      "The Kroger Co."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Allergy Alert: This product may cause a severe allergic reaction",
      "Symptoms may include: hives facial swelling wheezing/difficulty shock rash If an allergic reaction occurs, stop use and seek medical help right away",
      "For external use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching"
    ]
  },
  "docusate": {
    "ingredient": "docusate",
    "is_drug": true,
    "canonical_name": "docusate",
    "fda_search_term": "docusate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Docusate sodium",
      "SENNA-S",
      "Stool Softener Laxative"
    ],
    "generic_names": [
      "DOCUSATE SODIUM",
      "SENNA AND DOCUSATE SODIUM TABLETS, 8.6 MG AND 50 MG"
    ],
    "manufacturers": [
      "APNAR PHARMA LP",
      "CVS PHARMACY, INC",
      "HealthLife of USA LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Do not use if you are now taking mineral oil, unless directed by a doctor laxative products for longer than 1 week unless directed by a doctor Ask a doctor before use if you have stomach pain nausea vomiting noticed a sudden change in bowel habits that lasts over 2 weeks Stop use and ask a ",
      "These may indicate a serious condition",
      "If pregnant or breast-feeding , ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses relieves occasional constipation (irregularity) generally produces bowel movement in 6-12 hours"
    ]
  },
  "docusate sodium": {
    "ingredient": "docusate sodium",
    "is_drug": true,
    "canonical_name": "docusate",
    "fda_search_term": "docusate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Docusate sodium",
      "SENNA-S",
      "Stool Softener Laxative"
    ],
    "generic_names": [
      "DOCUSATE SODIUM",
      "SENNA AND DOCUSATE SODIUM TABLETS, 8.6 MG AND 50 MG"
    ],
    "manufacturers": [
      "APNAR PHARMA LP",
      "CVS PHARMACY, INC",
      "HealthLife of USA LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Do not use if you are now taking mineral oil, unless directed by a doctor laxative products for longer than 1 week unless directed by a doctor Ask a doctor before use if you have stomach pain nausea vomiting noticed a sudden change in bowel habits that lasts over 2 weeks Stop use and ask a ",
      "These may indicate a serious condition",
      "If pregnant or breast-feeding , ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses relieves occasional constipation (irregularity) generally produces bowel movement in 6-12 hours"
    ]
  },
  "dolutegravir": {
    "ingredient": "dolutegravir",
    "is_drug": true,
    "canonical_name": "dolutegravir",
    "fda_search_term": "dolutegravir",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Tivicay",
      "Tivicay PD",
      "Triumeq",
      "Triumeq PD"
    ],
    "generic_names": [
      "ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE",
      "DOLUTEGRAVIR SODIUM"
    ],
    "manufacturers": [
      "ST. MARY'S MEDICAL PARK PHARMACY",
      "ViiV Healthcare Company"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of TRIUMEQ or TRIUMEQ PD with other drugs can alter the concentration of other drugs and other drugs may alter the concentrations of TRIUMEQ or TRIUMEQ PD",
      "The potential drug-drug interactions must be considered prior to and during therapy",
      "( 4 , 7 , 12.3 ) 7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents In vitro, dolutegravir inhibited the renal organic cation transporters (OCT)2 (IC 50 = 1.93 microM) and multidrug and toxin extrusion transporter (MATE)1 (IC 50 = 6.34 microM)",
      "In vivo, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1",
      "Dolutegravir may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 (dofetilide, dalfampridine, and metformin) [see Contraindications ( 4 ), Drug Interactions ( 7.3 )] ",
      "In vitro, dolutegravir inhibited the basolateral renal transporters, organic anion transporter (OAT) 1 (IC 50 = 2.12 microM) and OAT3 (IC 50 = 1.97 microM)",
      "However, in vivo, dolutegravir did not alter the plasma concentrations of tenofovir or para-amino hippurate, substrates of OAT1 and OAT3",
      "In vitro, dolutegravir did not inhibit (IC 50 >50 microM) the following: cytochrome P450 (CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, uridine diphosphate (UDP)-glucuronosyl transferase (UGT)1A1, UGT2B7, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), bile salt ex",
      "In vitro, dolutegravir did not induce CYP1A2, CYP2B6, CYP3A4",
      "Based on these data and the results of drug interaction trials, dolutegravir is not expected to affect the pharmacokinetics of drugs that are substrates of these enzymes or transporters"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in other sections of the labeling:",
      "Serious and sometimes fatal hypersensitivity reaction [see Boxed Warning , Warnings and Precautions ( 5.1 )] ",
      "Exacerbations of hepatitis B [see Boxed Warning , Warnings and Precautions ( 5.3 )] ",
      "Hepatotoxicity [see Warnings and Precautions ( 5.3 )] ",
      "Lactic acidosis and severe hepatomegaly with steatosis [see Warnings and Precautions ( 5.4 )] ",
      "Immune reconstitution syndrome [see Warnings and Precautions ( 5.6 )] ",
      "Myocardial infarction [see Warnings and Precautions ( 5.8 )] ",
      "The most commonly reported adverse reactions of at least moderate intensity and incidence at least 2% (in those receiving TRIUMEQ) were insomnia, headache, and fatigue",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical prac",
      "Clinical Trials in Adults Serious and Fatal Abacavir-Associated Hypersensitivity Reactions: In clinical trials, serious and sometimes fatal hypersensitivity reactions have occurred with abacavir, a component of TRIUMEQ and TRIUMEQ PD [see Boxed Warning , Warnings and Precautions ( 5.1 )]",
      "These reactions have been characterized by 2 or more of the following signs or symptoms: (1) fever; (2) rash; (3) gastrointestinal symptoms (including nausea, vomiting, diarrhea, or abdominal pain); (4) constitutional symptoms (including generalized malaise, fatigue, or achiness); (5) respiratory sy",
      "Almost all abacavir hypersensitivity reactions include fever and/or rash as part of the syndrome",
      "Other signs and symptoms have included lethargy,"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg",
      "Limitations of Use: TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (INSTI) resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpo",
      "See full prescribing information for TIVICAY (dolutegravir)",
      "TRIUMEQ and TRIUMEQ PD are a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and w",
      "( 1 ) Limitations of Use: TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpopulations"
    ]
  },
  "domiphen bromide": {
    "ingredient": "domiphen bromide",
    "is_drug": true,
    "canonical_name": "domiphen bromide",
    "fda_search_term": "domiphen bromide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Methocarbamol"
    ],
    "generic_names": [
      "METHOCARBAMOL"
    ],
    "manufacturers": [
      "Proficient Rx LP"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, USP should be cautioned about combined effects with alcohol and other CNS depressants",
      "Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development",
      "There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol",
      "Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see Precautions, Pregnancy )",
      "Use In Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle",
      "Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities"
    ],
    "drug_interactions": [
      "Drug interactions See Warnings and Precautions for interaction with CNS drugs and alcohol",
      "Methocarbamol may inhibit the effect of pyridostigmine bromide",
      "Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Adverse reactions reported coincident with the administration of methocarbamol include: Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system: Dyspepsia, jau"
    ],
    "indications": [
      "INDICATIONS AND USAGE Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions",
      "The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties",
      "Methocarbamol does not directly relax tense skeletal muscles in man"
    ]
  },
  "donepezil": {
    "ingredient": "donepezil",
    "is_drug": true,
    "canonical_name": "donepezil",
    "fda_search_term": "donepezil",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DONEPEZIL HYDROCHLORIDE",
      "donepezil hydrochloride"
    ],
    "generic_names": [
      "DONEPEZIL HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Lupin Pharmaceuticals, Inc.",
      "Solco Healthcare US, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 )",
      "A synergistic effect may be expected with concomitant administration of succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists ( 7.2 )",
      "7.1 Use with Anticholinergics Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications",
      "7.2 Use with Cholinomimetics and Other Cholinesterase Inhibitors A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Most common adverse reactions in clinical studies of donepezil hydrochloride are nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc",
      "at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/ medwatch ",
      "The following serious adverse reactions are described below and elsewhere in the labeling: Cardiovascular Conditions [ see Warnings and Precautions ( 5.2 ) ]",
      "Nausea and Vomiting [ see Warnings and Precautions ( 5.3 ) ]",
      "Peptic Ulcer Disease and GI Bleeding [ see Warnings and Precautions ( 5.4 ) ]",
      "Weight Loss [ see Warnings and Precautions ( 5.5 ) ]",
      "Genitourinary Conditions [ see Warnings and Precautions ( 5.6 ) ]",
      "Neurological Conditions: Seizures [ see Warnings and Precautions ( 5.7 ) ]",
      "Pulmonary Conditions [ see Warnings and Precautions ( 5.8 ) ]",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Donepezil hydrochloride has been administered to over 1,700 individuals during clinical trials worldwide",
      "Approximately 1200 of these patients have been treated for at least 3 months and more than 1,000 patients have been treated for at least 6 months",
      "Controlled and uncontrolled trials in the United States included approximately 900 patients",
      "In regards to the highest dose of 10 mg/day, this population includes 650 patients treated for 3 months, 475 patients treated for 6 months, and 116 patients treated for over 1 year",
      "The range of patient exposure is from 1 to 1,214 days"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Donepezil hydrochloride tablet is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer's type",
      "Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's Disease ( 1 )",
      "Donepezil hydrochloride tablet is indicated for the treatment of dementia of the Alzheimer's type",
      "Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease"
    ]
  },
  "dopamine": {
    "ingredient": "dopamine",
    "is_drug": true,
    "canonical_name": "dopamine",
    "fda_search_term": "dopamine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dopamine Hydrochloride",
      "Dopamine Hydrochloride in Dextrose"
    ],
    "generic_names": [
      "DOPAMINE HYDROCHLORIDE",
      "DOPAMINE HYDROCHLORIDE IN DEXTROSE"
    ],
    "manufacturers": [
      "Hikma Pharmaceuticals USA Inc.",
      "Hospira, Inc.",
      "Medical Purchasing Solutions, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people",
      "The overall prevalence of sulfite sensitivity in the general population is unknown and probably low",
      "Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people",
      "Do NOT add dopamine HCl to any alkaline diluent solution since the drug is inactivated in alkaline solution",
      "Patients who have been receiving MAO inhibitors prior to the administration of dopamine HCl will require substantially reduced dosage",
      "See Drug Interactions below"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with dopamine",
      "Table 1: Clinically Significant Drug Interactions with Dopamine Halogenated Anesthetics Clinical Impact: Concomitant use may increase cardiac autonomic irritability and can sensitize the myocardium to the action of dopamine which may lead to ventricular arrhythmias and hypertension",
      "Intervention: Monitor cardiac rhythm",
      "Examples: desflurane, enflurane, isoflurane, and sevoflurane",
      "MAO Inhibitors Clinical Impact: Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine which may result in severe hypertension and cardiac arrhythmia",
      "Intervention: Reduce the recommended starting dosage to no greater than one-tenth (1/10) of the recommended dose in patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of Dopamine HCl in Dextrose Injection",
      "Examples: isocarboxazid, phenelzine, tranylcypromine, rasagiline, selegiline, linezolid",
      "Tricyclic Antidepressants Clinical Impact: Concomitant use may potentiate the cardiovascular effects of dopamine (e.g., hypertension)",
      "Intervention: Monitor blood pressure",
      "Examples: amitriptyline, desipramine, doxepin, imipramine, nortriptyline"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are described elsewhere in the labeling:",
      "Tissue Ischemia [see Warnings and Precautions (5.1) ]",
      "Cardiac Arrhythmias [see Warnings and Precautions (5.2) ]",
      "Hypotension [see Warnings and Precautions (5.3) ]",
      "Severe Hypersensitivity Reactions [see Warnings and Precautions (5.4) ] The following adverse reactions have been identified during post-approval use of dopamine",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure",
      "Cardiac Disorders : anginal pain, palpitation Gastrointestinal Disorders : nausea, vomiting Metabolism and Nutrition Disorders : azotemia Nervous System Disorders : headache, anxiety Respiratory Disorders : dyspnea Skin and Subcutaneous Tissue Disorders : piloerection Vascular Disorders : hypertensi",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc",
      "at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch "
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Dopamine Hydrochloride in Dextrose Injection is indicated to improve hemodynamic status in patients in distributive shock, or shock due to reduced cardiac output",
      "Dopamine HCl in Dextrose Injection is a catecholamine indicated to improve hemodynamic status in patients in shock"
    ]
  },
  "dorzolamide": {
    "ingredient": "dorzolamide",
    "is_drug": true,
    "canonical_name": "dorzolamide",
    "fda_search_term": "dorzolamide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE",
      "Dorzolamide Hydrochloride"
    ],
    "generic_names": [
      "DORZOLAMIDE HYDROCHLORIDE",
      "DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE"
    ],
    "manufacturers": [
      "Florida Pharmaceutical Products, LLC",
      "Sagent Pharmaceuticals",
      "Somerset Therapeutics, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Potential additive effect of oral carbonic anhydrase inhibitor with Dorzolamide Hydrochloride Ophthalmic Solution",
      "( 7.1 ) Potential acid-base and electrolyte disturbances",
      "( 7.2 ) 7.1 Oral Carbonic Anhydrase Inhibitors There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and Dorzolamide Hydrochloride Ophthalmic Solution",
      "The concomitant administration of Dorzolamide Hydrochloride Ophthalmic Solution and oral carbonic anhydrase inhibitors is not recommended",
      "7.2 High-Dose Salicylate Therapy Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug in",
      "Therefore, the potential for such drug interactions should be considered in patients receiving Dorzolamide Hydrochloride Ophthalmic Solution"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most frequently reported adverse reactions associated with Dorzolamide Hydrochloride Ophthalmic Solution were ocular burning, stinging, or discomfort immediately following ocular administration (approximately one-third of patients)",
      "Approximately one-quarter of patients noted a bitter taste following administration",
      "Superficial punctate keratitis occurred in 10 to 15% of patients and signs and symptoms of ocular allergic reaction in approximately 10%",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Controlled clinical trials : The most frequent adverse reactions associated with Dorzolamide Hydrochloride Ophthalmic Solution were ocular burning, stinging, or discomfort immediately following ocular administration (approximately one-third of patients)",
      "Approximately one-quarter of patients noted a bitter taste following administration",
      "Superficial punctate keratitis occurred in 10 to 15% of patients and signs and symptoms of ocular allergic reaction in approximately 10%",
      "Reactions occurring in approximately 1 to 5% of patients were conjunctivitis and lid reactions [see Warnings and Precautions ( 5.4 )] , blurred vision, eye redness, tearing, dryness, and photophobia",
      "Other ocular reactions and systemic reactions were reported infrequently, including headache, nausea, asthenia/fatigue; and, rarely, skin rashes, urolithiasis, and iridocyclitis",
      "In a 3-month, double-masked, active-treatment-controlled, multicenter study in pediatric patients, the adverse reactions profile of Dorzolamide Hydrochloride Ophthalmic Solution was comparable to that seen in adult patients"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Dorzolamide Hydrochloride Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma",
      "Dorzolamide Hydrochloride Ophthalmic Solution is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma"
    ]
  },
  "doxazosin": {
    "ingredient": "doxazosin",
    "is_drug": true,
    "canonical_name": "doxazosin",
    "fda_search_term": "doxazosin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Doxazosin"
    ],
    "generic_names": [
      "DOXAZOSIN",
      "DOXAZOSIN MESYLATE"
    ],
    "manufacturers": [
      "Aphena Pharma Solutions - Tennessee, LLC",
      "Cardinal Health 107, LLC",
      "Teva Pharmaceuticals USA, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Strong cytochrome P450 (CYP) 3A inhibitors may increase exposure to doxazosin and increased risk of hypotension",
      "Concomitant administration of doxazosin tablets with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension",
      "( 7.2 ) 7.1 CYP 3A Inhibitors In vitro studies suggest that doxazosin is a substrate of CYP 3A4",
      "Strong CYP3A inhibitors may increase exposure to doxazosin",
      "Monitor blood pressure and for symptoms of hypotension when doxazosin tablets are used concomitantly with strong CYP3A inhibitors [ see Clinical Pharmacology ( 12.3 ) ]",
      "7.2 Phosphodiesterase-5 (PDE-5) Inhibitors Concomitant administration of doxazosin tablets with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension",
      "Monitor blood pressure and for symptoms of hypotension [ see Warnings and Precautions ( 5.1 ) ]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most commonly reported adverse reactions from clinical trials are Fatigue, malaise, hypotension, and dizziness",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Benign Prostatic Hyperplasia (BPH) The incidence of adverse events has been ascertained from worldwide clinical trials in 965 BPH patients",
      "The incidence rates presented below (Table 2) are based on combined data from seven placebo-controlled trials involving once-daily administration of doxazosin tablets in doses of 1 to 16 mg in hypertensives and 0.5 to 8 mg in normotensives",
      "Adverse reactions occurring more than 1% more frequently in BPH patients treated with doxazosin tablets vs placebo are summarized in Table 1",
      "Adverse Reactions Occurring more than 1% More Frequently in BPH Patients Treated with Doxazosin Tablets Versus Placebo BODY SYSTEM Doxazosin Tablets N=665 Placebo N=300 NERVOUS SYSTEM DISORDERS Dizziness † 15.6% 9% Somnolence 3% 1% CARDIAC DISORDERS Hypotension 1.7% 0% RESPIRATORY, THORACIC AND MEDI",
      "Hypertension Doxazosin tablets has been administered to approximately 4,000 hypertensive patients in clinical trials, of whom 1,679 were included in the hypertension clinical development program",
      "In placebo-controlled studies,"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for:",
      "Signs and symptoms of Benign Prostatic Hyperplasia (BPH)",
      "Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH",
      "1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure",
      "Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions"
    ]
  },
  "doxorubicin": {
    "ingredient": "doxorubicin",
    "is_drug": true,
    "canonical_name": "doxorubicin",
    "fda_search_term": "doxorubicin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DOXORUBICIN HYDROCHLORIDE",
      "Doxorubicin Hydrochloride",
      "doxorubicin hydrochloride"
    ],
    "generic_names": [
      "DOXORUBICIN HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Dr. Reddy's Laboratories Inc.",
      "Lupin Pharmaceuticals, Inc.",
      "Pfizer Laboratories Div Pfizer Inc"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 )",
      "Do not administer doxorubicin hydrochloride in combination with trastuzumab due to increased risk of cardiac dysfunction ( 5.1 , 7.2 ) 7.1 Effect of Other Drugs on Doxorubicin Hydrochloride Injection Inhibitors of CYP3A4, CYP2D6, and P-gp Concomitant use of doxorubicin hydrochloride with inhibitors ",
      "Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp",
      "Inducers of CYP3A4, CYP2D6, or P-gp Concomitant use of doxorubicin hydrochloride with inducers of CYP3A4, CYP2D6, or P-gp may decrease the concentration of doxorubicin",
      "Avoid concomitant use of Doxorubicin Hydrochloride Injection with inducers of CYP3A4, CYP2D6, or P-gp",
      "Paclitaxel Paclitaxel, when given prior to doxorubicin hydrochloride, increases the plasma-concentrations of doxorubicin and its metabolites",
      "Administer Doxorubicin Hydrochloride Injection prior to paclitaxel if used concomitantly",
      "7.2 Concomitant Use of Trastuzumab Concomitant use of trastuzumab and doxorubicin hydrochloride results in an increased risk of cardiac dysfunction",
      "Avoid concomitant administration of Doxorubicin Hydrochloride Injection and trastuzumab [see Warnings and Precautions (5.1) ]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling",
      "Cardiomyopathy and Arrhythmias [see Warnings and Precautions (5.1) ]",
      "Secondary Malignancies [see Warnings and Precautions (5.2) ]",
      "Extravasation and Tissue Necrosis [see Warnings and Precautions (5.3) ]",
      "Severe Myelosuppression [see Warnings and Precautions (5.4) ]",
      "Tumor Lysis Syndrome [see Warnings and Precautions (5.6) ]",
      "Radiation Sensitization and Radiation Recall [see Warnings and Precautions (5.7) ] The most common (>10%) adverse reactions are alopecia, nausea and vomiting",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc",
      "at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Breast Cancer The safety data below were collected from 1492 women who received doxorubicin hydrochloride at a dose of 60 mg/m 2 and cyclophosphamide at a dose of 600 mg/m 2 (AC) every 3 weeks for 4 cycles for the adjuvant treatment of axillary lymph node positive breast cancer",
      "The median number of cycles received was 4",
      "Selected adverse reactions reported in this study are provided in Table 2",
      "No treatment-related deaths were reported in patients on either arm of the study",
      "Selected Adverse Reactions in Patients with Early Breast Cancer Involving Axillary Lymph Nodes Adverse Reactions AC Includes pooled data from patients who received either AC for 4 cycles or AC for 4 cycles followed by CMF for 3 cycles N = 1492 Conventional CMF N = 739 % % AC = doxorubicin hydrochlor"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated:",
      "as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 )",
      "for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic tra",
      "1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of",
      "acute lymphoblastic leukemia"
    ]
  },
  "doxycycilline": {
    "ingredient": "doxycycilline",
    "is_drug": true,
    "canonical_name": "doxycycline",
    "fda_search_term": "doxycycline",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DOXYCYCLINE",
      "DOXYCYCLINE HYCLATE",
      "doxycycline"
    ],
    "generic_names": [
      "DOXYCYCLINE",
      "DOXYCYCLINE HYCLATE"
    ],
    "manufacturers": [
      "NuCare Pharmaceuticals,Inc.",
      "Proficient Rx LP",
      "ST. MARY'S MEDICAL PARK PHARMACY"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown)",
      "This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses",
      "Enamel hypoplasia has also been reported",
      "Use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies",
      "Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline, and may range in severity from mild diarrhea to fatal colitis",
      "Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C",
      "difficile produces toxins A and B which contribute to the development of CDAD",
      "Hypertoxin producing strains of C",
      "difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy",
      "CDAD must be considered in all patients who present with diarrhea following the use of antibacterial drugs"
    ],
    "drug_interactions": [
      "Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage",
      "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin",
      "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations",
      "Absorption of tetracyclines is impaired by bismuth subsalicylate",
      "Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline",
      "The concurrent use of tetracycline and Penthrane ® (methoxyflurane) has been reported to result in fatal renal toxicity",
      "Concurrent use of tetracycline may render oral contraceptives less effective"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Due to oral doxycycline's virtually complete absorption, side effects of the lower bowel, particularly diarrhea, have been infrequent",
      "The following adverse reactions have been observed in patients receiving tetracyclines: Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region, and pancreatitis",
      "Hepatotoxicity has been reported rarely",
      "These reactions have been caused by both the oral and parenteral administration of tetracyclines",
      "Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported",
      "Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development",
      "(See WARNINGS .) Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of the drugs in the tetracycline class",
      "Most of these patients took medications immediately before going to bed",
      "(See D OSAGE AND ADMINISTRATION .) Skin: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, skin hyperpigmentation, maculopapular and erythematous rashes",
      "Exfoliative dermatitis has been reported but is uncommon",
      "Photosensitivity is discussed above",
      "(See WARNINGS .) Renal toxicity: Rise in BUN has been reported and is apparently dose related",
      "(See WARNINGS .) Immune: Hypersensitivity reactions including urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, exacerbation of systemic lupus erythematosus, drug reaction with eosinophilia and systemic symptoms (DRESS), and Jarisch-Herxherimer reactio",
      "Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported",
      "Other: Bulging fontanels in infants and intracrani"
    ],
    "indications": [
      "INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae",
      "Respiratory tract infections caused by Mycoplasma pneumoniae "
    ]
  },
  "doxycycline": {
    "ingredient": "doxycycline",
    "is_drug": true,
    "canonical_name": "doxycycline",
    "fda_search_term": "doxycycline",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DOXYCYCLINE",
      "DOXYCYCLINE HYCLATE",
      "doxycycline"
    ],
    "generic_names": [
      "DOXYCYCLINE",
      "DOXYCYCLINE HYCLATE"
    ],
    "manufacturers": [
      "NuCare Pharmaceuticals,Inc.",
      "Proficient Rx LP",
      "ST. MARY'S MEDICAL PARK PHARMACY"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown)",
      "This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses",
      "Enamel hypoplasia has also been reported",
      "Use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies",
      "Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline, and may range in severity from mild diarrhea to fatal colitis",
      "Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C",
      "difficile produces toxins A and B which contribute to the development of CDAD",
      "Hypertoxin producing strains of C",
      "difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy",
      "CDAD must be considered in all patients who present with diarrhea following the use of antibacterial drugs"
    ],
    "drug_interactions": [
      "Drug Interactions Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage",
      "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin",
      "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations",
      "Absorption of tetracyclines is impaired by bismuth subsalicylate",
      "Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline",
      "The concurrent use of tetracycline and Penthrane ® (methoxyflurane) has been reported to result in fatal renal toxicity",
      "Concurrent use of tetracycline may render oral contraceptives less effective"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Due to oral doxycycline's virtually complete absorption, side effects of the lower bowel, particularly diarrhea, have been infrequent",
      "The following adverse reactions have been observed in patients receiving tetracyclines: Gastrointestinal: anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region, and pancreatitis",
      "Hepatotoxicity has been reported rarely",
      "These reactions have been caused by both the oral and parenteral administration of tetracyclines",
      "Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported",
      "Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development",
      "(See WARNINGS .) Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of the drugs in the tetracycline class",
      "Most of these patients took medications immediately before going to bed",
      "(See D OSAGE AND ADMINISTRATION .) Skin: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, skin hyperpigmentation, maculopapular and erythematous rashes",
      "Exfoliative dermatitis has been reported but is uncommon",
      "Photosensitivity is discussed above",
      "(See WARNINGS .) Renal toxicity: Rise in BUN has been reported and is apparently dose related",
      "(See WARNINGS .) Immune: Hypersensitivity reactions including urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, exacerbation of systemic lupus erythematosus, drug reaction with eosinophilia and systemic symptoms (DRESS), and Jarisch-Herxherimer reactio",
      "Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported",
      "Other: Bulging fontanels in infants and intracrani"
    ],
    "indications": [
      "INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria",
      "When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy",
      "In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy",
      "Treatment: Doxycycline is indicated for the treatment of the following infections: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae",
      "Respiratory tract infections caused by Mycoplasma pneumoniae "
    ]
  },
  "doxylamine": {
    "ingredient": "doxylamine",
    "is_drug": true,
    "canonical_name": "doxylamine",
    "fda_search_term": "doxylamine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Night Time Cold and Flu",
      "Sleep Aid"
    ],
    "generic_names": [
      "ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE",
      "DOXYLAMINE SUCCINATE"
    ],
    "manufacturers": [
      "ARMY AND AIR FORCE EXCHANGE SERVICE",
      "The Kroger Co.",
      "United Natural Foods, Inc. dba UNFI"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Do not use in children under 12 years of age with any other product containing doxylamine unless you have time for a full night’s sleep Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma trouble urinating due to an enlarged prostate glan",
      "Insomnia may be a symptom of serious underlying medical illness",
      "If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Use helps to reduce difficulty in falling asleep"
    ]
  },
  "doxylamine succinate": {
    "ingredient": "doxylamine succinate",
    "is_drug": true,
    "canonical_name": "doxylamine",
    "fda_search_term": "doxylamine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Night Time Cold and Flu",
      "Sleep Aid"
    ],
    "generic_names": [
      "ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, DOXYLAMINE SUCCINATE",
      "DOXYLAMINE SUCCINATE"
    ],
    "manufacturers": [
      "ARMY AND AIR FORCE EXCHANGE SERVICE",
      "The Kroger Co.",
      "United Natural Foods, Inc. dba UNFI"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Do not use in children under 12 years of age with any other product containing doxylamine unless you have time for a full night’s sleep Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma trouble urinating due to an enlarged prostate glan",
      "Insomnia may be a symptom of serious underlying medical illness",
      "If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Use helps to reduce difficulty in falling asleep"
    ]
  },
  "dronedarone": {
    "ingredient": "dronedarone",
    "is_drug": true,
    "canonical_name": "dronedarone",
    "fda_search_term": "dronedarone",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Multaq"
    ],
    "generic_names": [
      "DRONEDARONE"
    ],
    "manufacturers": [
      "Cardinal Health 107, LLC",
      "Sanofi-Aventis U.S. LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Dronedarone is metabolized by CYP3A and is a moderate inhibitor of CYP3A and CYP2D6 and has potentially important pharmacodynamic interactions ( 7 )",
      "Class I or III antiarrhythmics: Contraindicated",
      "Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor digoxin levels",
      "Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability",
      "( 7.1 , 7.2 , 7.3 )",
      "Beta-blockers: May provoke excessive bradycardia",
      "Initiate with low dose and increase after ECG verification of tolerability",
      "CYP3A inducers: Avoid concomitant use",
      "Grapefruit juice: Avoid concomitant use",
      "Statins: Avoid simvastatin doses greater than 10 mg daily"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following safety concerns are described elsewhere in the label:",
      "New or worsening heart failure [see Warnings and Precautions (5.4) ]",
      "Liver Injury [see Warnings and Precautions (5.5) ]",
      "Pulmonary toxicity [see Warnings and Precautions (5.6) ]",
      "Hypokalemia and hypomagnesemia with potassium-depleting diuretics [see Warnings and Precautions (5.7) ]",
      "QT prolongation [see Warnings and Precautions (5.8) ] Most common adverse reactions (≥2%) are diarrhea, nausea, abdominal pain, vomiting, dyspepsia, bradycardia, skin issues (rashes, pruritus, eczema, dermatitis, dermatitis allergic), and asthenia ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact",
      "LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience The safety evaluation of dronedarone 400 mg twice daily in patients with AF or AFL is based on 5 placebo-controlled studies, ATHENA, EURIDIS, ADONIS, ERATO and DAFNE",
      "In these studies, a total of 6285 patients were randomized and treated, 3282 patients with MULTAQ 400 mg twice daily, and 2875 with placebo",
      "The mean exposure across studies was 12 months",
      "In ATHENA, the maximum follow-up was 30 months",
      "In clinical trials, premature discontinuation because of adverse reactions occurred in 11.8% of the dronedarone-treated patients and in 7.7% of the placebo-treated group",
      "The most common reasons for discontinuation of therapy with MULTAQ were gastrointestinal disorders (3.2% vs 1.8% in the placebo group) and QT prolongation (1.5% vs 0.5% in the placebo group)",
      "The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia",
      "Table 1 displays adverse reactions more common with dronedarone 400 mg twice daily than with placebo in AF or AFL patients, presented by system organ class and by decreasing order of frequency"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE MULTAQ ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) ] ",
      "MULTAQ is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF ( 1 , 14 )"
    ]
  },
  "dropripizine": {
    "ingredient": "dropripizine",
    "is_drug": true,
    "canonical_name": "droperidol",
    "fda_search_term": "droperidol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DROPERIDOL",
      "Droperidol"
    ],
    "generic_names": [
      "DROPERIDOL"
    ],
    "manufacturers": [
      "American Regent, Inc.",
      "Hikma Pharmaceuticals USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Droperidol should be administered with extreme caution in the presence of risk factors for development of prolonged QT syndrome, such as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrh",
      "Effects on Cardiac Conduction: A dose-dependent prolongation of the QT interval was observed within 10 minutes of droperidol administration in a study of 40 patients without known cardiac disease who underwent extracranial head and neck surgery",
      "Significant QT prolongation was observed at all three dose levels evaluated, with 0.1, 0.175, and 0.25 mg/kg associated with prolongation of median QTc by 37,44, and 59 msec, respectively",
      "Cases of QT prolongation and serious arrhythmias (e.g., torsade de pointes, ventricular arrhythmias, cardiac arrest, and death) have been observed during post-marketing treatment with droperidol",
      "Some cases have occurred in patients with no known risk factors and at doses at or below recommended doses",
      "There has been at least one case of nonfatal torsade de pointes confirmed by rechallenge",
      "Based on these reports, all patients should undergo a 12-lead ECG prior to administration of droperidol to determine if a prolonged QT interval (i.e., QTc greater than 440 msec for males or 450 msec for females) is present",
      "If there is a prolonged QT interval, droperidol should NOT be administered",
      "For patients in whom the potential benefit of droperidol treatment is felt to outweigh the risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2-3 hours"
    ],
    "drug_interactions": [
      "Drug Interactions Potentially Arrhythmogenic Agents: Any drug known to have the potential to prolong the QT interval should not be used together with droperidol",
      "Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants",
      "Caution should be used when patients are taking concomitant drugs known to induce hypokalemia or hypomagnesemia as they may precipitate QT prolongation and interact with droperidol",
      "These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential",
      "CNS Depressant Drugs: Other CNS depressant drugs (e.g",
      "barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with droperidol",
      "When patients have received such drugs, the dose of droperidol required will be less than usual",
      "Following the administration of droperidol, the dose of other CNS depressant drugs should be reduced"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS QT interval prolongation, torsade de pointes, cardiac arrest, and ventricular tachycardia have been reported in patients treated with droperidol",
      "Some of these cases were associated with death",
      "Some cases occurred in patients with no known risk factors, and some were associated with droperidol doses at or below recommended doses",
      "Physicians should be alert to palpitations, syncope, or other symptoms suggestive of episodes of irregular cardiac rhythm in patients taking droperidol and promptly evaluate such cases (see WARNINGS, Effects on Cardiac Conduction )",
      "The most common somatic adverse reactions reported to occur with droperidol are mild to moderate hypotension and tachycardia, but these effects usually subside without treatment",
      "If hypotension occurs and is severe or persists, the possibility of hypovolemia should be considered and managed with appropriate parenteral fluid therapy",
      "The most common behavioral adverse effects of droperidol include dysphoria, postoperative drowsiness, restlessness, hyperactivity and anxiety, which can either be the result of an inadequate dosage (lack of adequate treatment effect) or of an adverse drug reaction (part of the symptom complex of aka",
      "Care should be taken to search for extrapyramidal signs and symptoms (dystonia, akathisia, oculogyric crisis) to differentiate these different clinical conditions",
      "When extrapyramidal symptoms are the cause, they can usually be controlled with anticholinergic agents",
      "Postoperative hallucinatory episodes (sometimes associated with transient periods of mental depression) have also been reported",
      "Other less common reported adverse reactions include anaphylaxis, dizziness, chills and/or shivering, laryngospasm and bronchospasm",
      "Elevated blood pressure, with or without pre-existing hypertension, has been reported following administration of droperidol combined with fentanyl citrate or other parenteral analgesics",
      "This might be due to unexplained alterations in sympath"
    ],
    "indications": [
      "INDICATIONS AND USAGE Droperidol Injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures"
    ]
  },
  "drospirenone": {
    "ingredient": "drospirenone",
    "is_drug": true,
    "canonical_name": "drospirenone",
    "fda_search_term": "drospirenone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Angeliq"
    ],
    "generic_names": [
      "DROSPIRENONE AND ESTRADIOL"
    ],
    "manufacturers": [
      "Bayer HealthCare Pharmaceuticals Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Inducers and inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration",
      "Serum potassium concentration may increase in women taking drospirenone with other drugs that have the potential to increase potassium",
      "( 7.1 ) 7.1 Metabolic Interactions Effect of Drospirenone on Other Drugs The potential effect of DRSP on CYP2C19 activity was investigated in a clinical pharmacokinetic study using omeprazole as a marker substrate",
      "No significant effect of DRSP on the systemic clearance of the CYP3A4 product omeprazole sulfone was found",
      "These results demonstrated that DRSP did not inhibit CYP2C19 and CYP3A4 in vivo ",
      "Two further clinical drug-drug interaction studies using simvastatin and midazolam as marker substrates for CYP3A4, respectively, were performed and the results of these studies demonstrated that pharmacokinetics of the CYP3A4 substrates were not influenced by steady-state DRSP concentrations",
      "Co-administration of DRSP and drugs that may increase serum potassium: There is a potential for an increase in serum potassium in women taking DRSP with other drugs that may affect electrolytes, such as ACE inhibitors, angiotensin receptor blockers, or NSAIDs, more pronounced in diabetic women [see ",
      "Electrolytes were studied in postmenopausal women with hypertension and/or diabetes mellitus requiring an ACE inhibitor or angiotensin receptor blocker",
      "After 28 days of exposure to 1 mg E2 and 3 mg DRSP (n=112) or placebo (n=118)"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling:",
      "Cardiovascular Disorders [see Boxed Warning , Warnings and Precautions ( 5.1 )]",
      "Malignant Neoplasms [see Boxed Warning , Warnings and Precautions ( 5.3 )] The most common adverse reactions with Angeliq that occurred in at least 1% of users in clinical trials are: gastrointestinal and abdominal pain, female genital tract bleeding, breast pain and discomfort, and headache",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc",
      "at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of ano",
      "From clinical trials with different dose formulations of Angeliq containing E2 dose ranging from 0.5 mg to 1.0 mg combined with DRSP dose ranging from 0.25 mg to 3 mg:",
      "The most common adverse reactions were gastrointestinal and abdominal pain, female genital bleeding, breast pain and headache",
      "The frequencies of common adverse reactions, in general, were higher for the Angeliq dose formulation containing E2 1 mg compared to Angeliq containing E2 0.5 mg",
      "The most common adverse reactions leading to drug discontinuation in controlled clinical trials were abdominal pain, headache, postmenopausal bleeding, breast tenderness, and weight increased",
      "Placebo-Controlled Trial: In a placebo-controlled trial evaluating Angeliq 0.25 mg DRSP/0.5 mg E2, 183 postmenopausal women received at least one dose of DRSP 0.25 mg/0.5 mg E2 and 180 received placebo",
      "Study participants were treated for 3 cycles of 28 days each for a total of 12 weeks of treatment",
      "The median age was 53 years (range: 40-77 years) and over 50% of women had a hysterectomy, 68% were Caucasian"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Angeliq is a combination of an estrogen and progestin indicated in a woman with a uterus for the treatment of:",
      "Moderate to severe vasomotor symptoms due to menopause",
      "Moderate to severe vulvar and vaginal atrophy symptoms due to menopause",
      "( 1.2 ) Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products",
      "Use estrogen, alone or in combination with a progestogen, at the lowest effective dose and the shortest duration consistent with treatment goals and risks for the individual woman"
    ]
  },
  "dulaglutide": {
    "ingredient": "dulaglutide",
    "is_drug": true,
    "canonical_name": "dulaglutide",
    "fda_search_term": "dulaglutide",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "TRULICITY",
      "Trulicity"
    ],
    "generic_names": [
      "DULAGLUTIDE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Eli Lilly and Company"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Oral Medications: Delays gastric emptying and has the potential to reduce the rate of absorption of concomitantly administered oral medications ( 7.1 , 12.3 )",
      "7.1 Oral Medications TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications",
      "The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY [see Dosage and Administration ( 2.1 )] ",
      "The delay is largest after the first dose and diminishes with subsequent doses",
      "In clinical pharmacology studies, TRULICITY 1.5 mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree [see Clinical Pharmacology ( 12.3 )] ",
      "There is limited experience with the use of concomitant medications in clinical trials with TRULICITY doses of 3 mg and 4.5 mg",
      "Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY",
      "7.2 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions ( 5.3 ) "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] Pancreatitis [see Warnings and Precautions ( 5.2 )] Hypoglycemia with Concomitant Use of Insulin Secretagogues or ",
      "To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice",
      "Adverse Reactions in the Clinical Trials in Adults with Type 2 Diabetes Mellitus Pool of Adult Placebo-Controlled Trials for TRULICITY 0.75 mg and 1.5 mg Doses The data in Table 1 are derived from a pool of placebo-controlled trials and include 1,670 adult patients with type 2 diabetes mellitus expo",
      "The mean age of patients was 56 years, 1% were 75 years or older and 53% were male",
      "The population was 69% White, 7% Black or African American, 13% Asian; 30% were of Hispanic or Latino ethnicity",
      "At baseline, the population had diabetes for an average of 8 years, a mean HbA1c of 8.0%, and 2"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus",
      "To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors",
      "TRULICITY ® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated ( 1 ): As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus",
      "To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors",
      "Limitations of Use: Has not been studied in patients with a history of pancreatitis"
    ]
  },
  "dulcamarae": {
    "ingredient": "dulcamarae",
    "is_drug": true,
    "canonical_name": "duloxetine",
    "fda_search_term": "duloxetine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DULOXETINE HYDROCHLORIDE",
      "Duloxetine",
      "Duloxetine Delayed-Release"
    ],
    "generic_names": [
      "DULOXETINE",
      "DULOXETINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Limited",
      "Golden State Medical Supply, Inc.",
      "ST. MARY'S MEDICAL PARK PHARMACY"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism",
      "Potent inhibitors of CYP1A2 should be avoided ( 7.1 ) Potent inhibitors of CYP2D6 may increase Duloxetine delayed-release capsules concentrations ( 7.2 ) Duloxetine delayed-release capsules is a moderate inhibitor of CYP2D6 ( 7.9 ) 7.1 Inhibitors of CYP1A2 When duloxetine 60 mg was co-administered w",
      "Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin [see Warnings and Precautions (5.12) ]",
      "7.2 Inhibitors of CYP2D6 Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine",
      "Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.12) ]",
      "7.3 Dual Inhibition of CYP1A2 and CYP2D6 Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and C max",
      "7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) Serotonin release by platelets plays an important role in hemostasis",
      "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate",
      "Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are co-ad"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults [see Boxed Warning and Warnings and Precautions (5.1) ] Hepatotoxicity [see Warnings and Precautions (5.2) ] Ortho",
      "at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The stated frequencies of adverse reactions represent the proportion of patients who experienced, at least once, one treatment-emergen"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Duloxetine delayed-release capsules is indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Diabetic peripheral neuropathic pain in adults Fibromyalgia in adults and pediatri"
    ]
  },
  "duloxetine": {
    "ingredient": "duloxetine",
    "is_drug": true,
    "canonical_name": "duloxetine",
    "fda_search_term": "duloxetine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DULOXETINE HYDROCHLORIDE",
      "Duloxetine",
      "Duloxetine Delayed-Release"
    ],
    "generic_names": [
      "DULOXETINE",
      "DULOXETINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Limited",
      "Golden State Medical Supply, Inc.",
      "ST. MARY'S MEDICAL PARK PHARMACY"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism",
      "Potent inhibitors of CYP1A2 should be avoided ( 7.1 ) Potent inhibitors of CYP2D6 may increase Duloxetine delayed-release capsules concentrations ( 7.2 ) Duloxetine delayed-release capsules is a moderate inhibitor of CYP2D6 ( 7.9 ) 7.1 Inhibitors of CYP1A2 When duloxetine 60 mg was co-administered w",
      "Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin [see Warnings and Precautions (5.12) ]",
      "7.2 Inhibitors of CYP2D6 Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine",
      "Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see Warnings and Precautions (5.12) ]",
      "7.3 Dual Inhibition of CYP1A2 and CYP2D6 Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and C max",
      "7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) Serotonin release by platelets plays an important role in hemostasis",
      "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate",
      "Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are co-ad"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults [see Boxed Warning and Warnings and Precautions (5.1) ] Hepatotoxicity [see Warnings and Precautions (5.2) ] Ortho",
      "at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The stated frequencies of adverse reactions represent the proportion of patients who experienced, at least once, one treatment-emergen"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Duloxetine delayed-release capsules is indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Diabetic peripheral neuropathic pain in adults Fibromyalgia in adults and pediatri"
    ]
  },
  "dupilumab": {
    "ingredient": "dupilumab",
    "is_drug": true,
    "canonical_name": "dupilumab",
    "fda_search_term": "dupilumab",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dupixent"
    ],
    "generic_names": [
      "DUPILUMAB"
    ],
    "manufacturers": [
      "sanofi-aventis U.S. LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Warnings and Precautions (5.1) ] Conjunctivitis and Keratitis [see Warnings and Precautions (5.2) ] Psoriasis [see Warnings and Precautions (5.7) ] Arthralgia and",
      "( 6.1 ) Asthma (incidence ≥1%): injection site reactions, oropharyngeal pain, and eosinophilia",
      "( 6.1 ) Chronic Rhinosinusitis with Nasal Polyps (incidence ≥1%): injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis",
      "( 6.1 ) Eosinophilic Esophagitis (incidence ≥2%): injection site reactions, upper respiratory tract infections, arthralgia, and herpes viral infections",
      "( 6.1 ) Prurigo Nodularis (incidence ≥2%): nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea",
      "( 6.1 ) Chronic Obstructive Pulmonary Disease (incidence ≥2%): viral infection, headache, nasopharyngitis, back pain, diarrhea, arthralgia, urinary tract infection, local administration reactions, rhinitis, eosinophilia, toothache, and gastritis",
      "( 6.1 ) Chronic Spontaneous Urticaria (incidence ≥2%): injection site reactions",
      "( 6.1 ) Bullous Pemphigoid (incidence ≥2%): arthralgia, conjunctivitis, vision blurred, herpes viral infections, keratitis",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Regeneron at 1-844-387-4936 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when thos",
      "DUPIXENT can be used with or without topical corticosteroids",
      "( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma",
      "( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus",
      "( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)"
    ]
  },
  "durvalumab": {
    "ingredient": "durvalumab",
    "is_drug": true,
    "canonical_name": "durvalumab",
    "fda_search_term": "durvalumab",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "IMFINZI"
    ],
    "generic_names": [
      "DURVALUMAB"
    ],
    "manufacturers": [
      "AstraZeneca Pharmaceuticals LP"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling",
      "Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1) ]",
      "Infusion-Related Reactions [see Warnings and Precautions (5.2) ]",
      "IMFINZI in Combination with Chemotherapy",
      "Most common adverse reactions (≥ 20%) of patients with resectable, Stage II/III NSCLC [neoadjuvant /adjuvant]) are anemia, nausea, constipation, fatigue, musculoskeletal pain, and rash",
      "( 6.1 ) IMFINZI as a Single Agent",
      "Most common adverse reactions (≥ 20%) of patients with unresectable, Stage III NSCLC) are cough, fatigue, pneumonitis/radiation pneumonitis, upper respiratory tract infections, dyspnea, and rash",
      "( 6.1 ) IMFINZI in Combination with Tremelimumab-actl and Platinum-Based Chemothe rapy",
      "Most common adverse reactions (≥ 20%) of patients with metastatic NSCLC) are nausea, fatigue, musculoskeletal pain, decreased appetite, rash, and diarrhea",
      "( 6.1 ) IMFINZI as a Single Agent",
      "Most common adverse reactions (≥ 20%) of patients with limited-stage SCLC) are pneumonitis or radiation pneumonitis, and fatigue",
      "( 6.1 ) IMFINZI in Combination with Platinum-Based Chemotherapy",
      "Most common adverse reactions (≥ 20%) of patients with extensive-stage SCLC) are nausea, fatigue/asthenia, and alopecia",
      "( 6.1 ) IMFINZI in Combination with Gemcitabine and Cisplatin",
      "Most common adverse reactions (≥ 20%) of patients with BTC) are fatigue, nausea, constipation, decreased appetite, abdominal pain, rash, and pyrexia"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:",
      "in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known",
      "as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy",
      "in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations",
      "as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy"
    ]
  },
  "dutasteride": {
    "ingredient": "dutasteride",
    "is_drug": true,
    "canonical_name": "dutasteride",
    "fda_search_term": "dutasteride",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dutasteride",
      "Dutasteride and Tamsulosin Hydrochloride"
    ],
    "generic_names": [
      "DUTASTERIDE",
      "DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES"
    ],
    "manufacturers": [
      "AvKARE",
      "Bryant Ranch Prepack",
      "NuCare Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS There have been no drug interaction trials using dutasteride and tamsulosin hydrochloride capsules",
      "The following sections reflect information available for the individual components",
      "7.1 Cytochrome P450 Inhibition Dutasteride Dutasteride is extensively metabolized in humans by the CYP3A4 and CYP3A5 isoenzymes",
      "The effect of potent CYP3A4 inhibitors on dutasteride has not been studied",
      "Because of the potential for drug-drug interactions, use caution when prescribing a dutasteride-containing product, including dutasteride and tamsulosin hydrochloride capsules, to patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir) [see Clinical Pharmacology ( 12.3 ) ] ",
      "Tamsulosin Strong and Moderate Inhibitors of CYP3A4 or CYP2D6: Tamsulosin is extensively metabolized, mainly by CYP3A4 or CYP2D6",
      "Concomitant treatment with ketoconazole (a strong inhibitor of CYP3A4) resulted in increases in the C max and AUC of tamsulosin by factors of 2.2 and 2.8, respectively",
      "Concomitant treatment with paroxetine (a strong inhibitor of CYP2D6) resulted in increases in the C max and area under the concentration-time curve (AUC) of tamsulosin by factors of 1.3 and 1.6, respectively",
      "A similar increase in exposure is expected in poor metabolizers (PM) of CYP2D6 as compared to extensive metabolizers (EM)",
      "Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when tamsulosin 0.4 mg is coadministered with strong CYP3A4 inhibitors in CYP2D6 PMs, tamsulosin 0.4 mg capsules should not be used in combination with strong inhibitors of CYP3A4 ("
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions, reported in ≥1% of subjects treated with coadministered dutasteride and tamsulosin are ejaculation disorders, impotence, decreased libido, dizziness, and breast disorders",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience The clinical efficacy and safety of coadministered dutasteride and tamsulosin, which are individual components of dutasteride and tamsulosin hydrochloride capsules, have been evaluated in a multicenter, randomized, double-blind, parallel group trial (the Combination wi",
      "Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trial of another drug and may not reflect the rates observed in practice",
      "The most common adverse reactions reported in subjects receiving coadministered dutasteride and tamsulosin were impotence, decreased libido, breast disorders (including breast enlargement and tenderness), ejaculation disorders, and dizziness",
      "Ejaculation disorders occurred significantly more in subjects receiving coadministration therapy (11%) compared with those receiving dutasteride (2%) or tamsulosin (4%) as monotherapy",
      "Trial withdrawal due to adverse reactions occurred in 6% of subjects receiving coadministered dutasteride and tamsulosin and in 4% of subjects receiving dutasteride or tamsulosin as monotherapy",
      "The most common adverse reaction in all treatment arms leading to trial withdrawal was erectile dysfunction (1% to 1.5%)",
      "In the CombAT trial, over 4,800 male subjects with BPH were randomly assigned to receive 0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride, or coadministration therapy (0.5 mg dutasteride and 0.4 mg tamsulosin hydrochloride) administered once daily in a 4-year double-blind trial"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Dutasteride and tamsulosin hydrochloride capsules are a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate",
      "( 1.1 ) Limitations of Use: Dutasteride-containing products, including dutasteride and tamsulosin hydrochloride capsules, are not approved for the prevention of prostate cancer",
      "( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) Treatment Dutasteride and tamsulosin hydrochloride capsules are indicated for the treatment of symptomatic BPH in men with an enlarged prostate",
      "1.2 Limitations of Use Dutasteride-containing products, including dutasteride and tamsulosin hydrochloride capsules, are not approved for the prevention of prostate cancer"
    ]
  },
  "eclipta alba ext": {
    "ingredient": "eclipta alba ext",
    "is_drug": true,
    "canonical_name": "eclipta alba extract",
    "fda_search_term": "eclipta alba extract",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Quick Action"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "SALICYLIC ACID"
    ],
    "manufacturers": [
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only: hands only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTION Information: 1-888-287-1915 or Walmart.com/help DISTRIBUTED BY: Walmart Inc., Bentonville, AR 72716 PLASTIC TUBE Do Not Recycle how2recycle.info Made in the USA with domestic and imported ingredients",
      "Factory Certified"
    ],
    "indications": [
      "Use For handwashing to decrease bacteria on the skin"
    ]
  },
  "econazole": {
    "ingredient": "econazole",
    "is_drug": true,
    "canonical_name": "econazole",
    "fda_search_term": "econazole",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Econazole Nitrate",
      "Ecoza"
    ],
    "generic_names": [
      "ECONAZOLE NITRATE"
    ],
    "manufacturers": [
      "Padagis Israel Pharmaceuticals Ltd",
      "Preferred Pharmaceuticals Inc.",
      "Resilia Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Econazole Nitrate Cream is not for ophthalmic use"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect",
      "Most cases reported product application with use under occlusion, genital application, or application to a large body surface area which may increase the systemic absorption of econazole nitrate",
      "Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS During clinical trials with Ecoza topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Ecoza and vehicle arms",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Resilia Pharmaceuticals at 1-888-998-0770 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "In two double-blind, vehicle-controlled clinical trials, 495 subjects were exposed to Ecoza topical foam or vehicle (246 subjects were exposed to Ecoza topical foam, 1% and 249 were exposed to vehicle)",
      "Subjects with interdigital tinea pedis applied foam or vehicle once daily for approximately 28 days",
      "During clinical trials with Ecoza topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Ecoza and vehicle arms"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ecoza (econazole nitrate) topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older",
      "Ecoza is an azole antifungal indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes , and Epidermophyton floccosum in patients 12 years of age and older"
    ]
  },
  "econazole nitrate": {
    "ingredient": "econazole nitrate",
    "is_drug": true,
    "canonical_name": "econazole",
    "fda_search_term": "econazole",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Econazole Nitrate",
      "Ecoza"
    ],
    "generic_names": [
      "ECONAZOLE NITRATE"
    ],
    "manufacturers": [
      "Padagis Israel Pharmaceuticals Ltd",
      "Preferred Pharmaceuticals Inc.",
      "Resilia Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Econazole Nitrate Cream is not for ophthalmic use"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect",
      "Most cases reported product application with use under occlusion, genital application, or application to a large body surface area which may increase the systemic absorption of econazole nitrate",
      "Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS During clinical trials with Ecoza topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Ecoza and vehicle arms",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Resilia Pharmaceuticals at 1-888-998-0770 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "In two double-blind, vehicle-controlled clinical trials, 495 subjects were exposed to Ecoza topical foam or vehicle (246 subjects were exposed to Ecoza topical foam, 1% and 249 were exposed to vehicle)",
      "Subjects with interdigital tinea pedis applied foam or vehicle once daily for approximately 28 days",
      "During clinical trials with Ecoza topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the Ecoza and vehicle arms"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ecoza (econazole nitrate) topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older",
      "Ecoza is an azole antifungal indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes , and Epidermophyton floccosum in patients 12 years of age and older"
    ]
  },
  "ectoin": {
    "ingredient": "ectoin",
    "is_drug": true,
    "canonical_name": "ectoin",
    "fda_search_term": "ectoin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hemorrhoid and Fissure"
    ],
    "generic_names": [
      "GLYCERIN 6%,LIDOCAINE 4%,ECTOIN 0.12%"
    ],
    "manufacturers": [
      "FlexiGo Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS WARNINGS WARNINGS"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS & USAGE SECTION INDICATIONS & USAGE SECTION INDICATIONS & USAGE SECTION"
    ]
  },
  "edetate disodium": {
    "ingredient": "edetate disodium",
    "is_drug": true,
    "canonical_name": "edetate disodium",
    "fda_search_term": "edetate disodium",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Miracle FootCream Lavender",
      "Miracle FootCream Lemon"
    ],
    "generic_names": [
      "UREA, GLYCERIN, ALOE, DISODIUM EDTA"
    ],
    "manufacturers": [
      "Aloe Vera Korea Co.,Ltd."
    ],
    "dosage_forms": [],
    "warnings": [
      "don’t use on the part where there is injury, eczema, or dermatitis if swallowed, get medical help or contact a person control center immediately"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "taking off an appropriate amount you apply to your rough feet as you massage two or three times a day"
    ]
  },
  "edoxaban": {
    "ingredient": "edoxaban",
    "is_drug": true,
    "canonical_name": "edoxaban",
    "fda_search_term": "edoxaban",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "SAVAYSA"
    ],
    "generic_names": [
      "EDOXABAN TOSYLATE"
    ],
    "manufacturers": [
      "Daiichi Sankyo Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding",
      "( 7.1 ) Rifampin: Avoid concomitant use ( 7.2 ) 7.1 Anticoagulants, Antiplatelets, Thrombolytics, and SSRIs/SNRIs Co-administration of anticoagulants, antiplatelet drugs, thrombolytics and SSRIs or SNRIs may increase the risk of bleeding",
      "Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with anticoagulants, aspirin, other platelet aggregation inhibitors, and/or NSAIDs [see Warnings and Precautions (5.3) ] ",
      "Long-term concomitant treatment with SAVAYSA and other anticoagulants is not recommended because of increased risk of bleeding [see Warnings and Precautions (5.3) ] ",
      "Short term co-administration may be needed for patients transitioning to or from SAVAYSA [see Dosage and Administration (2.4) ] ",
      "In clinical studies with SAVAYSA concomitant use of aspirin (low dose ≤ 100 mg/day) or thienopyridines, and NSAIDs was permitted and resulted in increased rates of Clinically Relevant Bleeding",
      "Carefully monitor for bleeding in patients who require chronic treatment with low dose aspirin and/or NSAIDs [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ] ",
      "As with other anticoagulants the possibility may exist that patients are at an increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets [see Warnings and Precautions (5.3) ]",
      "7.2 P-gp Inducers Avoid the concomitant use of SAVAYSA with rifampin [see Clinical Pharmacology (12.3) ] ",
      "7.3 P-gp Inhibitors Treatment of NVAF Based on clinical experience from the ENGAGE AF-TIMI 48 study, dose reduction in patients concomitantly receiving P-gp inhibitors resulted in edoxaban blood levels that were lower than in patients who were given the full dose"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the prescribing information",
      "Increased Risk of Stroke with Discontinuation of SAVAYSA in Patients with Nonvalvular Atrial Fibrillation [see Warnings and Precautions (5.2) ] Risk of Bleeding [see Warnings and Precautions (5.3) ] Spinal/Epidural Anesthesia or Puncture [see Warnings and Precautions (5.4) ] Treatment of NVAF : The ",
      "at 1-877-437-7763 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The safety of SAVAYSA was evaluated in the ENGAGE AF-TIMI 48, Hokusai VTE, and Hokusai VTE Cancer studies including 11,530 patients exposed to SAVAYSA 60 mg and 7124 patients exposed to SAVAYSA 30 mg once daily [see Clinical Studies (14) ] ",
      "The ENGAGE AF-TIMI 48 Study In the ENGAGE AF-TIMI 48 study, the median study drug exposure for the SAVAYSA and warfarin treatment groups was 2.5 years",
      "Bleeding was the most common reason for treatment discontinuation",
      "Bleeding led to treatment discontinuation in 3.9% and 4.1% of patients in the SAVAYSA 60 mg and warfarin treatment groups, respectively",
      "In the overall population, major bleeding was lower in the SAVAYSA group compared to the warfarin group [HR 0.80 (0.70, 0.91), p < 0.001]",
      "Table 6.1 shows major bleeding events (percentage of patients with at least one bleeding event, per year) for the indicated population (CrCL ≤ 95 mL/min)"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min b",
      "Limitation of Use for NVAF SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin [see Dosage and Administration (2.1) , Warnings and Precautions (5.1) and Clinical Studies (14.1) ] ",
      "1.2 Treatment of Deep Vein Thrombosis and Pulmonary Embolism SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant"
    ]
  },
  "edta": {
    "ingredient": "edta",
    "is_drug": true,
    "canonical_name": "edetate",
    "fda_search_term": "edetate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Edetate Calcium Disodium",
      "Miracle FootCream Lavender",
      "Miracle FootCream Lemon"
    ],
    "generic_names": [
      "EDETATE CALCIUM DISODIUM",
      "UREA, GLYCERIN, ALOE, DISODIUM EDTA"
    ],
    "manufacturers": [
      "Aloe Vera Korea Co.,Ltd.",
      "Rising Pharma Holdings, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS See Boxed Warning"
    ],
    "drug_interactions": [
      "Drug Interactions There is no known drug interference with standard clinical laboratory tests",
      "Steroids enhance the renal toxicity of edetate calcium disodium in animals",
      "7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following adverse effects have been associated with the use of edetate calcium disodium: Body as a Whole: pain at intramuscular injection site, fever, chills, malaise, fatigue, myalgia, arthralgia",
      "Cardiovascular: hypotension, cardiac rhythm irregularities",
      "Renal: acute necrosis of proximal tubules (which may result in fatal nephrosis), infrequent changes in distal tubules and glomeruli",
      "Urinary: glycosuria, proteinuria, microscopic hematuria and large epithelial cells in urinary sediment",
      "Nervous System: tremors, headache, numbness, tingling",
      "Gastrointestinal: cheilosis, nausea, vomiting, anorexia, excessive thirst",
      "Hepatic: mild increases in SGOT and SGPT are common, and return to normal within 48 hours after cessation of therapy",
      "Immunogenic: histamine-like reactions (sneezing, nasal congestion, lacrimation), rash",
      "Hematopoietic: transient bone marrow depression, anemia",
      "Metabolic: zinc deficiency, hypercalcemia",
      "To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc",
      "at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch "
    ],
    "indications": [
      "INDICATIONS AND USAGE Edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults",
      "Chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead"
    ]
  },
  "efavirenz": {
    "ingredient": "efavirenz",
    "is_drug": true,
    "canonical_name": "efavirenz",
    "fda_search_term": "efavirenz",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Efavirenz",
      "Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate",
      "Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate"
    ],
    "generic_names": [
      "EFAVIRENZ",
      "EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE",
      "EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE"
    ],
    "manufacturers": [
      "Aurobindo Pharma Limited",
      "Laurus Labs Limited",
      "Macleods Pharmaceuticals Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of efavirenz can alter the concentrations of other drugs and other drugs may alter the concentrations of efavirenz",
      "The potential for drug-drug interactions should be considered before and during therapy",
      "( 7 ) 7.1 Potential for efavirenz to Affect other Drugs Efavirenz has been shown in vivo to induce CYP3A and CYP2B6",
      "Other compounds that are substrates of CYP3A or CYP2B6 may have decreased plasma concentrations when coadministered with efavirenz 7.2 Potential for Other Drugs to Affect efavirenz Drugs that induce CYP3A activity (e.g., phenobarbital, rifampin, rifabutin) would be expected to increase the clearance",
      "7.3 QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval",
      "QTc prolongation has been observed with the use of efavirenz [see Clinical Pharmacology ( 12.2 )]",
      "Consider alternatives to efavirenz when coadministered with a drug with a known risk of Torsade de Pointes",
      "7.4 Established and Other Potentially Significant Drug Interactions Drug interactions with efavirenz are summarized in Table 5",
      "For pharmacokinetics data, [see Clinical Pharmacology ( 12.3 )] Tables 7 and 8",
      "This table includes potentially significant interactions, but is not all inclusive Table 5: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted Interaction Concomitant Drug Class: Drug Name E"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most significant adverse reactions observed in patients treated with efavirenz are:",
      "psychiatric symptoms [see Warnings and Precautions ( 5.5 )],",
      "nervous system symptoms [see Warnings and Precautions ( 5.6 )],",
      "rash [see Warnings and Precautions ( 5.8 )]",
      "hepatotoxicity [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (>5%, moderate-severe) are impaired concentration, abnormal dreams, rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting.( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharmaceutical Ltd ",
      "6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, the adverse reaction rates reported cannot be directly compared to rates in other clinical studies and may not reflect the rates observed in clinical practice",
      "Adverse Reactions in Adults",
      "The most common (>5% in either efavirenz treatment group) adverse reactions of at least moderate severity among patients in Study 006 treated with efavirenz in combination with zidovudine/lamivudine or indinavir were rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting Selected clinica",
      "and Protease Inhibitor-Naive Patients Adverse Reactions Efavirenz b + ZDV/LAM (n=412) Efavirenz b + Indinavir (n=415) Indinavir + ZDV/LAM (n=401) Efavirenz b + Nelfinavir + NRTIs (n=64) Efavirenz b + NRTIs (n=65) Nelfinavir + NRTIs (n=66) 180 weeks c 102 weeks c 76 weeks c 71.1 weeks c 70.9 weeks c "
    ],
    "indications": [
      "1 INDICATIONS & USAGE Efavirenz in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg",
      "Efavirenz is a non-nucleoside reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.( 1 )"
    ]
  },
  "efedrin": {
    "ingredient": "efedrin",
    "is_drug": true,
    "canonical_name": "ephedrine",
    "fda_search_term": "ephedrine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Emerphed PFS",
      "Ephedrine Sulfate",
      "Ephedrine sulfate"
    ],
    "generic_names": [
      "EPHEDRINE SULFATE"
    ],
    "manufacturers": [
      "Caplin Steriles Limited",
      "Medical Purchasing Solutions, LLC",
      "Nexus Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Interactions that Augment the Pressor Effect Oxytocin and oxytocic drugs Clinical Impact: Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovi",
      "Some of these patients experienced a stroke",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and an oxytocic",
      "Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine Clinical Impact: These drugs augment the pressor effect of ephedrine",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs",
      "Interactions that Antagonize the Pressor Effect Clinical Impact: These drugs antagonize the pressor effect of ephedrine",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs",
      "Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions Guanethidine Clinical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness",
      "Intervention: Clinician should monitor patient for blood pressor response and adjust the dosage or choice of pressor accordingly",
      "Rocuronium Clinical Impact: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions associated with the use of ephedrine sulfate were identified in the literature",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure",
      "Gastrointestinal disorders: Nausea, vomiting Cardiac disorders: Tachycardia, palpitations (thumping heart), reactive hypertension, bradycardia, ventricular ectopics, R-R variability Nervous system disorders: Dizziness Psychiatric disorders: Restlessness Most common adverse reactions during treatment",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia",
      "Ephedrine sulfate injection is an alpha",
      "and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia"
    ]
  },
  "eflornithine": {
    "ingredient": "eflornithine",
    "is_drug": true,
    "canonical_name": "eflornithine",
    "fda_search_term": "eflornithine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "iwilfin"
    ],
    "generic_names": [
      "EFLORNITHINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "USWM, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Myelosuppression [see Warnings and Precautions (5.1) ] Hepatotoxicity [see Warnings and Precautions (5.2) ] Hearing Loss [see Warnings and Precautions (5.3) ] Most common adverse react",
      "( 6.1 ) Most common Grade 3 or 4 laboratory abnormalities (incidence ≥2%) are increased ALT, increased AST, decreased neutrophil count, and decreased hemoglobin",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact US WorldMeds at 1-877-IWILFIN or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug",
      "The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to IWILFIN as a single agent, taken orally at doses ranging from 192",
      "768 mg twice daily, based on body surface area (BSA), until disease progression, unacceptable toxicity, or for a maximum of 2 years in patients who demonstrated at least a partial response to prior multiagent, multimodality therapy for newly diagnosed or relapsed/refractory high-risk neuroblastoma i",
      "Among 360 patients who received IWILFIN, 84% were exposed for 6 months or longer and 73% were exposed for greater than one year",
      "In this pooled safety population, the most common (≥5%) adverse reactions were hearing loss (11%), otitis media (10%), pyrexia (7%), pneumonia (5%), and diarrhea (5%)",
      "The most common (≥2%) Grade 3 or 4 laboratory abnormalities were increased ALT (11%), increased AST (6%), decreased neutrophils (4.2%), and decreased hemoglobin (3.3%)",
      "Study 3b The safety of IW"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy",
      "IWILFIN is an ornithine decarboxylase inhibitor indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy"
    ]
  },
  "eicosapentaenoic": {
    "ingredient": "eicosapentaenoic",
    "is_drug": true,
    "canonical_name": "eicosapentaenoic acid",
    "fda_search_term": "eicosapentaenoic acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "eicosapentaenoic acid": {
    "ingredient": "eicosapentaenoic acid",
    "is_drug": true,
    "canonical_name": "eicosapentaenoic acid",
    "fda_search_term": "eicosapentaenoic acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "eletriptan": {
    "ingredient": "eletriptan",
    "is_drug": true,
    "canonical_name": "eletriptan",
    "fda_search_term": "eletriptan",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Eletriptan HBR",
      "Eletriptan Hydrobromide",
      "eletriptan hydrobromide"
    ],
    "generic_names": [
      "ELETRIPTAN HBR",
      "ELETRIPTAN HYDROBROMIDE"
    ],
    "manufacturers": [
      "Advanced Rx of Tennessee, LLC",
      "Direct_Rx",
      "Quality Care Products, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7.1 Ergot-Containing Drugs Including Other 5-HT 1B/1D Agonists Ergot-containing drugs have been reported to cause prolonged vasospastic reactions",
      "Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine [DHE] or methysergide) and eletriptan hydrobromide within 24 hours of each other is contraindicated",
      "Concomitant use of other 5-HT1 agonists within 24 hours of eletriptan hydrobromide treatment is contraindicated [see CONTRAINDICATIONS (4)]",
      "7.2 CYP3A4 Inhibitors Potent CYP3A4 inhibitors significantly increase the exposure of eletriptan hydrobromide",
      "Eletriptan hydrobromide should not be used within at least 72 hours of treatment with potent CYP3A4 inhibitors [see CONTRAINDICATIONS (4) and CLINICAL PHARMACOLOGY (12.3)]",
      "7.3 Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs and MAO inhibitors [see WARNINGS AND PRECAUTIONS (5.7)]"
    ],
    "adverse_reactions": [
      "The following adverse reactions are described elsewhere in other sections of the prescribing information: Myocardial ischemia and myocardial infarction, and Prinzmetal’s angina [see WARNINGS AND PRECAUTIONS (5.2)] Arrhythmias [see WARNINGS AND PRECAUTIONS (5.3)] Chest, throat, neck, and/or jaw pain/",
      "Among 4,597 patients who treated the first migraine headache with eletriptan hydrobromide in short-term placebo-controlled trials, the most common adverse reactions reported with treatment with eletriptan hydrobromide were asthenia, nausea, dizziness, and somnolence",
      "These reactions appear to be dose-related",
      "In long-term open-label studies where patients were allowed to treat multiple migraine attacks for up to 1 year, 128 (8.3%) out of 1,544 patients discontinued treatment due to adverse reactions",
      "Table 1 lists adverse reactions that occurred in the subset of 5,125 migraineurs who received eletriptan doses of 20 mg, 40 mg and 80 mg or placebo in worldwide placebo-controlled clinical trials",
      "Only adverse reactions that were more frequent in a eletriptan hydrobromide treatment group compared to the placebo group with an incidence greater than or equal to 2% are included in Table 1",
      "Table 1: Adverse Reactions Incidence in Placebo-Cont"
    ],
    "indications": [
      "Eletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults",
      "Limitations of Use: Use only if a clear diagnosis of migraine has been established",
      "If a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks",
      "Eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks",
      "Safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache"
    ]
  },
  "eltrombopag olamine": {
    "ingredient": "eltrombopag olamine",
    "is_drug": true,
    "canonical_name": "eltrombopag",
    "fda_search_term": "eltrombopag",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ELTROMBOPAG",
      "Eltrombopag Olamine"
    ],
    "generic_names": [
      "ELTROMBOPAG"
    ],
    "manufacturers": [
      "Amneal Pharmaceuticals NY LLC",
      "AvKARE",
      "Zydus Pharmaceuticals USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids",
      "Take eltrombopag tablets at least 2 hours before or 4 hours after any medications or products containing polyvalent cations, such as antacids, dairy products, and mineral supplements to avoid significant reduction in absorption of eltrombopag due to chelation [see Dosage and Administration (2.4) , C",
      "7.2 Transporters Use caution when concomitantly administering eltrombopag and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite ",
      "Monitor patients closely for signs and symptoms of excessive exposure to the drugs that are substrates of OATP1B1 or BCRP and consider reduction of the dose of these drugs, if appropriate",
      "In clinical trials with eltrombopag, a dose reduction of rosuvastatin by 50% was recommended",
      "7.3 Protease Inhibitors HIV Protease Inhibitors: No dose adjustment is recommended when eltrombopag is co-administered with lopinavir/ritonavir (LPV/RTV)",
      "Drug interactions with other HIV protease inhibitors have not been evaluated",
      "Hepatitis C Virus Protease Inhibitors: No dose adjustments are recommended when eltrombopag is co-administered with boceprevir or telaprevir",
      "Drug interactions with other hepatitis C virus (HCV) protease inhibitors have not been evaluated",
      "7.4 Peginterferon Alfa-2a/b Therapy No dose adjustments are recommended when eltrombopag is co-administered with peginterferon alfa-2a (PEGASYS ® ) or -2b (PEGINTRON ® )"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions associated with eltrombopag are described in other sections",
      "Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1) ] Hepatotoxicity [see Warnings and Precautions (5.2) ] Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia [see Warnings and Precautions (5.3) ] Thrombotic/Throm",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Persistent or Chronic Immune Thrombocytopenia Adults In clinical trials, hemorrhage was the most common serious adverse reaction and most hemorrhagic reactions followed discontinuation of eltrombopag",
      "Other serious adverse reactions included thrombotic/thromboembolic complications [see Warnings and Precautions (5.4) ] ",
      "The data described below reflect exposure of eltrombopag to patients with persistent or chronic ITP aged 18 to 85 years, of whom 66% were female, in three placebo-controlled trials and one open-label extension trial [see Clinical Studies (14.1) ] ",
      "Eltrombopag was administered to 330 patients for at least 6 months and 218 patients for at least 1 year",
      "Table 8 presents the most common adverse drug reactions (experienced by greater than or equal to 3% of patients receiving eltrombopag) from"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Eltrombopag is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulin",
      "Eltrombopag tablets should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding",
      "( 1.1 ) for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy",
      "Eltrombopag tablets should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy",
      "( 1.2 ) in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia"
    ]
  },
  "emepronium bromide": {
    "ingredient": "emepronium bromide",
    "is_drug": true,
    "canonical_name": "empronium bromide",
    "fda_search_term": "empronium bromide",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Methocarbamol"
    ],
    "generic_names": [
      "METHOCARBAMOL"
    ],
    "manufacturers": [
      "Proficient Rx LP"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, USP should be cautioned about combined effects with alcohol and other CNS depressants",
      "Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development",
      "There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol",
      "Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see Precautions, Pregnancy )",
      "Use In Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle",
      "Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities"
    ],
    "drug_interactions": [
      "Drug interactions See Warnings and Precautions for interaction with CNS drugs and alcohol",
      "Methocarbamol may inhibit the effect of pyridostigmine bromide",
      "Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Adverse reactions reported coincident with the administration of methocarbamol include: Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system: Dyspepsia, jau"
    ],
    "indications": [
      "INDICATIONS AND USAGE Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions",
      "The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties",
      "Methocarbamol does not directly relax tense skeletal muscles in man"
    ]
  },
  "emicizumab": {
    "ingredient": "emicizumab",
    "is_drug": true,
    "canonical_name": "emicizumab",
    "fda_search_term": "emicizumab",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hemlibra"
    ],
    "generic_names": [
      "EMICIZUMAB"
    ],
    "manufacturers": [
      "Genentech, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Hypercoagulability with Concomitant Use of aPCC Clinical experience suggests that a drug interaction exists with HEMLIBRA and aPCC [see Warnings and Precautions (5.1 , 5.2) ] ",
      "7.2 Drug-Laboratory Test Interactions HEMLIBRA restores the tenase cofactor activity of missing activated factor VIII (FVIIIa)",
      "Coagulation laboratory tests based on intrinsic clotting (i.e., aPTT) measure the total clotting time including time needed for activation of FVIII to FVIIIa by thrombin",
      "Such intrinsic pathway-based tests will yield overly shortened clotting times with HEMLIBRA, which does not require activation by thrombin",
      "The overly shortened intrinsic clotting time will then disturb all single-factor assays based on aPTT, such as the one-stage FVIII activity assay; however, single-factor assays utilizing chromogenic or immuno-based methods are unaffected by HEMLIBRA and may be used to monitor coagulation parameters ",
      "Chromogenic FVIII activity tests may be manufactured with either human or bovine coagulation proteins",
      "Assays containing human coagulation factors are responsive to HEMLIBRA but may overestimate the clinical hemostatic potential of HEMLIBRA",
      "In contrast, assays containing bovine coagulation factors are insensitive to HEMLIBRA (no activity measured) and can be used to monitor endogenous or infused FVIII activity, or to measure anti-FVIII inhibitors",
      "HEMLIBRA remains active in the presence of inhibitors against FVIII, so it will produce a false-negative result in clotting-based Bethesda assays for functional inhibition of FVIII",
      "Instead, a chromogenic Bethesda assay utilizing a bovine-based FVIII chromogenic test that is insensitive to HEMLIBRA may be used"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Thrombotic Microangiopathy Associated with HEMLIBRA and aPCC [see Warnings and Precautions (5.1) ] Thromboembolism Associated with HEMLIBRA and aPCC [see Warnings and Precautions (5.2) ] Most common ",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The following adverse reactions are based on pooled data from two randomized trials in adult and adolescent patients (HAVEN 1 and HAVEN 3), one single-arm trial in adult and adolescent patients (HAVEN 4), one single-arm trial in pediatric patients (HAVEN 2), and one dose-finding trial, in which a to",
      "Two hundred eighty-one patients (72%) were adults (18 years and older), 50 (13%) were adolescents (12 years up to less than 18 years), 55 (14%) were children (2 years up to less than 12 years), and five (1%) were infants (1 month up to less than 2 years)",
      "The median duration of exposure across the studies was 34.1 weeks (0.1 to 224.4 weeks)",
      "The most frequently reported adverse reactions observed in ≥ 10% of patients treated with HEMLIBRA were injection site reactions, headache, and arthralgia",
      "Four patients (1%) in the clinical trials receiving HEMLIBRA prophylaxis withdrew from treatment due to adverse reactions, which were thrombotic microangiopathy, skin necrosis and superficial thrombophlebitis, headache, and injection site reaction",
      "Adverse reactions observe"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors",
      "HEMLIBRA is a bispecific factor IXa",
      "and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors"
    ]
  },
  "empagliflozin": {
    "ingredient": "empagliflozin",
    "is_drug": true,
    "canonical_name": "empagliflozin",
    "fda_search_term": "empagliflozin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "JARDIANCE",
      "Jardiance",
      "Synjardy"
    ],
    "generic_names": [
      "EMPAGLIFLOZIN",
      "EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Aphena Pharma Solutions - Tennessee, LLC",
      "Boehringer Ingelheim Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 4 for clinically relevant interactions with SYNJARDY or SYNJARDY XR",
      "Table 4 Clinically Relevant Interactions with SYNJARDY or SYNJARDY XR Carbonic Anhydrase Inhibitors Clinical Impact Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hype",
      "Concomitant use of these drugs with SYNJARDY or SYNJARDY XR may increase the risk of lactic acidosis",
      "Intervention Consider more frequent monitoring of these patients",
      "Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, ",
      "Intervention Consider the benefits and risks of concomitant use",
      "Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism",
      "Intervention Warn patients against excessive alcohol intake while receiving SYNJARDY or SYNJARDY XR",
      "Diuretics Clinical Impact Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion",
      "Intervention Before initiating SYNJARDY or SYNJARDY XR, assess volume status and renal function"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following important adverse reactions are described below and elsewhere in the labeling: Lactic Acidosis [see Boxed Warning and Warnings and Precautions (5.1) ] Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis [see Warnings and Precaution",
      "( 6.1 ) Most common adverse reactions associated with metformin HCl (>5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc",
      "at 1-800-542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The safety of concomitantly administered empagliflozin (daily dosage 10 mg or 25 mg) and metformin HCl (mean daily dosage of approximately 1,800 mg) has been evaluated in 3,456 adult patients with type 2 diabetes mellitus treated for 16 to 24 weeks, of which 926 patients received placebo, 1,271 pati"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients",
      "SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ",
      "Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease",
      "( 1 ) CV death and hospitalization for heart failure in adults with heart failure",
      "( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression"
    ]
  },
  "empagliflozine": {
    "ingredient": "empagliflozine",
    "is_drug": true,
    "canonical_name": "empagliflozin",
    "fda_search_term": "empagliflozin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "JARDIANCE",
      "Jardiance",
      "Synjardy"
    ],
    "generic_names": [
      "EMPAGLIFLOZIN",
      "EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Aphena Pharma Solutions - Tennessee, LLC",
      "Boehringer Ingelheim Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 4 for clinically relevant interactions with SYNJARDY or SYNJARDY XR",
      "Table 4 Clinically Relevant Interactions with SYNJARDY or SYNJARDY XR Carbonic Anhydrase Inhibitors Clinical Impact Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hype",
      "Concomitant use of these drugs with SYNJARDY or SYNJARDY XR may increase the risk of lactic acidosis",
      "Intervention Consider more frequent monitoring of these patients",
      "Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, ",
      "Intervention Consider the benefits and risks of concomitant use",
      "Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism",
      "Intervention Warn patients against excessive alcohol intake while receiving SYNJARDY or SYNJARDY XR",
      "Diuretics Clinical Impact Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion",
      "Intervention Before initiating SYNJARDY or SYNJARDY XR, assess volume status and renal function"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following important adverse reactions are described below and elsewhere in the labeling: Lactic Acidosis [see Boxed Warning and Warnings and Precautions (5.1) ] Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis [see Warnings and Precaution",
      "( 6.1 ) Most common adverse reactions associated with metformin HCl (>5%) are diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, and headache",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc",
      "at 1-800-542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The safety of concomitantly administered empagliflozin (daily dosage 10 mg or 25 mg) and metformin HCl (mean daily dosage of approximately 1,800 mg) has been evaluated in 3,456 adult patients with type 2 diabetes mellitus treated for 16 to 24 weeks, of which 926 patients received placebo, 1,271 pati"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients",
      "SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ",
      "Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease",
      "( 1 ) CV death and hospitalization for heart failure in adults with heart failure",
      "( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression"
    ]
  },
  "enalapril": {
    "ingredient": "enalapril",
    "is_drug": true,
    "canonical_name": "enalapril",
    "fda_search_term": "enalapril",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Enalapril Maleate"
    ],
    "generic_names": [
      "ENALAPRIL MALEATE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Golden State Medical Supply, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including enalapril maleate) may be subject to a variety of adv",
      "Head and Neck Angioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril maleate",
      "This may occur at any time during treatment",
      "In such cases enalapril maleate should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred",
      "In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms",
      "Angioedema associated with laryngeal edema may be fatal",
      "Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (see ADVERSE REACTIONS )",
      "Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS )",
      "Intestinal Angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors",
      "These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C1 esterase levels were normal"
    ],
    "drug_interactions": [
      "Drug Interactions Neprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema (see WARNINGS )",
      "Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy",
      "Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy",
      "In general, avoid combined use of RAS inhibitors",
      "Closely monitor blood pressure, renal function, and electrolytes in patients on enalapril maleate and other agents that affect the RAS",
      "Do not coadminister aliskiren with enalapril maleate in patients with diabetes",
      "Avoid use of aliskiren with enalapril maleate in patients with renal impairment (GFR <60 mL/min)",
      "Hypotension — Patients on Diuretic Therapy Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril",
      "The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril",
      "If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour (See WARNINGS, Hypotension and DOSAGE AND ADMINISTRATION )"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Enalapril maleate has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more",
      "Enalapril maleate has been found to be generally well tolerated in controlled clinical trials involving 2987 patients",
      "For the most part, adverse experiences were mild and transient in nature",
      "In clinical trials, discontinuation of therapy due to clinical adverse experiences was required in 3.3 percent of patients with hypertension and in 5.7 percent of patients with heart failure",
      "The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges",
      "In patients with hypertension the overall percentage of patients treated with enalapril maleate reporting adverse experiences was comparable to placebo",
      "Hypertension Adverse experiences occurring in greater than one percent of patients with hypertension treated with enalapril maleate in controlled clinical trials are shown below",
      "In patients treated with enalapril maleate, the maximum duration of therapy was three years; in placebo-treated patients the maximum duration of therapy was 12 weeks",
      "Enalapril Maleate (n = 2314) Incidence (discontinuation) Placebo (n = 230) Incidence Body As A Whole Fatigue 3.0 (<0.1) 2.6 Orthostatic Effects 1.2 (<0.1) 0.0 Asthenia 1.1 (0.1) 0.9 Digestive Diarrhea 1.4 (<0.1) 1.7 Nausea 1.4 (0.2) 1.7 Nervous/Psychiatric Headache 5.2 (0.3) 9.1 Dizziness 4.3 (0.4) ",
      "The incidences represent the experiences from both controlled and uncontrolled clinical trials (maximum duration of therapy was approximately one year)",
      "In the placebo-treated patients, the incidences reported are from the controlled trials (maximum duration of therapy is 12 weeks)",
      "The percentage of patients with severe heart failure (NYHA"
    ],
    "indications": [
      "INDICATIONS AND USAGE Hypertension Enalapril maleate is indicated for the treatment of hypertension",
      "Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics",
      "The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive",
      "Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis",
      "In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials)"
    ]
  },
  "enalapril maleate": {
    "ingredient": "enalapril maleate",
    "is_drug": true,
    "canonical_name": "enalapril",
    "fda_search_term": "enalapril",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Enalapril Maleate"
    ],
    "generic_names": [
      "ENALAPRIL MALEATE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Golden State Medical Supply, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including enalapril maleate) may be subject to a variety of adv",
      "Head and Neck Angioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril maleate",
      "This may occur at any time during treatment",
      "In such cases enalapril maleate should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred",
      "In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms",
      "Angioedema associated with laryngeal edema may be fatal",
      "Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (see ADVERSE REACTIONS )",
      "Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS )",
      "Intestinal Angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors",
      "These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C1 esterase levels were normal"
    ],
    "drug_interactions": [
      "Drug Interactions Neprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema (see WARNINGS )",
      "Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy",
      "Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy",
      "In general, avoid combined use of RAS inhibitors",
      "Closely monitor blood pressure, renal function, and electrolytes in patients on enalapril maleate and other agents that affect the RAS",
      "Do not coadminister aliskiren with enalapril maleate in patients with diabetes",
      "Avoid use of aliskiren with enalapril maleate in patients with renal impairment (GFR <60 mL/min)",
      "Hypotension — Patients on Diuretic Therapy Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril",
      "The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril",
      "If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour (See WARNINGS, Hypotension and DOSAGE AND ADMINISTRATION )"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Enalapril maleate has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more",
      "Enalapril maleate has been found to be generally well tolerated in controlled clinical trials involving 2987 patients",
      "For the most part, adverse experiences were mild and transient in nature",
      "In clinical trials, discontinuation of therapy due to clinical adverse experiences was required in 3.3 percent of patients with hypertension and in 5.7 percent of patients with heart failure",
      "The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges",
      "In patients with hypertension the overall percentage of patients treated with enalapril maleate reporting adverse experiences was comparable to placebo",
      "Hypertension Adverse experiences occurring in greater than one percent of patients with hypertension treated with enalapril maleate in controlled clinical trials are shown below",
      "In patients treated with enalapril maleate, the maximum duration of therapy was three years; in placebo-treated patients the maximum duration of therapy was 12 weeks",
      "Enalapril Maleate (n = 2314) Incidence (discontinuation) Placebo (n = 230) Incidence Body As A Whole Fatigue 3.0 (<0.1) 2.6 Orthostatic Effects 1.2 (<0.1) 0.0 Asthenia 1.1 (0.1) 0.9 Digestive Diarrhea 1.4 (<0.1) 1.7 Nausea 1.4 (0.2) 1.7 Nervous/Psychiatric Headache 5.2 (0.3) 9.1 Dizziness 4.3 (0.4) ",
      "The incidences represent the experiences from both controlled and uncontrolled clinical trials (maximum duration of therapy was approximately one year)",
      "In the placebo-treated patients, the incidences reported are from the controlled trials (maximum duration of therapy is 12 weeks)",
      "The percentage of patients with severe heart failure (NYHA"
    ],
    "indications": [
      "INDICATIONS AND USAGE Hypertension Enalapril maleate is indicated for the treatment of hypertension",
      "Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics",
      "The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive",
      "Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis",
      "In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials)"
    ]
  },
  "enoxaparin sodium": {
    "ingredient": "enoxaparin sodium",
    "is_drug": true,
    "canonical_name": "enoxaparin",
    "fda_search_term": "enoxaparin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Enoxaparin Sodium",
      "Enoxaparin sodium"
    ],
    "generic_names": [
      "ENOXAPARIN SODIUM"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "NorthStar RxLLC",
      "Sanofi-Aventis U.S. LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of enoxaparin sodium therapy",
      "These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone",
      "If coadministration is essential, conduct close clinical and laboratory monitoring [see Warnings and Precautions (5.1) ] ",
      "Discontinue agents which may enhance hemorrhage risk prior to initiation of enoxaparin sodium or conduct close clinical and laboratory monitoring ( 2.6 , 7 )"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are also discussed in other sections of the labeling:",
      "Spinal/epidural hematomas [see Boxed Warning and Warnings and Precautions ( 5.1 )]",
      "Increased Risk of Hemorrhage [see Warnings and Precautions ( 5.1 )]",
      "Thrombocytopenia [see Warnings and Precautions ( 5.5 )] Most common adverse reactions (>1%) were bleeding, anemia, thrombocytopenia, elevation of serum aminotransferase, diarrhea, nausea, ecchymosis, fever, edema, peripheral edema, dyspnea, confusion, and injection site pain ( 6.1 ) To report SUSPEC",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "During clinical development for the approved indications, 15,918 patients were exposed to enoxaparin sodium",
      "These included 1,228 for prophylaxis of deep vein thrombosis following abdominal surgery in patients at risk for thromboembolic complications, 1,368 for prophylaxis of deep vein thrombosis following hip or knee replacement surgery, 711 for prophylaxis of deep vein thrombosis in medical patients with",
      "Enoxaparin sodium doses in the clinical trials for prophylaxis of deep vein thrombosis following abdominal or hip or knee replacement surgery or in medical patients with severely restricted mobility during acute illness ranged from 40 mg subcutaneously once daily to 30 mg subcutaneously twice daily"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Enoxaparin sodium injection is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( ",
      "1.4 Treatment of Acute ST-Segment Elevation Myocardial Infarction Eno"
    ]
  },
  "enoxaparine sodium": {
    "ingredient": "enoxaparine sodium",
    "is_drug": true,
    "canonical_name": "enoxaparin",
    "fda_search_term": "enoxaparin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Enoxaparin Sodium",
      "Enoxaparin sodium"
    ],
    "generic_names": [
      "ENOXAPARIN SODIUM"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "NorthStar RxLLC",
      "Sanofi-Aventis U.S. LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of enoxaparin sodium therapy",
      "These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone",
      "If coadministration is essential, conduct close clinical and laboratory monitoring [see Warnings and Precautions (5.1) ] ",
      "Discontinue agents which may enhance hemorrhage risk prior to initiation of enoxaparin sodium or conduct close clinical and laboratory monitoring ( 2.6 , 7 )"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are also discussed in other sections of the labeling:",
      "Spinal/epidural hematomas [see Boxed Warning and Warnings and Precautions ( 5.1 )]",
      "Increased Risk of Hemorrhage [see Warnings and Precautions ( 5.1 )]",
      "Thrombocytopenia [see Warnings and Precautions ( 5.5 )] Most common adverse reactions (>1%) were bleeding, anemia, thrombocytopenia, elevation of serum aminotransferase, diarrhea, nausea, ecchymosis, fever, edema, peripheral edema, dyspnea, confusion, and injection site pain ( 6.1 ) To report SUSPEC",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "During clinical development for the approved indications, 15,918 patients were exposed to enoxaparin sodium",
      "These included 1,228 for prophylaxis of deep vein thrombosis following abdominal surgery in patients at risk for thromboembolic complications, 1,368 for prophylaxis of deep vein thrombosis following hip or knee replacement surgery, 711 for prophylaxis of deep vein thrombosis in medical patients with",
      "Enoxaparin sodium doses in the clinical trials for prophylaxis of deep vein thrombosis following abdominal or hip or knee replacement surgery or in medical patients with severely restricted mobility during acute illness ranged from 40 mg subcutaneously once daily to 30 mg subcutaneously twice daily"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Enoxaparin sodium injection is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( ",
      "1.4 Treatment of Acute ST-Segment Elevation Myocardial Infarction Eno"
    ]
  },
  "entacapone": {
    "ingredient": "entacapone",
    "is_drug": true,
    "canonical_name": "entacapone",
    "fda_search_term": "entacapone",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Entacapone"
    ],
    "generic_names": [
      "ENTACAPONE"
    ],
    "manufacturers": [
      "AvPAK",
      "Lannett Company, Inc.",
      "Sun Pharmaceutical Industries, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Monoamine oxidase (MAO) and COMT are the two major enzyme systems involved in the metabolism of catecholamines",
      "It is theoretically possible, therefore, that the combination of entacapone and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism",
      "For this reason, patients should ordinarily not be treated concomitantly with entacapone and a non-selective MAO inhibitor",
      "Entacapone can be taken concomitantly with a selective MAO-B inhibitor (e.g., selegiline)",
      "Drugs Metabolized By Catechol-O-Methyltransferase (COMT) When a single 400 mg dose of entacapone was given with intravenous isoprenaline (isoproterenol) and epinephrine without coadministered levodopa and dopa decarboxylase inhibitor, the overall mean maximal changes in heart rate during infusion we",
      "Therefore, drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (inclu",
      "Ventricular tachycardia was noted in one 32-year-old healthy male volunteer in an interaction study after epinephrine infusion and oral entacapone administration",
      "Treatment with propranolol was required",
      "A causal relationship to entacapone administration appears probable but cannot be attributed with certainty",
      "Falling Asleep During Activities of Daily Living and Somnolence Patients with Parkinson's disease treated with entacapone, which increases plasma levodopa levels, or with levodopa have reported suddenly falling asleep without prior warning of sleepiness while"
    ],
    "drug_interactions": [
      "Drug Interactions See PRECAUTIONS, Drug Interactions "
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Because clinical studies are conducted under widely varying conditions, the incidence of adverse reactions (number of unique patients experiencing an adverse reaction associated with treatment per total number of patients treated) observed in the clinical studies of a drug cannot b",
      "A total of 1,450 patients with Parkinson's disease were treated with entacapone in premarketing clinical studies",
      "Included were patients with fluctuating symptoms, as well as those with stable responses to levodopa therapy",
      "All patients received concomitant treatment with levodopa preparations, however, and were similar in other clinical aspects",
      "The most commonly observed adverse reactions (incidence at least 3% greater than placebo) in double-blind, placebo-controlled studies (N=1,003) associated with the use of entacapone were: dyskinesia, urine discoloration, diarrhea, nausea, hyperkinesia, abdominal pain, vomiting, and dry mouth",
      "Approximately 14% of the 603 patients given entacapone in the double-blind, placebo-controlled studies discontinued treatment due to adverse reactions, compared to 9% of the 400 patients who received placebo",
      "The most frequent causes of discontinuation in decreasing order were: psychiatric disorders (2% vs",
      "1%), diarrhea (2% vs",
      "0%), dyskinesia and hyperkinesia (2% vs",
      "1%), nausea (2% vs",
      "1%), and abdominal pain (1% vs",
      "Adverse Event Incidence in Controlled Clinical Studies Table 4 lists treatment-emergent adverse events that occurred in at least 1% of patients treated with entacapone participating in the double-blind, placebo-controlled studies and that were numerically more common in the entacapone group, compare",
      "In these studies, either entacapone or placebo was added to levodopa and carbidopa (or levodopa and benserazide)",
      "Table 4: Summary of Patie"
    ],
    "indications": [
      "INDICATIONS AND USAGE Entacapone tablets USP are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose \"wearing-off\" in patients with Parkinson's disease (see CLINICAL PHARMACOLOGY, Clinical Studies )",
      "Entacapone's effectiveness has not been systematically evaluated in patients with Parkinson's disease who do not experience end-of-dose \"wearing-off\""
    ]
  },
  "entecavir": {
    "ingredient": "entecavir",
    "is_drug": true,
    "canonical_name": "entecavir",
    "fda_search_term": "entecavir",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "BARACLUDE",
      "Entecavir"
    ],
    "generic_names": [
      "ENTECAVIR"
    ],
    "manufacturers": [
      "Amneal Pharmaceuticals LLC",
      "Camber Pharmaceuticals, Inc.",
      "E.R. Squibb & Sons, L.L.C."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Since entecavir is primarily eliminated by the kidneys [see Clinical Pharmacology (12.3) ] , co-administration of entecavir with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the co-administered d",
      "Co-administration of entecavir with lamivudine, adefovir dipivoxil, or tenofovir disoproxil fumarate did not result in significant drug interactions",
      "The effects of co-administration of entecavir with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when entecavir is co-administered with such drugs"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in other sections of the labeling: Exacerbations of hepatitis after discontinuation of treatment [see Boxed Warning , Warnings and Precautions (5.1) ] ",
      "Lactic acidosis and severe hepatomegaly with steatosis [see Boxed Warning , Warnings and Precautions (5.3) ] ",
      "In adults, the most common adverse reactions (≥3%, all severity grades) are headache, fatigue, dizziness, and nausea",
      "The adverse reactions observed in pediatric patients were consistent with those observed in adults",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Clinical Trial Experience in Adults Compensated Liver Disease Assessment of adverse reactions is based on four studies (AI463014, AI463022, AI463026, and AI463027) in which 1,720 subjects with chronic hepatitis B virus infection and compensated liver disease received double-blind treatment with ente",
      "Median duration of therapy was 69 weeks for entecavir-treated subjects and 63 weeks for lamivudine-treated subjects in Studies AI463022 and AI463027 and 73 weeks for entecavir-treated subjects and 51 weeks for lamivudine-treated subjects in Studies AI463026 and AI463014",
      "The safety profiles of entecavir and lamivudine were comparable in these studies",
      "The most common adverse reactions of any severity (≥3%) with at least a possible relation to study drug for entecavir-treated subjects were headache, fatigue, dizziness, and nausea",
      "The most common adverse reactions among lamivudine-treated subjects were headach"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or",
      "Entecavir tablets are a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in se"
    ]
  },
  "enzalutamide": {
    "ingredient": "enzalutamide",
    "is_drug": true,
    "canonical_name": "enzalutamide",
    "fda_search_term": "enzalutamide",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Xtandi"
    ],
    "generic_names": [
      "ENZALUTAMIDE"
    ],
    "manufacturers": [
      "Astellas Pharma US, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Strong CYP2C8 Inhibitors: Avoid strong CYP2C8 inhibitors",
      "If coadministration cannot be avoided, reduce the dosage of XTANDI",
      "Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers",
      "If coadministration cannot be avoided, increase the dosage of XTANDI",
      "Avoid coadministration with certain CYP3A4, CYP2C9, or CYP2C19 substrates for which a minimal decrease in concentration may lead to therapeutic failure of the substrate",
      "In cases where active metabolites are formed, there may be increased exposure to the active metabolites",
      "( 7.2 ) 7.1 Effect of Other Drugs on XTANDI Strong CYP2C8 Inhibitors The coadministration of XTANDI with gemfibrozil (a strong CYP2C8 inhibitor) increases plasma concentrations of enzalutamide plus N-desmethyl enzalutamide, which may increase the incidence and severity of adverse reactions of XTANDI",
      "Avoid the coadministration of XTANDI with strong CYP2C8 inhibitors",
      "If the coadministration of XTANDI with a strong CYP2C8 inhibitor cannot be avoided, reduce the dosage of XTANDI [see Dosage and Administration ( 2.3 ), Clinical Pharmacology ( 12.3 )]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following is discussed in more detail in other sections of the labeling:",
      "Seizure [see Warnings and Precautions ( 5.1 )]",
      "Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions ( 5.2 )]",
      "Hypersensitivity [see Warnings and Precautions ( 5.3 )]",
      "Ischemic Heart Disease [see Warnings and Precautions ( 5.4 )]",
      "Falls and Fractures [see Warnings and Precautions ( 5.5 )]",
      "Dysphagia or Choking [see Warnings and Precautions ( 5.7 )] The most common adverse reactions (≥ 10%) that occurred more frequently (≥ 2% over placebo) in the XTANDI-treated patients are musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhea, hypertension, hemorrhage, f",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc",
      "at 1-800-727-7003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The data in WARNINGS and PRECAUTIONS reflect eight randomized, controlled trials [AFFIRM, PREVAIL, TERRAIN, PROSPER, ARCHES, EMBARK, Asian PREVAIL (NCT02294461), and STRIVE (NCT01664923)] that were pooled to conduct safety analyses in patients with CRPC (N = 3651), mCSPC (N = 752), or nmCSPC with hi",
      "Patients received XTANDI 160 mg (N = 5110) or placebo orally once daily (N = 2829) or bicalutamide 50 mg orally once daily (N = 387)",
      "In these eight trials, the median duration of treatment was 22.1 months (range: < 0.1 to 95.0) in patients that received XTANDI",
      "In five placebo-controlled trials (AFFIRM, PROSPER, PREVAIL, ARCHES, and EMBARK), the median duration of treatment was 19.4 months (range: < 0.1 to 90.4) in the XTANDI group [see Clinical Studies ("
    ],
    "indications": [
      "1 INDICATIONS AND USAGE XTANDI ® is indicated for the treatment of patients with:",
      "castration-resistant prostate cancer (CRPC)",
      "metastatic castration-sensitive prostate cancer (mCSPC)",
      "non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with:",
      "castration-resistant prostate cancer"
    ]
  },
  "ephedrine": {
    "ingredient": "ephedrine",
    "is_drug": true,
    "canonical_name": "ephedrine",
    "fda_search_term": "ephedrine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Emerphed PFS",
      "Ephedrine Sulfate",
      "Ephedrine sulfate"
    ],
    "generic_names": [
      "EPHEDRINE SULFATE"
    ],
    "manufacturers": [
      "Caplin Steriles Limited",
      "Medical Purchasing Solutions, LLC",
      "Nexus Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Interactions that Augment the Pressor Effect Oxytocin and oxytocic drugs Clinical Impact: Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovi",
      "Some of these patients experienced a stroke",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and an oxytocic",
      "Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine Clinical Impact: These drugs augment the pressor effect of ephedrine",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs",
      "Interactions that Antagonize the Pressor Effect Clinical Impact: These drugs antagonize the pressor effect of ephedrine",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs",
      "Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions Guanethidine Clinical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness",
      "Intervention: Clinician should monitor patient for blood pressor response and adjust the dosage or choice of pressor accordingly",
      "Rocuronium Clinical Impact: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions associated with the use of ephedrine sulfate were identified in the literature",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure",
      "Gastrointestinal disorders: Nausea, vomiting Cardiac disorders: Tachycardia, palpitations (thumping heart), reactive hypertension, bradycardia, ventricular ectopics, R-R variability Nervous system disorders: Dizziness Psychiatric disorders: Restlessness Most common adverse reactions during treatment",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia",
      "Ephedrine sulfate injection is an alpha",
      "and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia"
    ]
  },
  "ephedrine hcl": {
    "ingredient": "ephedrine hcl",
    "is_drug": true,
    "canonical_name": "ephedrine",
    "fda_search_term": "ephedrine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Emerphed PFS",
      "Ephedrine Sulfate",
      "Ephedrine sulfate"
    ],
    "generic_names": [
      "EPHEDRINE SULFATE"
    ],
    "manufacturers": [
      "Caplin Steriles Limited",
      "Medical Purchasing Solutions, LLC",
      "Nexus Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Interactions that Augment the Pressor Effect Oxytocin and oxytocic drugs Clinical Impact: Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovi",
      "Some of these patients experienced a stroke",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and an oxytocic",
      "Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine Clinical Impact: These drugs augment the pressor effect of ephedrine",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs",
      "Interactions that Antagonize the Pressor Effect Clinical Impact: These drugs antagonize the pressor effect of ephedrine",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs",
      "Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions Guanethidine Clinical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness",
      "Intervention: Clinician should monitor patient for blood pressor response and adjust the dosage or choice of pressor accordingly",
      "Rocuronium Clinical Impact: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions associated with the use of ephedrine sulfate were identified in the literature",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure",
      "Gastrointestinal disorders: Nausea, vomiting Cardiac disorders: Tachycardia, palpitations (thumping heart), reactive hypertension, bradycardia, ventricular ectopics, R-R variability Nervous system disorders: Dizziness Psychiatric disorders: Restlessness Most common adverse reactions during treatment",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia",
      "Ephedrine sulfate injection is an alpha",
      "and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia"
    ]
  },
  "ephedrine hydrochloride": {
    "ingredient": "ephedrine hydrochloride",
    "is_drug": true,
    "canonical_name": "ephedrine",
    "fda_search_term": "ephedrine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Emerphed PFS",
      "Ephedrine Sulfate",
      "Ephedrine sulfate"
    ],
    "generic_names": [
      "EPHEDRINE SULFATE"
    ],
    "manufacturers": [
      "Caplin Steriles Limited",
      "Medical Purchasing Solutions, LLC",
      "Nexus Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Interactions that Augment the Pressor Effect Oxytocin and oxytocic drugs Clinical Impact: Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovi",
      "Some of these patients experienced a stroke",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and an oxytocic",
      "Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine Clinical Impact: These drugs augment the pressor effect of ephedrine",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs",
      "Interactions that Antagonize the Pressor Effect Clinical Impact: These drugs antagonize the pressor effect of ephedrine",
      "Intervention: Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs",
      "Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions Guanethidine Clinical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness",
      "Intervention: Clinician should monitor patient for blood pressor response and adjust the dosage or choice of pressor accordingly",
      "Rocuronium Clinical Impact: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions associated with the use of ephedrine sulfate were identified in the literature",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure",
      "Gastrointestinal disorders: Nausea, vomiting Cardiac disorders: Tachycardia, palpitations (thumping heart), reactive hypertension, bradycardia, ventricular ectopics, R-R variability Nervous system disorders: Dizziness Psychiatric disorders: Restlessness Most common adverse reactions during treatment",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia",
      "Ephedrine sulfate injection is an alpha",
      "and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia"
    ]
  },
  "epinastine": {
    "ingredient": "epinastine",
    "is_drug": true,
    "canonical_name": "epinastine",
    "fda_search_term": "epinastine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EPINASTINE HYDROCHLORIDE"
    ],
    "generic_names": [
      "EPINASTINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Somerset Therapeutics, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common ocular adverse reactions (incidence occurring in approximately 1% to 10% of epinastine HCl-treated eyes were burning sensation in the eye, folliculosis, hyperemia, and pruritus",
      "The most common non-ocular adverse reactions, occurring in 10% epinastine HCl-treated eyes, were infection (cold symptoms and upper respiratory infections)",
      "To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at +1 800-417-9175 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice",
      "The most frequently reported ocular adverse reactions occurring in approximately 1 to 10% of patients were burning sensation in the eye, folliculosis, hyperemia, and pruritus",
      "The most frequently reported non-ocular adverse reactions were infection (cold symptoms and upper respiratory infections), seen in approximately 10% of patients, and headache, rhinitis, sinusitis, increased cough, and pharyngitis, seen in approximately 1 to 3% of patients",
      "Some of these reactions were similar to the underlying disease being studied",
      "6.2 Postmarketing Experience The following reactions have been identified during postmarketing use of epinastine HCl in clinical practice",
      "Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made",
      "The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to epinastine HCl, or a combination of these factors, include: lacrimation increased"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Epinastine HCl ophthalmic solution is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis",
      "Epinastine HCl ophthalmic solution is indicated for the prevention of itching associated with allergic conjunctivitis"
    ]
  },
  "epinephrine": {
    "ingredient": "epinephrine",
    "is_drug": true,
    "canonical_name": "epinephrine",
    "fda_search_term": "epinephrine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Epinephrine",
      "Histastat Pollen",
      "epinephrine"
    ],
    "generic_names": [
      "BAPTISIA TINCTORIA, ECHINACEA (ANGUSTIFOLIA), ADRENALINUM, ALLIUM CEPA, AMBROSIA ARTEMISIAEFOLIA, ARSENICUM ALBUM, EUPHRASIA OFFICINALIS, HISTAMINUM HYDROCHLORICUM, NATRUM MURIATICUM, NATRUM SULPHURICUM, NUX VOMICA, PHOSPHORUS, PULSATILLA (PRATENSIS), SABADILLA, SINAPIS NIGRA, SOLIDAGO VIRGAUREA, SULPHUR, WYETHIA HELENIOIDES",
      "EPINEPHRINE"
    ],
    "manufacturers": [
      "Energique, Inc.",
      "GLENMARK PHARMACEUTICALS INC., USA",
      "REMEDYREPACK INC."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "Do not use if tamper evident seal is broken or missing",
      "Store in a cool, dry place"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids",
      "( 7 .1) Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines",
      "( 7 .2) Drugs that increase the arrhythmogenic potential of epinephrine include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, quinidine, antihistamines, exogenous thyroid hormones, diuretics, and cardiac glycosides",
      "Observe for development of cardiac arrhythmias",
      "( 7 .3) Potassium-depleting drugs, including corticosteroids, diuretics, and theophylline, potentiate the hypokalemic effects of epinephrine",
      "( 7 .4) 7.1 Drugs Antagonizing Pressor Effects of Epinephrine",
      "α-blockers, such as phentolamine",
      "Vasodilators, such as nitrates",
      "Antihypertensives",
      "Phenothiazine antipsychotics 7.2 Drugs Potentiating Pressor Effects of Epinephrine"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in labeling:",
      "Hypertension [see Warnings and Precautions (5.1)]",
      "Pulmonary Edema [see Warnings and Precautions (5.2)]",
      "Cardiac Arrhythmias and Ischemia [see Warnings and Precautions (5.3)]",
      "Extravassation and Tissue Necrosis with Intravenous Infusion [see Warnings and Precautions (5.4)]",
      "Renal Impairment [see Warnings and Precautions (5.5)]",
      "Allergic Reactions associated with Sulfite [see Warnings and Precautions (5.6)] The following adverse reactions associated with the infusion of epinephrine were identified in the literature",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure",
      "Cardiovascular disorders: tachycardia, supraventricular tachycardia, ventricular arrhythmias, myocardial ischemia, myocardial infarction, limb ischemia, pulmonary edema Gastrointestinal disorders : Nausea, vomiting General disorders and administrative site conditions : Chest pain, extravasation Meta",
      "Arrhythmias, including fatal ventricular fibrillation, rapid rises in blood pressure producing cerebral hemorrhage, and angina have occurred",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS,"
    ],
    "indications": [
      "INDICATIONS: May temporarily relieve sinus congestion, runny nose, and sneezing.** **Claims based on traditional homeopathic practice, not accepted medical evidence",
      "Not FDA evaluated"
    ]
  },
  "epirubicin": {
    "ingredient": "epirubicin",
    "is_drug": true,
    "canonical_name": "epirubicin",
    "fda_search_term": "epirubicin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ellence"
    ],
    "generic_names": [
      "EPIRUBICIN HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Pharmacia & Upjohn Company LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Avoid using cardiotoxic agents in combination with ELLENCE ( 7.1 )",
      "Discontinue cimetidine during treatment with ELLENCE ( 7.2 )",
      "7.1 Cardiotoxic Agents Closely monitor cardiac function when ELLENCE is used in combination with other cardiotoxic agents",
      "Patients receiving ELLENCE after stopping treatment with other cardiotoxic agents, especially those with long half-lives such as trastuzumab, may be at an increased risk of developing cardiotoxicity [see Dosage and Administration (2) and Warnings and Precautions (5.1) ] ",
      "Trastuzumab may persist in the circulation for up to 7 months",
      "Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible",
      "Monitor the patient's cardiac function closely if anthracyclines are used before this time",
      "Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment",
      "7.2 Cimetidine Cimetidine increases the exposure to epirubicin [see Clinical Pharmacology (12.3) ]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:",
      "Cardiac Toxicity [see Warnings and Precautions (5.1) ]",
      "Secondary Malignancies [see Warnings and Precautions (5.2) ]",
      "Extravasation and Tissue Necrosis [see Warnings and Precautions (5.3) ]",
      "Severe Myelosuppression [see Warnings and Precautions (5.4) ]",
      "Tumor-Lysis Syndrome [see Warnings and Precautions (5.7) ]",
      "Thrombophlebitis and Thromboembolic Events [see Warnings and Precautions (5.9) ]",
      "Potentiation of Radiation Toxicity and Radiation Recall [see Warnings and Precautions (5.10) ] The most common adverse reactions (≥10%) are leukopenia, neutropenia, anemia, thrombocytopenia, amenorrhea, lethargy, nausea/vomiting, mucositis, diarrhea, infection, conjunctivitis/keratitis, alopecia, lo",
      "To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The safety of ELLENCE was evaluated in two studies (Studies MA-5 and GFEA-05) evaluating combination regimens in patients with early breast cancer [see Clinical Studies (14.1) ] ",
      "Of the 1260 patients treated in these studies, 620 patients received the higher-dose ELLENCE regimen (FEC-100/CEF-120), 280 patients received the lower-dose ELLENCE regimen (FEC-50), and 360 patients received CMF",
      "Serotonin-specific antiemetic therapy and colony-stimulating factors were not used in these trials",
      "Clinically relevant adverse reactions are summarized in Table 1",
      "Adverse Reactions in Patients with Early Breast Cancer Event % of Patients FEC-100/CEF-120 (N=620) FEC-50 (N=280) CMF (N=360) Grades 1–4 Grades 3/4 G"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] ",
      "ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 )"
    ]
  },
  "eplerenone": {
    "ingredient": "eplerenone",
    "is_drug": true,
    "canonical_name": "eplerenone",
    "fda_search_term": "eplerenone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EPLERENONE",
      "Eplerenone",
      "Inspra"
    ],
    "generic_names": [
      "EPLERENONE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Camber Pharmaceuticals, Inc.",
      "Viatris Specialty LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "CYP3A Inhibitors: In post-MI HFrEF patients, do not exceed 25 mg once daily when used with moderate CYP3A inhibitors (e.g., verapamil, erythromycin, saquinavir, fluconazole)",
      "In patients with hypertension, initiate at 25 mg once daily",
      "For inadequate blood pressure response, dosing may be increased to a maximum of 25 mg twice daily",
      "( 2.4 , 7.1 , 12.3 ) 7.1 CYP3A Inhibitors Eplerenone metabolism is predominantly mediated via CYP3A",
      "Do not use INSPRA with drugs that are strong inhibitors of CYP3A [see Contraindications (4) and Clinical Pharmacology (12.3) ] ",
      "In post-MI HFrEF patients taking a moderate CYP3A inhibitor, do not exceed 25 mg once daily",
      "In patients with hypertension taking a moderate CYP3A inhibitor, initiate at 25 mg once daily",
      "For inadequate blood pressure response, dosing may be increased to a maximum of 25 mg twice daily [see Dosage and Administration (2.3 , 2.4) and Clinical Pharmacology (12.3) ] ",
      "7.2 ACE Inhibitors and Angiotensin II Receptor Antagonists The risk of hyperkalemia increases when eplerenone is used in combination with an ACE inhibitor and/or an ARB"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Hyperkalemia [see Warnings and Precautions (5.1) ] HFrEF Post-MI: Most common adverse reactions (>2% and more frequent than with placebo): hyperkalemia and increased creatinine",
      "( 6.1 ) Hypertension: In clinical studies, adverse reactions with INSPRA were uncommon",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice",
      "Heart Failure Post-Myocardial Infarction In EPHESUS, safety was evaluated in 3307 patients treated with INSPRA and 3301 placebo-treated patients",
      "The overall incidence of adverse events reported with INSPRA (78.9%) was similar to placebo (79.5%)",
      "Adverse events occurred at a similar rate regardless of age, gender, or race",
      "Patients discontinued treatment due to an adverse event at similar rates in either treatment group (4.4% INSPRA vs",
      "4.3% placebo), with the most common reasons for discontinuation being hyperkalemia, MI, and abnormal renal function",
      "Adverse reactions that occurred more frequently in patients treated with INSPRA than placebo were hyperkalemia (3.4% vs",
      "2.0%) and increased creatinine (2.4% vs",
      "Discontinuations due to hyperkalemia or abnormal renal function were less than 1.0% in both groups",
      "Hypertension INSPRA has been evaluated for safety in 3091 patients treated for hypertension",
      "A total of 690 patients were treated for over 6 months and 106 patients were treated for over 1 year"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE INSPRA is an aldosterone antagonist indicated for:",
      "Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction",
      "The treatment of hypertension in adults, to lower blood pressure",
      "Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions",
      "( 1.2 ) 1.1 Heart Failure Post-Myocardial Infarction INSPRA is indicated to improve survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (≤40%) (HFrEF) after an acute myocardial infarction (MI)"
    ]
  },
  "epoetin beta": {
    "ingredient": "epoetin beta",
    "is_drug": true,
    "canonical_name": "epoetin beta",
    "fda_search_term": "epoetin beta",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Mircera"
    ],
    "generic_names": [
      "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA"
    ],
    "manufacturers": [
      "Vifor (International) Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism [see Warnings and Precautions ( 5.1 )]",
      "Increased Mortality and/or Tumor Progression in Patients with Cancer [see Warnings and Precautions ( 5.2 )]",
      "Hypertension [see Warnings and Precautions ( 5.3 )]",
      "Seizures [see Warnings and Precautions ( 5.4 )]",
      "Pure Red Cell Aplasia [see Warnings and Precautions ( 5.6 )]",
      "Serious Allergic Reactions [see Warnings and Precautions ( 5.7 )]",
      "Severe Cutaneous Reactions [see Warnings and Precautions ( 5.8 )] The most common adverse reactions (≥ 10%) are hypertension, diarrhea, nasopharyngitis ( 6 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Vifor (International) Inc",
      "at 1-800-576-8295, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of Mircera cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice",
      "Adult Patients The data described below reflect exposure to Mircera in 2737 patients, including 1451 exposed for 6 months and 1144 exposed for greater than one year",
      "Mircera was studied primarily in active-controlled studies (n=1789 received Mircera, and n=948 received another ESA) and in long-term follow up studies",
      "The population was 18 to 92 years of age, 58% male, and the percentage of Caucasian, Black (including African Americans), Asian and Hispanic patients were 73%, 20%, 5%, and 9%, respectively",
      "Approximately 85% of the patients were receiving dialysis"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Mircera is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD) in:",
      "adult patients on dialysis and adult patients not on dialysis ( 1.1 )",
      "pediatric patients 3 months to 17 years of age on dialysis or not on dialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA ( 1.1 )",
      "Limitations of Use Mircera is not indicated and is not recommended for use:",
      "In the treatment of anemia due to cancer chemotherapy ( 5.2 )"
    ]
  },
  "epoetin beta i u": {
    "ingredient": "epoetin beta i u",
    "is_drug": true,
    "canonical_name": "epoetin beta",
    "fda_search_term": "epoetin beta",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Mircera"
    ],
    "generic_names": [
      "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA"
    ],
    "manufacturers": [
      "Vifor (International) Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism [see Warnings and Precautions ( 5.1 )]",
      "Increased Mortality and/or Tumor Progression in Patients with Cancer [see Warnings and Precautions ( 5.2 )]",
      "Hypertension [see Warnings and Precautions ( 5.3 )]",
      "Seizures [see Warnings and Precautions ( 5.4 )]",
      "Pure Red Cell Aplasia [see Warnings and Precautions ( 5.6 )]",
      "Serious Allergic Reactions [see Warnings and Precautions ( 5.7 )]",
      "Severe Cutaneous Reactions [see Warnings and Precautions ( 5.8 )] The most common adverse reactions (≥ 10%) are hypertension, diarrhea, nasopharyngitis ( 6 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Vifor (International) Inc",
      "at 1-800-576-8295, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of Mircera cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice",
      "Adult Patients The data described below reflect exposure to Mircera in 2737 patients, including 1451 exposed for 6 months and 1144 exposed for greater than one year",
      "Mircera was studied primarily in active-controlled studies (n=1789 received Mircera, and n=948 received another ESA) and in long-term follow up studies",
      "The population was 18 to 92 years of age, 58% male, and the percentage of Caucasian, Black (including African Americans), Asian and Hispanic patients were 73%, 20%, 5%, and 9%, respectively",
      "Approximately 85% of the patients were receiving dialysis"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Mircera is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD) in:",
      "adult patients on dialysis and adult patients not on dialysis ( 1.1 )",
      "pediatric patients 3 months to 17 years of age on dialysis or not on dialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA ( 1.1 )",
      "Limitations of Use Mircera is not indicated and is not recommended for use:",
      "In the treatment of anemia due to cancer chemotherapy ( 5.2 )"
    ]
  },
  "eptifibatide": {
    "ingredient": "eptifibatide",
    "is_drug": true,
    "canonical_name": "eptifibatide",
    "fda_search_term": "eptifibatide",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Eptifibatide"
    ],
    "generic_names": [
      "EPTIFIBATIDE"
    ],
    "manufacturers": [
      "Eugia US LLC",
      "Meitheal Pharmaceuticals Inc.",
      "Slate Run Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding",
      "Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors",
      "(7.1) 7.1 Use of Thrombolytics, Anticoagulants, and Other Antiplatelet Agents Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding",
      "Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding [see Contraindications (4) and Warnings and Precautions (5.1) ] Bleeding and hypotension are the most commonly reported adverse reactions",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Eugia US LLC at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical prac",
      "A total of 16,782 patients were treated in the Phase III clinical trials (PURSUIT, ESPRIT, and IMPACT II) [see Clinical Studies (14) ] ",
      "These 16,782 patients had a mean age of 62 years (range: 20 to 94 years)",
      "Eighty-nine percent of the patients were Caucasian, with the remainder being predominantly Black (5%) and Hispanic (5%)",
      "Sixty-eight percent were men",
      "Because of the different regimens used in PURSUIT, IMPACT II, and ESPRIT, data from the 3 studies were not pooled",
      "Bleeding and hypotension were the most commonly reported adverse reactions (incidence ≥5% and greater than placebo) in the eptifibatide controlled clinical trial database",
      "Bleeding The incidence of bleeding and transfusions in the PURSUIT and ESPRIT studies are shown in Table 2",
      "Bleeding was classified as major or minor by the criteria of the TIMI study group",
      "Major bleeding consisted of intracranial hemorrhage and other bleeding that led to decreases in hemoglobin greater than 5 g/dL",
      "Minor bleeding included spontaneous gross hematuria, spontaneous hematemesis, other observed blood loss with a hemoglobin decrease of more than 3 g/dL, and other hemoglobin decreases that were greater than 4 g/dL but less than 5 g/dL",
      "In patients who received transfusions, the corresponding loss in hemoglobin was estimated through an ada"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) (1.1) Treatment of patients undergoing PCI (including intracoronary stenting) (1.2) 1.1 Acut",
      "1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting [see Clinical Studies (14.1, 14.2) ] "
    ]
  },
  "erdafitinib": {
    "ingredient": "erdafitinib",
    "is_drug": true,
    "canonical_name": "erdafitinib",
    "fda_search_term": "erdafitinib",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "BALVERSA"
    ],
    "generic_names": [
      "ERDAFITINIB"
    ],
    "manufacturers": [
      "Janssen Products LP"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Moderate CYP2C9 or strong CYP3A4 inhibitors: Consider alternative agents or monitor closely for adverse reactions",
      "( 7.1 ) Strong CYP3A4 inducers: Avoid concomitant use with BALVERSA",
      "( 7.1 ) Moderate CYP3A4 inducers: Administer BALVERSA at a dose of 9 mg",
      "( 7.1 ) Serum phosphate level-altering agents: Avoid concomitant use with agents that can alter serum phosphate levels before the initial dose modification period",
      "( 2.3 , 7.1 ) P-gp substrates: Separate BALVERSA administration by at least 6 hours before or after administration of P-gp substrates with narrow therapeutic indices",
      "( 7.2 ) 7.1 Effect of Other Drugs on BALVERSA Table 7 summarizes drug interactions that affect the exposure of BALVERSA or serum phosphate level and their clinical management",
      "Table 7: Drug Interactions that Affect BALVERSA Moderate CYP2C9 or Strong CYP3A4 Inhibitors Clinical Impact Co-administration of BALVERSA with moderate CYP2C9 or strong CYP3A4 inhibitors increased erdafitinib plasma concentrations [see Clinical Pharmacology (12.3) ]",
      "Increased erdafitinib plasma concentrations may lead to increased drug-related toxicity [see Warnings and Precautions (5) ]",
      "Clinical Management Consider alternative therapies that are not moderate CYP2C9 or strong CYP3A4 inhibitors during treatment with BALVERSA",
      "If co-administration of a moderate CYP2C9 or strong CYP3A4 inhibitor is unavoidable, monitor closely for adverse reactions and consider dose modifications accordingly [see Dosage and Administration (2.3) ]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are also described elsewhere in the labeling: Ocular Disorders [see Warnings and Precautions (5.1) ] ",
      "Hyperphosphatemia [see Warnings and Precautions (5.2) ] ",
      "The most common (>20%) adverse reactions, including laboratory abnormalities, were increased phosphate, nail disorders, stomatitis, diarrhea, increased creatinine, increased alkaline phosphatase, increased alanine aminotransferase, decreased hemoglobin, decreased sodium, increased aspartate aminotra",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Janssen Products, LP",
      "at 1-800-526-7736 (1-800-JANSSEN and www.BALVERSA.com) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to BALVERSA as a single agent at the recommended dose (8 to 9 mg orally daily) in 479 patients with advanced urothelial cancer and FGFR alterations in 42756493BLC3001 (NCT03390504), 42756493BLC2001 (NCT02365597)",
      "Among 479 patients who received BALVERSA, the median duration of treatment was 4.8 months (range: 0.1 to 43 months)",
      "In this pooled safety population, the most common (>20%) adverse reactions, including laboratory abnormalities, were increased phosphate, nail disorders, stomatitis, diarrhea, increased creatinine, increased alkaline phosphatase, increased alanine aminotransferase, decrease"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy",
      "Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] ",
      "BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy",
      "Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA",
      "( 1 , 2.1 ) Limitations of Use BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy"
    ]
  },
  "erenumab": {
    "ingredient": "erenumab",
    "is_drug": true,
    "canonical_name": "erenumab",
    "fda_search_term": "erenumab",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AIMOVIG"
    ],
    "generic_names": [
      "ERENUMAB-AOOE"
    ],
    "manufacturers": [
      "Amgen Inc"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] Constipation with Serious Complications [see Warnings and Precautions (5.2) ] Hypertension [see Warnings and Precautions (5.",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "The safety of AIMOVIG has been evaluated in 2537 patients with migraine who received at least one dose of AIMOVIG, representing 3040.2 patient-years of exposure",
      "Of these, 2271 patients were exposed to 70 mg or 140 mg once monthly for at least 6 months, 1305 patients were exposed for at least 12 months, and 216 patients were exposed through 5 years",
      "In placebo-controlled clinical studies (Studies 1, 2, and 3) of 2184 patients, 787 patients received at least one dose of AIMOVIG 70 mg once monthly, 507 patients received at least one dose of AIMOVIG 140 mg once monthly, and 890 patients received placebo during 3 months or 6 months of double-blind ",
      "Approximately 84% were female, 91% were white, and the mean age was 42 years at study entry",
      "The most common adverse reactions (incidence ≥ 3% and more often than placebo) in the migraine studies were injection site reactions and constipation",
      "Table 1 summarizes the adverse reactions tha"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE AIMOVIG is indicated for the preventive treatment of migraine in adults",
      "AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults"
    ]
  },
  "ergocalciferol": {
    "ingredient": "ergocalciferol",
    "is_drug": true,
    "canonical_name": "ergocalciferol",
    "fda_search_term": "ergocalciferol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ergocalciferol",
      "VITAMIN D"
    ],
    "generic_names": [
      "ERGOCALCIFEROL"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Golden State Medical Supply, Inc.",
      "PD-Rx Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia",
      "In these cases vitamin D must be strictly restricted",
      "Keep out of the reach of children"
    ],
    "drug_interactions": [
      "Drug Interactions Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations",
      "Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Hypervitaminosis D is characterized by effects on the following organ system: Renal: Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insu",
      "CNS: Mental retardation",
      "Soft Tissues: Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs",
      "Skeletal: Bone demineralization (osteoporosis) in adults occurs concomitantly",
      "Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism), vague aches, stiffness, and weakness",
      "Gastrointestinal: Nausea, anorexia, constipation",
      "Metabolic: Mild acidosis, anemia, weight loss",
      "To report SUSPECTED ADVERSE REACTIONS, contact Bionpharma Inc",
      "at 1-888-235-2466 or FDA at 1-800-FDA-1088 or www.fda.gov/ medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia"
    ]
  },
  "ergotamin": {
    "ingredient": "ergotamin",
    "is_drug": true,
    "canonical_name": "ergotamine",
    "fda_search_term": "ergotamine",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ergomar Sublingual",
      "MIGERGOT",
      "ergotamine tartrate and caffeine"
    ],
    "generic_names": [
      "ERGOTAMINE TARTRATE",
      "ERGOTAMINE TARTRATE AND CAFFEINE"
    ],
    "manufacturers": [
      "Cintex Services, LLC",
      "Cosette Pharmaceuticals, Inc.",
      "Pangea Pharmaceuticals LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS CYP 3A4 Inhibitors (e.g",
      "Macrolide Antibiotics and Protease Inhibitors) Coadministration of ergotamine with potent CYP 3A4 inhibitors such as protease inhibitors or macrolide antibiotics has been associated with serious adverse events; for this reason, these drugs should not be given concomitantly with ergotamine (See CONTR",
      "While these reactions have not been reported with less potent CYP 3A4 inhibitors, there is a potential risk for serious toxicity including vasospasm when these drugs are used with ergotamine",
      "Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole",
      "These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with ergotamine",
      "Fibrotic Complications There have been a few reports of patients on ergotamine tartrate and caffeine therapy developing retroperitoneal and/or pleuropulmonary fibrosis",
      "There have also been rare reports of fibrotic thickening of the aortic, mitral, tricuspid, and/or pulmonary valves with long-term continuous use of ergotamine tartrate and caffeine",
      "Ergotamine tartrate suppositories should not be used for chronic daily administration (see DOSAGE AND ADMINISTRATION )"
    ],
    "drug_interactions": [
      "Drug Interactions CYP 3A4 Inhibitors (e.g",
      "Macrolide Antibiotics and Protease Inhibitors) See CONTRAINDICATIONS and WARNINGS ",
      "Ergotamine tartrate and caffeine tablets should not be administered with other vasoconstrictors",
      "Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure",
      "The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine",
      "Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy",
      "The blood levels of ergotamine-containing drugs are reported to be elevated by the concomitant administration of macrolide antibiotics and vasospastic reactions have been reported with therapeutic doses of the ergotamine-containing drugs when coadministered with these antibiotics"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Cardiovascular: Vasoconstrictive complications of a serious nature may occur at times",
      "These include ischemia, cyanosis, absence of pulse, cold extremities, gangrene, precordial distress and pain, EKG changes and muscle pains",
      "Although these effects occur most commonly with long-term therapy at relatively high doses, they have also been reported with short-term or normal doses",
      "Other cardiovascular adverse effects include transient tachycardia or bradycardia and hypertension",
      "Gastrointestinal: Nausea and vomiting; rectal or anal ulcer (from overuse of suppositories)",
      "Neurological: Paresthesias, numbness, weakness, and vertigo",
      "Allergic: Localized edema and itching",
      "Fibrotic Complications: (See WARNINGS )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc",
      "at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ergotamine Tartrate and Caffeine Indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”"
    ]
  },
  "ergotamine": {
    "ingredient": "ergotamine",
    "is_drug": true,
    "canonical_name": "ergotamine",
    "fda_search_term": "ergotamine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ergomar Sublingual",
      "MIGERGOT",
      "ergotamine tartrate and caffeine"
    ],
    "generic_names": [
      "ERGOTAMINE TARTRATE",
      "ERGOTAMINE TARTRATE AND CAFFEINE"
    ],
    "manufacturers": [
      "Cintex Services, LLC",
      "Cosette Pharmaceuticals, Inc.",
      "Pangea Pharmaceuticals LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS CYP 3A4 Inhibitors (e.g",
      "Macrolide Antibiotics and Protease Inhibitors) Coadministration of ergotamine with potent CYP 3A4 inhibitors such as protease inhibitors or macrolide antibiotics has been associated with serious adverse events; for this reason, these drugs should not be given concomitantly with ergotamine (See CONTR",
      "While these reactions have not been reported with less potent CYP 3A4 inhibitors, there is a potential risk for serious toxicity including vasospasm when these drugs are used with ergotamine",
      "Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole",
      "These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with ergotamine",
      "Fibrotic Complications There have been a few reports of patients on ergotamine tartrate and caffeine therapy developing retroperitoneal and/or pleuropulmonary fibrosis",
      "There have also been rare reports of fibrotic thickening of the aortic, mitral, tricuspid, and/or pulmonary valves with long-term continuous use of ergotamine tartrate and caffeine",
      "Ergotamine tartrate suppositories should not be used for chronic daily administration (see DOSAGE AND ADMINISTRATION )"
    ],
    "drug_interactions": [
      "Drug Interactions CYP 3A4 Inhibitors (e.g",
      "Macrolide Antibiotics and Protease Inhibitors) See CONTRAINDICATIONS and WARNINGS ",
      "Ergotamine tartrate and caffeine tablets should not be administered with other vasoconstrictors",
      "Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure",
      "The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine",
      "Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy",
      "The blood levels of ergotamine-containing drugs are reported to be elevated by the concomitant administration of macrolide antibiotics and vasospastic reactions have been reported with therapeutic doses of the ergotamine-containing drugs when coadministered with these antibiotics"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Cardiovascular: Vasoconstrictive complications of a serious nature may occur at times",
      "These include ischemia, cyanosis, absence of pulse, cold extremities, gangrene, precordial distress and pain, EKG changes and muscle pains",
      "Although these effects occur most commonly with long-term therapy at relatively high doses, they have also been reported with short-term or normal doses",
      "Other cardiovascular adverse effects include transient tachycardia or bradycardia and hypertension",
      "Gastrointestinal: Nausea and vomiting; rectal or anal ulcer (from overuse of suppositories)",
      "Neurological: Paresthesias, numbness, weakness, and vertigo",
      "Allergic: Localized edema and itching",
      "Fibrotic Complications: (See WARNINGS )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc",
      "at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ergotamine Tartrate and Caffeine Indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”"
    ]
  },
  "ergotamine tartarate": {
    "ingredient": "ergotamine tartarate",
    "is_drug": true,
    "canonical_name": "ergotamine",
    "fda_search_term": "ergotamine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ergomar Sublingual",
      "MIGERGOT",
      "ergotamine tartrate and caffeine"
    ],
    "generic_names": [
      "ERGOTAMINE TARTRATE",
      "ERGOTAMINE TARTRATE AND CAFFEINE"
    ],
    "manufacturers": [
      "Cintex Services, LLC",
      "Cosette Pharmaceuticals, Inc.",
      "Pangea Pharmaceuticals LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS CYP 3A4 Inhibitors (e.g",
      "Macrolide Antibiotics and Protease Inhibitors) Coadministration of ergotamine with potent CYP 3A4 inhibitors such as protease inhibitors or macrolide antibiotics has been associated with serious adverse events; for this reason, these drugs should not be given concomitantly with ergotamine (See CONTR",
      "While these reactions have not been reported with less potent CYP 3A4 inhibitors, there is a potential risk for serious toxicity including vasospasm when these drugs are used with ergotamine",
      "Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole",
      "These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with ergotamine",
      "Fibrotic Complications There have been a few reports of patients on ergotamine tartrate and caffeine therapy developing retroperitoneal and/or pleuropulmonary fibrosis",
      "There have also been rare reports of fibrotic thickening of the aortic, mitral, tricuspid, and/or pulmonary valves with long-term continuous use of ergotamine tartrate and caffeine",
      "Ergotamine tartrate suppositories should not be used for chronic daily administration (see DOSAGE AND ADMINISTRATION )"
    ],
    "drug_interactions": [
      "Drug Interactions CYP 3A4 Inhibitors (e.g",
      "Macrolide Antibiotics and Protease Inhibitors) See CONTRAINDICATIONS and WARNINGS ",
      "Ergotamine tartrate and caffeine tablets should not be administered with other vasoconstrictors",
      "Use with sympathomimetics (pressor agents) may cause extreme elevation of blood pressure",
      "The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine",
      "Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy",
      "The blood levels of ergotamine-containing drugs are reported to be elevated by the concomitant administration of macrolide antibiotics and vasospastic reactions have been reported with therapeutic doses of the ergotamine-containing drugs when coadministered with these antibiotics"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Cardiovascular: Vasoconstrictive complications of a serious nature may occur at times",
      "These include ischemia, cyanosis, absence of pulse, cold extremities, gangrene, precordial distress and pain, EKG changes and muscle pains",
      "Although these effects occur most commonly with long-term therapy at relatively high doses, they have also been reported with short-term or normal doses",
      "Other cardiovascular adverse effects include transient tachycardia or bradycardia and hypertension",
      "Gastrointestinal: Nausea and vomiting; rectal or anal ulcer (from overuse of suppositories)",
      "Neurological: Paresthesias, numbness, weakness, and vertigo",
      "Allergic: Localized edema and itching",
      "Fibrotic Complications: (See WARNINGS )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc",
      "at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ergotamine Tartrate and Caffeine Indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”"
    ]
  },
  "eribulin": {
    "ingredient": "eribulin",
    "is_drug": true,
    "canonical_name": "eribulin",
    "fda_search_term": "eribulin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ERIBULIN MESYLATE",
      "Eribulin Mesylate"
    ],
    "generic_names": [
      "ERIBULIN MESYLATE"
    ],
    "manufacturers": [
      "BluePoint Laboratories",
      "Dr. Reddys Laboratories Inc",
      "Sun Pharmaceutical Industries Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Effects of Other Drugs on Eribulin Mesylate No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P‑glycoprotein (P-gp) inhibitors",
      "Clinically meaningful differences in exposure (AUC) were not observed in patients with advanced solid tumors when eribulin mesylate was administered with or without ketoconazole (a strong inhibitor of CYP3A4 and a P-gp inhibitor) and when eribulin mesylate was administered with or without rifampin (",
      "7.2 Effects of Eribulin Mesylate on Other Drugs Eribulin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 enzymes or induce CYP1A2, CYP2C9, CYP2C19 or CYP3A4 enzymes at relevant clinical concentrations",
      "Eribulin is not expected to alter the plasma concentrations of drugs that are substrates of these enzymes [see Clinical Pharmacology ( 12.3 )]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions (≥25%) in metastatic breast cancer were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation",
      "( 6.1 ) The most common adverse reactions (≥25%) in liposarcoma and leiomyosarcoma were fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, and pyrexia",
      "The most common (≥5%) Grade 3 to 4 laboratory abnormalities in liposarcoma and leiomyosarcoma were neutropenia, hypokalemia, and hypocalcemia",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Dr",
      "Reddy’s Laboratories, Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice",
      "The following adverse reactions are discussed in detail in other sections of the labeling: Neutropenia [see Warnings and Precautions ( 5.1) ] Peripheral neuropathy [see Warnings and Precautions (5.2) ] QT prolongation [see Warnings and Precautions (5.4) ] In clinical trials, eribulin mesylate has be",
      "The majority of the 1,963 patients were women (92%) with a median age of 55 years (range: 17 to 85 years)",
      "The racial and ethnic distribution was White (72%), Black (4%), Asian (9%), and other (3%)",
      "Metastatic Breast Cancer The most common adverse reactions (≥25%) reported in patients receiving eribulin mesylate were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation",
      "The most common serious adverse reactions reported in patients receiving eribulin mesylate were febrile neutropenia (4%) and neutropenia (2%)",
      "The most common adverse reaction resulting in discontinuation of"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease",
      "Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting",
      "( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen",
      "( 1.2 ) 1.1 Metastatic Breast Cancer Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease",
      "Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting [see Clinical Studies ( 14.1 )]"
    ]
  },
  "erlotinib": {
    "ingredient": "erlotinib",
    "is_drug": true,
    "canonical_name": "erlotinib",
    "fda_search_term": "erlotinib",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Erlotinib",
      "Erlotinib Hydrochloride"
    ],
    "generic_names": [
      "ERLOTINIB",
      "ERLOTINIB HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Armas Pharmaceuticals Inc.",
      "Aurobindo Pharma Limited",
      "Novadoz Pharmaceuticals LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 Inhibitors Co-administration of erlotinib tablets with a strong CYP3A4 inhibitor or a combined CYP3A4 and CYP1A2 inhibitor increased erlotinib exposure",
      "Erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2",
      "Increased erlotinib exposure may increase the risk of exposure-related toxicity [see Clinical Pharmacology (12.3) ] ",
      "Avoid co-administering erlotinib tablets with strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelﬁnavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice) o",
      "Reduce the erlotinib tablets dosage when co-administering with a strong CYP3A4 inhibitor or a combined CYP3A4 and CYP1A2 inhibitor if co-administration is unavoidable [see Dosage and Administration (2.4) ] ",
      "CYP3A4 Inducers Pre-treatment with a CYP3A4 inducer prior to erlotinib tablets decreased erlotinib exposure [see Clinical Pharmacology (12.3) ] ",
      "Increase the erlotinib tablets dosage if co-administration with CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, rifabutin, rifapentine, phenobarbital and St",
      "John's wort) is unavoidable [see Dosage and Administration (2.4) ]",
      "CYP1A2 Inducers and Cigarette Smoking Cigarette smoking decreased erlotinib exposure",
      "Avoid smoking tobacco (CYP1A2 inducer) and avoid concomitant use of erlotinib tablets with moderate CYP1A2 inducers (e.g., teriﬂunomide, rifampin, or phenytoin)"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions, which may include fatalities, are discussed in greater detail in other sections of the labeling: Interstitial Lung Disease (ILD) [see Warnings and Precautions (5.1) ] Renal Failure [see Warnings and Precautions (5.2) ] Hepatotoxicity with ",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact 1-888-557-1212 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch 6.1 Clinical Trials Safety Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug ",
      "Safety evaluation of erlotinib tablet is based on more than 1200 cancer patients who received erlotinib tablet as monotherapy, more than 300 patients who received erlotinib tablet 100 or 150 mg plus gemcitabine, and 1228 patients who received erlotinib tablet concurrently with other chemotherapies",
      "The most common adverse reactions with erlotinib tablet are rash and diarrhea usually with onset during the ﬁrst month of treatment",
      "The incidences of rash and diarrhea from"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Erlotinib tablet is a kinase inhibitor indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-appro",
      "( 1.2 ) Limitations of Use: Safety and efﬁcacy of erlotinib tablets have not been established in patients with NSCLC whose tumors have other EGFR mutations",
      "( 1.1 ) Erlotinib tablets are not recommended for use in combination with platinum-based chemotherapy",
      "( 1.1 ) 1.1 Non-Small Cell Lung Cancer (NSCLC) Erlotinib Tablets was indicated for: The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA",
      "Limitations of use: Safety and efﬁcacy of erlotinib have not been established in patients with NSCLC whose tumors have other EGFR mutations [see Clinical Studies (14.1, 14.2) ]"
    ]
  },
  "ertapenem": {
    "ingredient": "ertapenem",
    "is_drug": true,
    "canonical_name": "ertapenem",
    "fda_search_term": "ertapenem",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ERTAPENEM SODIUM",
      "Ertapenem"
    ],
    "generic_names": [
      "ERTAPENEM",
      "ERTAPENEM SODIUM"
    ],
    "manufacturers": [
      "Hospira, Inc.",
      "NorthStar RxLLC",
      "Sagent Pharmaceuticals"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Co-administration with probenecid inhibits the renal excretion of ertapenem and is therefore not recommended",
      "( 7.1 ) The concomitant use of ertapenem and valproic acid/divalproex sodium is generally not recommended",
      "Anti-bacterials other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium",
      "( 5.2 , 7.2 ) 7.1 Probenecid Probenecid interferes with the active tubular secretion of ertapenem, resulting in increased plasma concentrations of ertapenem [see Clinical Pharmacology ( 12.3 )] ",
      "Co-administration of probenecid with ertapenem is not recommended",
      "7.2 Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including ertapenem, to patients receiving valproic acid or divalproex sodium results in a reduction of valproic acid concentrations",
      "The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures",
      "Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid [see Warnings and Precau"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following are described in greater detail in the Warnings and Precautions section",
      "Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] Seizure Potential [see Warnings and Precautions ( 5.2 )] Interaction with Valproic Acid [see Warnings and Precautions ( 5.3 )] Clostridioides difficile -Associated Diarrhea (CDAD) [see Warnings and Precautions ( 5.4 )] Caution with In",
      "( 6.1 ) In the prophylaxis indication the overall adverse experience profile was generally comparable to that observed for ertapenem in other clinical trials",
      "( 6.1 ) Pediatrics: Adverse reactions in this population were comparable to adults",
      "The most common adverse reactions (≥5%) in pediatric patients treated with ertapenem for injection, including those who were switched to therapy with an oral antimicrobial, were diarrhea, vomiting and infusion site pain",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adults Receiving Ertapenem for Injection as a Treatment Regimen Clinical trials enrolled 1954 patients treated with ertapenem for injection; in some of the clinical trials, parenteral therapy was followed by a switch to an appropriate oral antimicrobial"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: Complicated intra-abdominal infections",
      "( 1.1 ) Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis",
      "( 1.2 ) Community-acquired pneumonia",
      "( 1.3 ) Complicated urinary tract infections including pyelonephritis",
      "( 1.4 ) Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections"
    ]
  },
  "erythromycin": {
    "ingredient": "erythromycin",
    "is_drug": true,
    "canonical_name": "erythromycin",
    "fda_search_term": "erythromycin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ery-Ped",
      "Erythromycin",
      "erythromycin"
    ],
    "generic_names": [
      "ERYTHROMYCIN",
      "ERYTHROMYCIN ETHYLSUCCINATE"
    ],
    "manufacturers": [
      "Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)",
      "Bryant Ranch Prepack",
      "Zydus Pharmaceuticals USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening",
      "Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents",
      "Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia",
      "Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”",
      "After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated",
      "Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone",
      "In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C",
      "difficile colitis"
    ],
    "drug_interactions": [
      "Drug Interactions Serious adverse reactions have been reported in patients taking erythromycin concomitantly with CYP3A4 substrates",
      "These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin and atorvastatin; and hypotension with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) (see PRECAUTIONS",
      "Drug Interactions )",
      "There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine",
      "This interaction is potentially life-threatening and may occur while using both drugs at their recommended doses (see PRECAUTIONS",
      "Drug Interactions )",
      "Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin",
      "Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels",
      "(See package insert for lovastatin)"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness",
      "Irritation of the eyes and tenderness of the skin have also been reported with topical use of erythromycin",
      "Generalized urticarial reactions possibly related to the use of erythromycin, which required systemic steroid therapy have been reported"
    ],
    "indications": [
      "INDICATIONS AND USAGE Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris"
    ]
  },
  "erythromycin sulfisoxazole": {
    "ingredient": "erythromycin sulfisoxazole",
    "is_drug": true,
    "canonical_name": "erythromycin",
    "fda_search_term": "erythromycin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ery-Ped",
      "Erythromycin",
      "erythromycin"
    ],
    "generic_names": [
      "ERYTHROMYCIN",
      "ERYTHROMYCIN ETHYLSUCCINATE"
    ],
    "manufacturers": [
      "Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)",
      "Bryant Ranch Prepack",
      "Zydus Pharmaceuticals USA Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Pseudomembranous colitis has been reported with nearly all antibacterial agents, including erythromycin, and may range in severity from mild to life-threatening",
      "Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents",
      "Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia",
      "Studies indicate that a toxin produced by Clostridium difficile is one primary cause of “antibiotic-associated colitis”",
      "After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated",
      "Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone",
      "In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial drug clinically effective against C",
      "difficile colitis"
    ],
    "drug_interactions": [
      "Drug Interactions Serious adverse reactions have been reported in patients taking erythromycin concomitantly with CYP3A4 substrates",
      "These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin and atorvastatin; and hypotension with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) (see PRECAUTIONS",
      "Drug Interactions )",
      "There have been post-marketing reports of colchicine toxicity with concomitant use of erythromycin and colchicine",
      "This interaction is potentially life-threatening and may occur while using both drugs at their recommended doses (see PRECAUTIONS",
      "Drug Interactions )",
      "Rhabdomyolysis with or without renal impairment has been reported in seriously ill patients receiving erythromycin concomitantly with lovastatin",
      "Therefore, patients receiving concomitant lovastatin and erythromycin should be carefully monitored for creatine kinase (CK) and serum transaminase levels",
      "(See package insert for lovastatin)"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following local adverse reactions have been reported occasionally: peeling, dryness, itching, erythema, and oiliness",
      "Irritation of the eyes and tenderness of the skin have also been reported with topical use of erythromycin",
      "Generalized urticarial reactions possibly related to the use of erythromycin, which required systemic steroid therapy have been reported"
    ],
    "indications": [
      "INDICATIONS AND USAGE Erythromycin Topical Solution USP, 2% is indicated for the topical treatment of acne vulgaris"
    ]
  },
  "erythropoietin": {
    "ingredient": "erythropoietin",
    "is_drug": true,
    "canonical_name": "erythropoietin",
    "fda_search_term": "erythropoietin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "PROCRIT"
    ],
    "generic_names": [
      "ERYTHROPOIETIN"
    ],
    "manufacturers": [
      "Janssen Products, LP"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in greater detail in other sections of the label: Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism [see Warnings and Precautions (5.1) ] Increased Mortality and/or Increased Risk of Tumor Progression or ",
      "Patients on Zidovudine due to HIV Infection: Adverse reactions in ≥ 5% of PROCRIT-treated patients in clinical studies were pyrexia, cough, rash, and injection site irritation ( 6.1 )",
      "Patients with Cancer on Chemotherapy: Adverse reactions in ≥ 5% of PROCRIT-treated patients in clinical studies were nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, insomnia, headache, depression, dysphagia, hypokalemia, and thro",
      "Surgery Patients: Adverse reactions in ≥ 5% of PROCRIT-treated patients in clinical studies were nausea, vomiting, pruritus, headache, injection site pain, chills, deep vein thrombosis, cough, and hypertension ( 6.1 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Janssen Products, LP at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of ot"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 )",
      "Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 )",
      "The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 )",
      "Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 )",
      "Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 )"
    ]
  },
  "escitalopram": {
    "ingredient": "escitalopram",
    "is_drug": true,
    "canonical_name": "escitalopram",
    "fda_search_term": "escitalopram",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Escitalopram Oral Solution",
      "Escitalopram Oxalate",
      "escitalopram"
    ],
    "generic_names": [
      "ESCITALOPRAM",
      "ESCITALOPRAM ORAL"
    ],
    "manufacturers": [
      "Amneal Pharmaceuticals LLC",
      "Chartwell RX, LLC",
      "Torrent Pharmaceuticals Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 6 presents clinically important drug interactions with escitalopram",
      "TABLE 6 Clinically Important Drug Interactions with Escitalopram Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs, including escitalopram, and MAOIs increases the risk of serotonin syndrome",
      "Intervention: Escitalopram is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [ see Dosage and Administration (2.7) , Contraindications (4) , and Warnings and Precautions (5.2) ] Pimozide Clinical Impact: Concomitant use of racemic citalopram",
      "Intervention: Escitalopram is contraindicated in patients taking pimozide [ see Contraindications (4) ]",
      "Other Serotonergic Drugs Clinical Impact: Concomitant use of escitalopram and other serotonergic drugs (including other SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St",
      "John’s Wort) increases the risk of serotonin syndrome",
      "Intervention: Monitor patients for signs and symptoms of serotonin syndrome, particularly during escitalopram initiation and dosage increases",
      "If serotonin syndrome occurs, consider discontinuation of escitalopram and/or concomitant serotonergic drugs [ see Warnings and Precautions(5.2) ] Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.) Clinical Impact: Concomitant use of escitalopram and an antiplatelet or anticoagul",
      "Intervention: Inform patients of the increased risk of bleeding associated with the concomitant use of escitalopram and antiplatelet agents and anticoagulants",
      "For patients taking warfarin, carefully monitor the internationalnormalized ratio [ see"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Suicidal thoughts and behaviors in adolescents and young adults [ see Warnings and Precautions (5.1) ] Serotonin syndrome [ see Warnings and Precautions(5.2) ] Discontinuation syndr",
      "at 1-845-232-1683, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice",
      "Clinical Trial Data Sources Adults Adverse reactions information for escitalopram was collected from 715 patients with major depressive disorder who were exposed to escitalopram and from 592 patients who were exposed to placebo in double-blind, placebo-controlled trials",
      "An additional 284 patients with major depressive disorder were newly exposed to escitalopram in open-label trials",
      "The adverse reaction information for"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Escitalopram is indicated for the treatment of: major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older",
      "generalized anxiety disorder (GAD) in adults",
      "Additional pediatric use information is approved for AbbVie Inc.’s Lexapro (escitalopram) tablets and LEXAPRO (escitalopram) oral solution",
      "However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that information",
      "Escitalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for the: treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older ( 1 ) treatment of generalized anxiety disorder (GAD) in adults ( 1 )"
    ]
  },
  "esketamine": {
    "ingredient": "esketamine",
    "is_drug": true,
    "canonical_name": "esketamine",
    "fda_search_term": "esketamine",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Spravato"
    ],
    "generic_names": [
      "ESKETAMINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Janssen Pharmaceuticals Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Central Nervous System Depressants Concomitant use with CNS depressants (e.g., benzodiazepines, opioids, alcohol) may increase sedation [see Warnings and Precautions (5.1) ] ",
      "Closely monitor for sedation with concomitant use of SPRAVATO with CNS depressants",
      "7.2 Psychostimulants Concomitant use with psychostimulants (e.g., amphetamines, methylphenidate, modafinil, armodafinil) may increase blood pressure [see Warnings and Precautions (5.7) ] ",
      "Closely monitor blood pressure with concomitant use of SPRAVATO with psychostimulants",
      "7.3 Monoamine Oxidase Inhibitors (MAOIs) Concomitant use with monoamine oxidase inhibitors (MAOIs) may increase blood pressure [see Warnings and Precautions (5.7) ] ",
      "Closely monitor blood pressure with concomitant use of SPRAVATO with MAOIs"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Sedation [see Warnings and Precautions (5.1) ] Dissociation [see Warnings and Precautions (5.2) ] Respiratory Depression [see Warnings and Precautions (5.3) ] Increase in Blood Pressur",
      "( 6 ) Treatment of depressive symptoms in adults with MDD with acute suicidal ideation or behavior: dissociation, dizziness, sedation, blood pressure increased, hypoesthesia, vomiting, euphoric mood, and vertigo",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc",
      "at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "Treatment-Resistant Depression In Conjunction with an Oral Antidepressant SPRAVATO was evaluated for safety in 1709 adults diagnosed with treatment-resistant depression (TRD) [see Clinical Studies (14.1) ] from five Phase 3 studies (3 short-term and 2 long-term studies) and one Phase 2 dose-ranging ",
      "Of all SPRAVATO-treated patients in the completed Phase 3 studies, 479 (30%) received at least 6 months of treatment, and 178 (11%) rece"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE SPRAVATO is indicated for the treatment of: Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction w",
      "( 1 ) Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant",
      "( 1 ) Limitations of Use: The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated",
      "Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO",
      "( 1 ) SPRAVATO is not approved as an anesthetic agent"
    ]
  }
}